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Cancer treatment has been subject of discussion for centuries. Surgery was already 
practiced (unsuccessfully) back in ancient Egypt,1 but until recent ages every type of 
cancer was deemed incurable, if detected at all. Whereas methods of surgery and 
radiotherapy were evolving in a revolutionary way during the 19th and early 20th century, 
systemic anti-cancer treatment only found its way into the clinic in the second half of the 
previous century. After World War I, the myelotoxic effect of mustard gas was noticed and 
translated into the first chemotherapy: nitrogen mustard.2 Since then, many other 
systemic anti-cancer agents have been developed for the treatment of many different 
types of cancer. The first group of patients that benefited from systemic anti-cancer 
treatment were those with hematological cancers. Nowadays, many leukemia and 
lymphoma patients can even be cured by systemic treatment sometimes combined with 
radiotherapy. However, except for patients with germline tumors and for the use in 
adjuvant or neoadjuvant setting, systemic therapies still rarely cure patients with solid 
tumors. This indicates that, despite all progress that has been made, there is much to win 
in this field of medicine. 
Although there is still much to be learned, the biological behavior of tumors has 
been scrutinized in parallel to the advent of chemotherapy. Since the 1950s, many 
researchers have examined cancer cells and have – successfully – found ways to stop 
these cells from proliferating. One of the earliest examples of the translation of increasing 
biological understanding into anti-cancer drugs is the group of fluoropyrimidines.3 Basic 
research had shown that rat hepatoma cells take up much more uracil than other 
(healthy) tissue. By attaching the toxic atom fluorine to an uracil base, resulting in 5-
fluorouracil (5-FU), the cytostatic effects of this drug are predominantly, but not 
exclusively, localized in cancer cells. Despite its age, 5-FU is currently still standard of care 
for the treatment of several cancer types.  
Accordingly, the increasing biological knowledge has led to the discovery of many 
other ways to kill cancer cells. Hormones appeared to stimulate cancer cell growth, which 
could be stopped by inhibiting this hormonal signaling, e.g. with the famous selective 
estrogen receptor modulator tamoxifen. Similarly, many other (non-hormonal) signaling 
pathways have been identified. Currently, a number of genes have been described that, 
when mutated or overexpressed, cause either activation of proliferative signaling (proto-
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oncogenes) or inhibition of anti-proliferative signaling (tumor suppressor genes). A 
schematic description of these processes is depicted in Figure 1.  
 
 
Figure 1. A schematic depiction of oncogenes and tumor suppressor genes. (A) Proto-oncogenes are 
physiologically involved in the normal process of cell cycle regulation. Mutated proto-oncogenes can 
become oncogenes and become constitutively activated, which leads to continuous proliferative 
signaling. (B) Tumor suppressor genes are physiologically involved in suppressing cell proliferation. 
When mutated, they can lose their suppressive function, which leads to increased proliferative 
signaling. 
 
Just as for the anti-hormonal agents, drugs are being developed to specifically target these 
aberrant proliferative signals. This has resulted broad spectrum of targeted anti-cancer 
drugs with different mechanisms of decreasing intracellular signaling: tyrosine kinase 
inhibitors (TKIs) prevent the phosphorylation of intracellular proteins, monoclonal 
antibodies (mABs) target extracellular receptors that initiate the intracellular signaling, 
and there are many other examples such as drugs that inhibit mammalian target of 
rapamycin (mTOR-inhibitors). 
 
Precision Medicine 
The first – and still the most impressive – example of a targeted anti-cancer agent is the 
TKI imatinib. In 1996, imatinib was found to inhibit the growth of chronic myelogenous 
leukemia (CML) cells that contained the BCR-ABL translocation.4 Patients with BCR-ABL-
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positive leukemia now have considerably increased chances of long term survival: 83% of 
patient remains recurrence-free after 5 years of systemic treatment.5 Similarly, patients 
with gastrointestinal stromal tumors (GIST) that harbor a mutation in a specific proto-
oncogene, KIT, live substantially longer when treated with imatinib (median overall 
survival (OS) > 50 months)6 than when treated with conventional chemotherapy (median 
OS in doxorubicin treated patients was only 9 months).7 For decades, cancers were 
categorized by their histological features. Recently, however, insight into the biology of 
cancer (which stimuli cause cancer cells to proliferate) has increased rapidly.8, 9 Many 
tumors appear to exhibit unrestrained proliferative signaling, initiated by a “driver” 
mutation. Following the example of imatinib, these proliferative signals are being targeted 
by the increasing number of available targeted agents. By complementing cancer 
diagnostics with molecular tumor cell characteristics, such as the presence of (potential) 
driver mutations, systemic treatment can be allocated much more specific to the patients 
that truly benefit from it. This specification of the diagnostic process is referred to as 
“precision medicine” or as “personalized medicine.” With a rapidly growing number of 
drugs to target the proliferative signaling pathways, precision medicine is thought to 
ultimately result in playing chess with cancer: each step cancer makes to proliferate is 
ideally counteracted by reversing that step with a specific drug. Within that context, the 
Dutch Center for Personalized Cancer Treatment (CPCT) was formed, in which many 
oncology centers currently collaborate. The CPCT investigates intratumoral genetic 
aberrations that are predictive for clinical outcome of existing systemic therapies. Since 
the molecular characteristics of tumors can change over time (and space),10 tumor 
biopsies are obtained from a metastatic lesion, which is likely to represent the most actual 
– and therefore the most malignant – status of the tumor. Subsequently, the DNA of these 
tumors is analyzed using next-generation sequencing (NGS) platforms and compared to 
treatment outcome, i.e. tumor response and survival. Before collecting tumor biopsies on 
a large scale, safety of the biopsy procedures and feasibility of the DNA extraction should 
be assured. These aspects are described in Chapter 2. 
Although the arsenal of available therapies has increased drastically, drugs need 
to be invented to target newly discovered oncogenic pathways. Originally, phase I trials 
were designed to assess the safety of drugs during their first clinical application, and to 
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identify the optimal dose for further study in phase II and III setting. The early phase 
clinical research, however, is also subject to the era of precision medicine and patient 
stratification is increasingly being based upon molecular profile of the tumor, even in 
phase I studies where safety is the primary endpoint.11 That way, endpoints biological 
mechanisms, such as changes in protein expression or phosphorylation, can already be 
integrated in this setting in order to optimize the efficiency of drug development. Even 
treatment effect is being assessed earlier during treatment. Since overall survival (OS), the 
most solid endpoint for treatment effect, will take much longer to investigate than the 
other phase I endpoints, alternatives are sought to determine treatment effect at an 
earlier time point. In Chapter 3, a cohort of everolimus treated patients was used to 
investigate if a novel volumetric surrogate endpoint, i.e. the time to progression (TTP) 
ratio, is a better parameter for detecting clinical benefit in early phase research. 
 
Pharmacokinetics 
Treatment effect is not only a matter of hitting the right target. It is equally important to 
hit the target with sufficient strength. One can envision that (too) low drug concentrations 
in the systemic circulation may lead to insufficient drug exposure in the tumor and, 
consequently, to treatment failure. Vice versa, (too) high systemic concentrations increase 
the risk of causing excessive harm to healthy tissue. Currently, for many anti-cancer drugs, 
especially cytostatic agents, the administered dose is based on body surface area (BSA), 
which is deduced from a patient’s height and weight. The lack of rationale to correct the 
dose for BSA is described in Chapter 4. Over the last years, research has focused 
increasingly on individual characteristics that influence a patient’s exposure to the drug, 
such as activity of drug metabolizing enzymes and drug transporters. The function of these 
enzymes and transporters can be influenced by a variety of factors: their function can be 
inhibited and induced by concomitantly administered drugs (“drug-drug interactions”),12 
by germline genetic polymorphisms in the encoding genes (“pharmacogenetics”),13 or by 
more trivial factors such as organ function.14 When the elimination of a drug is slowed 
down due to inhibition of an efflux transporter, the drug will accumulate within the 
systemic circulation and both tumor and healthy tissue will be exposed increasingly to it. 
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The increased exposure might lead to a better anti-cancer effect, but also to more side 
effects. Vice versa, reduced exposure may cause a drug to be less effective. This illustrates 
the importance of quantifying the influence that different factors have on drug exposure, 
especially in drugs with a wide interindividual variability (IIV) in exposure, such as the TKI 
sorafenib that is used for the treatment of hepatocellular carcinoma (HCC), renal cell 
carcinoma (RCC) and differentiated thyroid cancer (DTC). Once the individual factors that 
cause these interindividual differences in pharmacokinetics (PK) are characterized, the 
dose of sorafenib can be adjusted for those factors. That is another form of precision 
medicine, by which patients ideally experience optimal anti-cancer effects and suffer as 
little as possible from the side effects of a drug. Early steps in characterizing the factors 
that influence sorafenib PK are described in this thesis. In Chapter 5, the efflux transporter 
OATP1B was inhibited – both genetically and chemically – in order to find out if the 
hepatobiliary efflux of sorafenib’s metabolite sorafenib-glucuronide is influenced by this 
process. Since this study only assessed the pharmacokinetics of this TKI, the clinical effects 
of OATP1B inhibition were evaluated in Chapter 6, where the association between single 
nucleotide polymorphisms (SNPs) in the genes encoding for OATP1B (SLCO1B) and the 
clinical outcome was tested retrospectively in sorafenib treated patients.  
  
Changes in exposure over time 
Drug exposure is not a constant, as many of the factors mentioned above change over 
time: concomitant medication can be added or stopped during treatment, but also renal 
or hepatic function can deteriorate. Even without these conditions changing, systemic 
drug exposure can change over time. Systemic imatinib exposure, for example, decreases 
by 30% after three months of treatment.15 At first, this was attributed to decreased 
imatinib absorption from the intestine due to change in drug transporter activity,15 but in 
an alternative explanation it was suggested that decreased inflammatory state would lead 
to decreased presence of alpha-1 acid glycoprotein (AGP, an acute phase protein to which 
imatinib binds predominantly in the systemic circulation) and hence would facilitate 
increased clearance of imatinib.16 In Chapter 7, imatinib treated patients were followed 
for 1 year after imatinib treatment start in order to prospectively assess the course of AGP 
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concentrations during this period and the correlation between AGP levels and imatinib 
pharmacokinetics (PK). 
 
Therapeutic drug monitoring (TDM) 
Based on the variability in exposure, it has become common to monitor systemic drug 
concentrations in other fields of medicine, e.g. infectious diseases or psychiatry.17, 18 If 
drug concentrations are too low and patients are unlikely to benefit from treatment, the 
dose can be increased in order to optimize the treatment effect. Vice versa, too high drug 
concentrations might lead to severe toxicity on the long term, which could be prevented 
by decreasing the dose early during treatment. In oncology, however, TDM has not found 
its way into clinical practice yet, although many anti-cancer drugs lend themselves to 
TDM.19 Imatinib concentrations treatment were retrospectively found to be correlated 
with tumor response in patients with gastrointestinal stromal tumor (GIST)20 and in 
patients with chronic myeloid leukemia (CML).21 For 5-FU, similar results have been 
found.22 Pazopanib is another TKI, for which the relationship between systemic exposure 
and treatment outcome has been described.23 In Chapter 8, it was evaluated if it was 
feasible to increase exposure by increasing dose in pazopanib treated patients that have 
too low exposure on the original dose of 800 mg daily. Additionally, several methods to 
measure the concentration, i.e. by blood withdrawal and by dried blood spot (DBS), were 
compared in the same study (Chapter 9). 
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ABSTRACT 
Background. The discovery of novel biomarkers that predict treatment response in 
advanced cancer patients requires acquisition of high-quality tumor samples. As cancer 
evolves over time, tissue is ideally obtained before the start of each treatment. Preferably, 
samples are freshly frozen to allow analysis by next-generation DNA/RNA sequencing 
(NGS) but also for making other emerging systematic techniques such as proteomics and 
metabolomics possible. Here, we describe the first 469 image-guided biopsies collected in 
a large collaboration in the Netherlands (Center for Personalized Cancer Treatment) and 
show the utility of these specimens for NGS analysis. 
Patients and methods. Image-guided tumor biopsies were performed in advanced cancer 
patients. Samples were fresh frozen, vital tumor cellularity was estimated, and DNA was 
isolated after macrodissection of tumor-rich areas. Safety of the image-guided biopsy 
procedures was assessed by reporting of serious adverse events within 14 days after the 
biopsy procedure. 
Results. Biopsy procedures were generally well tolerated. Major complications occurred in 
2.1%, most frequently consisting of pain. In 7.3% of the percutaneous lung biopsies, 
pneumothorax requiring drainage occurred. The majority of samples (81%) contained a 
vital tumor percentage of at least 30%, from which at least 500 ng DNA could be isolated 
in 91%. Given our preset criteria, 74% of samples were of sufficient quality for biomarker 
discovery. The NGS results in this cohort were in line with those in other groups. 
Conclusion. Image-guided biopsy procedures for biomarker discovery to enable 
personalized cancer treatment are safe and feasible and yield a highly valuable biobank. 
Implications for Practice. This study shows that it is safe to perform image-guided biopsy 
procedures to obtain fresh frozen tumor samples and that it is feasible to use these 
biopsies for biomarker discovery purposes in a Dutch multicenter collaboration. From the 
majority of the samples, sufficient DNA could be yielded to perform next-generation 
sequencing. These results indicate that the way is paved for consortia to prospectively 
collect fresh frozen tumor tissue. 
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INTRODUCTION 
In oncology, the prediction of treatment outcome remains an important issue. The 
number of available treatments steadily increases and re-emphasizes our need for 
guidance on which treatment to choose for a specific patient. Hypothesis-driven 
biomarkers have been successful: For example, BRAF mutations in melanoma predict 
response to BRAF inhibitors.1 However, other effective treatments such as immune 
checkpoint blockers and novel targeted treatments often lack obvious hypothesis-driven 
biomarkers. Therefore, unbiased, large-scale approaches such as next-generation 
DNA/RNA sequencing (NGS), proteomics, and metabolomics may improve the search for 
more and better predictive biomarkers. To enable the use of these large- scale 
technologies on clinical samples, it is essential to start the systematic collection of well 
annotated tissue samples. Because snap freezing is considered the most optimal 
preservation method for nucleic acids as well as proteins and metabolites, this should be 
the preferred way clinical samples intended for current and future biomarker discovery 
are processed.  
One major issue in biomarker discovery remains the heterogeneity of tumors. 
Genetic heterogeneity has been described extensively, and this heterogeneity spans both 
temporal and spatial differences.2-5 Consequently, any biomarker discovery study should 
try to minimize the time elapsing between sampling and treatment and document the 
sampling site. Moreover, imaging and pathology studies have shown extensive 
intralesional heterogeneity with respect to important features such as angiogenesis, 
oxygen supply, energy consumption, and stromal content.6-8 This heterogeneity will cause 
a baseline variability despite any effort to homogenize the sampling time and location. 
Thus, obtaining a large enough sample size to average out our baseline variation is 
required for the detection of true differences. The actual sample size needed to detect a 
meaningful difference remains an elusive matter. However, despite all these potential 
factors that may cause failure to find novel biomarker profiles, there is an increasing 
number of successful examples of biomarker detection using NGS, including a study that 
showed that novel T-cell epitopes predict efficacy of immunotherapy, in which the authors 
were able to detect a meaningful difference in a sample of 11 responders and 14 
nonresponders.9 Therefore, collecting materials from patients who undergo specified 
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treatments could yield interesting results even when only limited patient numbers are 
included, given the proper preservation of such materials. 
Any large-scale technology that uses unbiased data collection suffers from 
difficulty in analysis because of the amount of data generated. This problem needs to be 
addressed at the start of any sample collection project. For NGS-based DNA sequencing 
the collection of adequate germline samples is essential for the detection of somatic 
genetic alteration. Also, sampling multiple times from the same patient allows detection 
of resistance mechanisms.10-12 Thus any protocol should encourage repetitive sampling.  
In the Netherlands, all large oncology centers, including the nine academic 
centers, are now collaborating in the Center for Personalized Cancer Treatment (CPCT). 
The CPCT has set up a pipeline for the collection of fresh frozen tumor tissue and for 
storage in a central biobank. In parallel, all relevant clinical data are recorded in an 
electronic case record form and can be linked to the results of the tests performed on the 
tumor material. The primary objective of this biobanking effort is to analyze the individual 
cancer genome in advanced cancer patients to develop future predictors for response to 
systemic treatment. Here, we show that it is feasible to set up such a multicenter initiative 
by presenting the safety of the first 469 image-guided tumor biopsy procedures and by 
providing the DNA sequencing results of a selected set of 73 biopsy specimens. 
 
PATIENTS AND METHODS 
Study Design 
To obtain research-related biopsies from advanced cancer patients without curative 
treatment options, the institutional review board of the participating centers approved a 
protocol. An important characteristic of the protocol was that it allowed the recruitment 
of patients with all solid tumor types and multiple treatment protocols. Therefore, it was 
called the “umbrella” biopsy protocol (NCT01855477). This umbrella protocol was a 
prospective multicenter trial protocol in which biopsies are obtained to perform next-
generation sequencing on fresh frozen biopsy specimens to allow for biomarker detection 
as well as exploratory biomarker discovery. Patients did not receive systemic treatment as 
part of this protocol itself. Patients participated in the umbrella protocol and received 
Large-Scale Biobank of Fresh Frozen Tumor Tissue| 21 
 
systemic treatment, either standard of care or experimental treatment, within a different 
protocol.  
Within the umbrella protocol a baseline biopsy procedure was performed, and clinical 
data were collected, including radiological response data. The protocol allowed for 
multiple biopsy procedures at different time points to document changes in genetic 
profiles upon treatment. Study related procedures were (a) screening procedures to 
ascertain eligibility and safety of the biopsy procedure, (b) biopsy procedures, and (c) a 
blood draw to determine germline DNA. The umbrella protocol defined radiological tumor 
assessments within 8 to 12 weeks after the start of the first initiated treatment after 
baseline biopsy. The study was conducted in accordance with the latest versions of the 
Declaration of Helsinki and Good Clinical Practice guidelines. 
 
Patient Selection 
All patients provided written informed consent before any of the study-related 
procedures. Patients aged ≥18 years with a locally advanced or metastatic solid tumor 
without curative treatment options were eligible for inclusion. Patients were eligible only 
if systemic treatment according to standard of care or with experimental anticancer 
agents was planned. Eligible patients had an Eastern Cooperative Oncology Group 
performance status of 0 (asymptomatic) to 2, measurable lesions according to Response 
Evaluation Criteria in Solid Tumors,13 and adequate renal and hepatic functions. Patients 
with a history of bleeding disorders or bleeding complications, using anticoagulant 
medication in which discontinuation of anticoagulants was unadvisable, and patients with 
a contraindication for lidocaine and, if applicable, midazolam or phentanyl (or their 
derivatives) were excluded. Biopsy of a locally advanced or metastatic lesion had to be 
considered safe according to the intervening physician. 
 
Blood Sample Collection and Processing 
Tumor-matched blood samples were collected to determine patient’s germline variation. 
This information was used to differentiate between somatic and germline mutations in the 
tumor and was specifically not used to detect cancer predisposition. Venous blood was 
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collected in K2EDTA tubes. Blood samples were shipped at room temperature to the 
central core facility of the CPCT for subsequent processing. 
 
Biopsy Procedure 
Percutaneous biopsy procedures were performed under ultrasound or computed 
tomographic guidance after local anesthesia (and in incidental cases under conscious 
sedation). Whether a guiding needle was used mainly depended on tumor localization and 
on the preference of the individual physician. We aimed to retrieve two to four core 
biopsy specimens, preferably with at least an 18-gauge biopsy needle. If appropriate, a 
gastroenterologist performed an endoscopic (ultrasound) guided procedure using a 19-
gauge endoscopic ultrasound histology needle under sedation with midazolam and 
opioids (phentanyl) for pain relief. When we suspected possible complications with 
patients, we used ultrasound or computed tomography (CT) to check for major 
complications (e.g., pneumothorax or initial bleeding complications). 
 
Biopsy Sample Processing 
Biopsy specimens were labeled and snap-frozen directly after the biopsy procedure. 
Subsequently, the specimens were stored at -80°C until they were shipped on dry ice to 
the central core facility of the CPCT. 
 
Histological Assessment 
From each biopsy, 4-mm frozen sections were cut and stained for hematoxylin and eosin. 
A dedicated pathologist (S.M.W. or P.J.D.) performed histological assessment to confirm 
the presence of tumor tissue as well as the percentage of tumor cells based on the 
quantity of nuclei and tumor cell vitality. Tissue morphology was comparable to frozen 
sections and allowed for reliable confirmation of the presence of cancer. Obvious tumor-
rich islands within the sections were marked to obtain an optimal tumor cellularity and 
quality and to facilitate macrodissection, during which regions of interest were scraped off 
with a scalpel and collected in phosphate-buffered saline solution. Only when the 
percentage of vital tumor cells was at least 30%, we proceeded to DNA isolation after 
macrodissection of indicated areas. 
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DNA Isolation 
DNA was isolated from 500 mL of whole blood and from approximately five 
macrodissected 20-mm sections using the NorDiag Arrow machine (Isogen Life Science, De 
Meern, The Netherlands, http://www.isogen-lifescience.com) for isolation and purification 
of the DNA. DNA extraction was performed in batches (1 to 12 samples per run) using 230 
mL of lysis buffer and 20 mL of proteinase K and comprised two washing steps with a final 
elution volume of 100 mL, according to the manufacturer’s protocol. DNA quantity was 
measured with the Qubit 2.0 fluorometer (Thermo Fisher Scientific Life Sciences, 
Waltham, MA, http://www.thermofisher.com). Depending on DNA quantity, the protocol 
was repeated on additional tissue sections to aim for a DNA quantity of at least 500 ng of 
DNA.DNA was stored at220°C until sequencing was performed. 
 
Safety Evaluation 
Observation after the biopsy procedure was performed according to local protocols. No 
observation was required for patients undergoing superficial tumor biopsies (e.g., biopsy 
of a subcutaneous lesion or low-risk biopsy of a superficial lymph node). After a 
percutaneous lung biopsy, a chest x-ray was routinely performed after 1 to 4 hours, 
depending on local protocols, which in some cases required overnight hospitalization. 
After all other biopsy procedures, patients were clinically observed for 1 to 4 hours.  
Biopsy procedures of individual patients were included in the safety evaluation if 
specimens for research purposes had been retrieved. All major complications, defined as 
any adverse events grade 3 or higher related to the biopsy procedure, and all serious 
adverse events (SAE) occurring within 14 days after tumor biopsy, were registered 
prospectively. Adverse events were graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (version 4).14 An SAE was defined in the 
protocol as any complication that resulted in death, was life threatening, required 
prolonged hospitalization, resulted in persistent or significant disability or incapacity, or 
was a congenital anomaly or birth defect. Clinical observation or hospitalization to 
facilitate biopsy procedures was not considered a criterion for seriousness. Special 
attention was paid to the occurrence of bleeding complications and to pneumothorax 
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Biopsy Sample Processing 
Biopsy specimens were labeled and snap-frozen directly after the biopsy procedure. 
Subsequently, the specimens were stored at -80°C until they were shipped on dry ice to 
the central core facility of the CPCT. 
 
Histological Assessment 
From each biopsy, 4-mm frozen sections were cut and stained for hematoxylin and eosin. 
A dedicated pathologist (S.M.W. or P.J.D.) performed histological assessment to confirm 
the presence of tumor tissue as well as the percentage of tumor cells based on the 
quantity of nuclei and tumor cell vitality. Tissue morphology was comparable to frozen 
sections and allowed for reliable confirmation of the presence of cancer. Obvious tumor-
rich islands within the sections were marked to obtain an optimal tumor cellularity and 
quality and to facilitate macrodissection, during which regions of interest were scraped off 
with a scalpel and collected in phosphate-buffered saline solution. Only when the 
percentage of vital tumor cells was at least 30%, we proceeded to DNA isolation after 
macrodissection of indicated areas. 
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DNA Isolation 
DNA was isolated from 500 mL of whole blood and from approximately five 
macrodissected 20-mm sections using the NorDiag Arrow machine (Isogen Life Science, De 
Meern, The Netherlands, http://www.isogen-lifescience.com) for isolation and purification 
of the DNA. DNA extraction was performed in batches (1 to 12 samples per run) using 230 
mL of lysis buffer and 20 mL of proteinase K and comprised two washing steps with a final 
elution volume of 100 mL, according to the manufacturer’s protocol. DNA quantity was 
measured with the Qubit 2.0 fluorometer (Thermo Fisher Scientific Life Sciences, 
Waltham, MA, http://www.thermofisher.com). Depending on DNA quantity, the protocol 
was repeated on additional tissue sections to aim for a DNA quantity of at least 500 ng of 
DNA.DNA was stored at220°C until sequencing was performed. 
 
Safety Evaluation 
Observation after the biopsy procedure was performed according to local protocols. No 
observation was required for patients undergoing superficial tumor biopsies (e.g., biopsy 
of a subcutaneous lesion or low-risk biopsy of a superficial lymph node). After a 
percutaneous lung biopsy, a chest x-ray was routinely performed after 1 to 4 hours, 
depending on local protocols, which in some cases required overnight hospitalization. 
After all other biopsy procedures, patients were clinically observed for 1 to 4 hours.  
Biopsy procedures of individual patients were included in the safety evaluation if 
specimens for research purposes had been retrieved. All major complications, defined as 
any adverse events grade 3 or higher related to the biopsy procedure, and all serious 
adverse events (SAE) occurring within 14 days after tumor biopsy, were registered 
prospectively. Adverse events were graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (version 4).14 An SAE was defined in the 
protocol as any complication that resulted in death, was life threatening, required 
prolonged hospitalization, resulted in persistent or significant disability or incapacity, or 
was a congenital anomaly or birth defect. Clinical observation or hospitalization to 
facilitate biopsy procedures was not considered a criterion for seriousness. Special 
attention was paid to the occurrence of bleeding complications and to pneumothorax 
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after transthoracic biopsy. Pneumothorax and hematothorax are treated invasively at 
grade 2 and were therefore registered at that grade or higher. 
 
Feasibility 
Within the umbrella protocol, retrieval of research specimens for biomarker analyses 
could be combined with a biopsy procedure for diagnostic assessment. All the image-
guided biopsy procedures during which research specimens were retrieved were 
evaluable for quantification of vital tumor cellularity. Sequencing was performed if DNA 
yield was at least 500 ng. Performing extended sequencing on paired blood samples 
(germline DNA) allowed for filtering for true somatic mutations in tumor samples. 
 
DNA Sequencing 
Two different platforms have been used for DNA sequencing, that is, a targeted panel 
analysis using SOLiD sequencing and exome sequencing analysis using Illumina 
sequencing.  
For SOLiD, single nucleotide variants and insertions or deletions (INDELs) were 
detected by targeted sequencing of a designed “cancer mini-genome” consisting of 1,977 
cancer genes (Supplementary Table S1). Barcoded fragment libraries were generated 
from 2 mg of isolated DNA from tumor and control samples, as described previously.15 
Pools of libraries were enriched for 1,977 cancer-related genes (cancer mini-genome16 
using SureSelect technology [Agilent, Santa Clara, CA, http://www.agilent.com/home]). 
Enriched libraries were sequenced on a SOLiD 5500xl instrument, according to the 
manufacturer’s protocol. Reads were mapped on the human genome (GRCh37) by using 
Burrows-Wheeler Aligner (BWA)17 with the following parameters: -c –l 25 –k 2 –n 10. 
Variant calling was done using a custom pipeline identifying variants with at 
least103coverage,an allele frequency of 15%, and multiple (>2) occurrences in the seed 
(the first 25 base pairs [bp] most accurately mapped part of the read), as well as support 
from independent reads (>3). All variant positions identified were subsequently 
genotyped in the raw datasets of all samples using SAMtools mpileup (SourceForge.net, 
http://samtools.sourceforge.net/mpileup.shtml) to ensure the presence or absence of 
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possible low-frequency variants. To identify somatic mutations, we excluded all variants 
identified in both tumor and blood from further analysis.  
The Illumina data were processed with an in-house developed pipeline (version 
1.2.1) (https://github.com/CuppenResearch/IAP), including GATK v3.2.2,18 according to 
the best- practices guidelines.19 Briefly, we mapped the pairs withBWA-MEMv0.7.5a,17 
marked duplicates, merged lanes, and realigned INDELs. Base recalibration did not 
improve our exome results, so this step was skipped. Next, GATK Haplotype caller was 
used to call single nucleotide polymorphisms (SNPs) and INDELs. Variants are flagged as 
PASS only if they do not meet the following criteria: QD < 2.0, MQ < 40.0, FS > 60.0, 
HaplotypeScore > 13.0, MQRankSum < -12.5, ReadPosRankSum < -8.0, snpclusters ≥ 3 in 
35 bp. For INDELs: QD < 2.0, FS >200.0, ReadPosRankSum < -20.0. Effect predictions and 
annotation were added using snpEFF20 and dbNSFP.21 Somatic mutation is determined by 
providing the reference and tumor sequencing data to the following algorithms: Strelka 
v1.0.14,22 Varscan v2.3.7,23 and Freebayes v0.9.20.24 High-confident variants are 
determined by the tool-filtering steps and merged to a single .vcf file. 
 
Statistical Analysis 
All baseline patient characteristics, image-guided biopsy procedure characteristics, and 
other described analyses were performed using descriptive statistics (Microsoft Excel 
2010; Microsoft, Redmond, WA, https://www.microsoft.com/en-us). Tumor cellularity and 
DNA yield were recorded as continuous variables but were grouped (on the basis of our 
preset criteria) to allow for descriptive analysis. 
 
RESULTS 
Baseline Characteristics 
From August 17, 2011, until December 31, 2013, a total of 500 patients signed informed 
consent and were included in the study. In 50 patients, the biopsy procedure was not 
performed, because the procedure was not deemed safe or because of clinical progression 
before the planned biopsy. In Table 1, baseline characteristics are depicted for the 450 
biopsied patients, of which the majority had been diagnosed with breast cancer, lung 
cancer, colorectal cancer, or melanoma.  
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providing the reference and tumor sequencing data to the following algorithms: Strelka 
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DNA yield were recorded as continuous variables but were grouped (on the basis of our 
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RESULTS 
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From August 17, 2011, until December 31, 2013, a total of 500 patients signed informed 
consent and were included in the study. In 50 patients, the biopsy procedure was not 
performed, because the procedure was not deemed safe or because of clinical progression 
before the planned biopsy. In Table 1, baseline characteristics are depicted for the 450 
biopsied patients, of which the majority had been diagnosed with breast cancer, lung 
cancer, colorectal cancer, or melanoma.  
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Biopsy Procedures 
In order to be evaluable for this study, patients had to be biopsied at least once before the 
start of designated treatment. We attempted to obtain other biopsies during or directly 
after treatment. Multiple biopsies for study purposes were performed in 44 patients, that 
is, two biopsies in 37 patients, three biopsies in 5 patients, and four biopsies in 2 patients. 
Of the 503 biopsy procedures in this study, 469 were performed under image guidance of 
ultrasonography, CT scan, or endoscopy (Figure 1, Table 2). Most image-guided biopsies 
were performed on the liver (n 5 185; 39%). Other abdominal organs (n 5 94; 20%) and 
intrathoracic organs (n 5 56; 12%) were also biopsied frequently. Superficial lesions such 
as cutaneous, subcutaneous, and soft tissue lesions were biopsied in 120 procedures 
(26%) and osseous lesions in 14 (3%). 
 
 
Table 1. Baseline characteristics. 
 Biopsied patients 
N=450 
Sequenced biopsies 
N=73 
Age   mean (SD) 59  (11) 58  (11) 
Sex  Male 
 Female 
239  (53%) 
211  (47%) 
37  (51%) 
36  (49%) 
Primary  GI: CRC 
tumor     Lung cancer 
 Breast cancer 
 Melanoma 
 Hepatobiliary cancer 
 GI: other 
 Gynecological cancer 
 GU cancer 
 Other 
 Sarcoma 
 Head / neck cancer 
99  (22%) 
61  (14%) 
49  (11%) 
44  (10%) 
37  (8%) 
32  (7%) 
31  (7%) 
31  (7%) 
27  (6%) 
26  (6%) 
13  (3%) 
16  (22%) 
3  (4%) 
5  (7%) 
16  (22%) 
6  (8%) 
7  (10%) 
5  (7%) 
2  (3%) 
6  (8%) 
4  (5%) 
3  (4%) 
Abbreviations: CRC, colorectal cancer; GI, gastrointestinal tract; GU, genitourinary tract. 
 
 
Fig
ur
e 
1.
 St
ud
y f
lo
wc
ha
rt.
 
    
Ta
bl
e 
2.
 B
io
ps
y c
ha
ra
ct
er
ist
ics
. 
a.
 Su
pe
rfi
cia
l le
sio
ns
 in
clu
de
 a
ll s
ub
cu
ta
ne
ou
s t
um
or
s, 
su
pe
rfi
cia
l ly
m
ph
 
no
de
s a
nd
 b
re
as
t t
um
or
s. 
b.
 T
ho
ra
cic
 le
sio
ns
 in
clu
de
 p
ul
m
on
ar
y t
um
or
s, 
pl
eu
ra
l t
um
or
s, 
in
tra
th
or
ac
ic 
lym
ph
 n
od
es
 a
nd
 th
ym
ic 
tu
m
or
s. 
c. 
En
do
sc
op
y w
as
 p
er
fo
rm
ed
 a
s g
as
tro
sc
op
y (
N=
5)
, c
ol
on
os
co
py
 (N
=1
), 
br
on
ch
os
co
py
 (N
=1
) o
r e
nd
os
co
pi
c u
ltr
as
on
og
ra
ph
y (
N=
1)
. 
  
Re
gis
te
re
d
pa
tie
nt
s
N=
50
0
Pa
tie
nt
sb
io
ps
ie
d
N=
 4
50
No
tb
io
ps
ie
d
N=
 5
0
To
ta
l b
io
ps
ie
s
N=
 5
03
Se
qu
en
tia
lb
io
ps
ie
s 
N=
 5
3
Im
ag
e-
gu
id
ed
bi
op
sie
s
N=
46
9
No
n 
im
ag
e-
gu
id
ed
bi
op
sie
s
N=
34
Ch
ar
ac
te
ris
tic
s 
Im
ag
e-
gu
id
ed
 b
io
ps
ie
s 
N=
46
9 
Bi
op
sy
 ti
m
in
g 
- 
Ba
se
lin
e 
- 
On
-/
po
st
-tr
ea
tm
en
t 
 Bi
op
sy
 lo
ca
liz
at
io
n 
- 
Ab
do
m
in
al
: l
ive
r 
- 
Ab
do
m
in
al
: o
th
er
 
- 
Su
pe
rfi
cia
la  
- 
Th
or
ac
icb
 
- 
Bo
ne
 
 Im
ag
in
g m
od
al
ity
 
- 
CT
-sc
an
 
- 
Ul
tra
so
no
gr
ap
hy
 
- 
En
do
sc
op
yc
 
 41
9 
 
(8
9%
) 
50
  
(1
1%
) 
  18
5 
 
(3
9%
) 
94
  
(2
0%
) 
12
0 
 
(2
6%
) 
56
  
(1
2%
) 
14
  
(3
%)
 
  10
1 
 
(2
2%
) 
36
0 
 
(7
7%
) 
8 
 
(2
%)
 
226 | Chapter 2 
 
 
 
Biopsy Procedures 
In order to be evaluable for this study, patients had to be biopsied at least once before the 
start of designated treatment. We attempted to obtain other biopsies during or directly 
after treatment. Multiple biopsies for study purposes were performed in 44 patients, that 
is, two biopsies in 37 patients, three biopsies in 5 patients, and four biopsies in 2 patients. 
Of the 503 biopsy procedures in this study, 469 were performed under image guidance of 
ultrasonography, CT scan, or endoscopy (Figure 1, Table 2). Most image-guided biopsies 
were performed on the liver (n 5 185; 39%). Other abdominal organs (n 5 94; 20%) and 
intrathoracic organs (n 5 56; 12%) were also biopsied frequently. Superficial lesions such 
as cutaneous, subcutaneous, and soft tissue lesions were biopsied in 120 procedures 
(26%) and osseous lesions in 14 (3%). 
 
 
Table 1. Baseline characteristics. 
 Biopsied patients 
N=450 
Sequenced biopsies 
N=73 
Age   mean (SD) 59  (11) 58  (11) 
Sex  Male 
 Female 
239  (53%) 
211  (47%) 
37  (51%) 
36  (49%) 
Primary  GI: CRC 
tumor     Lung cancer 
 Breast cancer 
 Melanoma 
 Hepatobiliary cancer 
 GI: other 
 Gynecological cancer 
 GU cancer 
 Other 
 Sarcoma 
 Head / neck cancer 
99  (22%) 
61  (14%) 
49  (11%) 
44  (10%) 
37  (8%) 
32  (7%) 
31  (7%) 
31  (7%) 
27  (6%) 
26  (6%) 
13  (3%) 
16  (22%) 
3  (4%) 
5  (7%) 
16  (22%) 
6  (8%) 
7  (10%) 
5  (7%) 
2  (3%) 
6  (8%) 
4  (5%) 
3  (4%) 
Abbreviations: CRC, colorectal cancer; GI, gastrointestinal tract; GU, genitourinary tract. 
 
 
Fig
ur
e 
1.
 St
ud
y f
lo
wc
ha
rt.
 
    
Ta
bl
e 
2.
 B
io
ps
y c
ha
ra
ct
er
ist
ics
. 
a.
 Su
pe
rfi
cia
l le
sio
ns
 in
clu
de
 a
ll s
ub
cu
ta
ne
ou
s t
um
or
s, 
su
pe
rfi
cia
l ly
m
ph
 
no
de
s a
nd
 b
re
as
t t
um
or
s. 
b.
 T
ho
ra
cic
 le
sio
ns
 in
clu
de
 p
ul
m
on
ar
y t
um
or
s, 
pl
eu
ra
l t
um
or
s, 
in
tra
th
or
ac
ic 
lym
ph
 n
od
es
 a
nd
 th
ym
ic 
tu
m
or
s. 
c. 
En
do
sc
op
y w
as
 p
er
fo
rm
ed
 a
s g
as
tro
sc
op
y (
N=
5)
, c
ol
on
os
co
py
 (N
=1
), 
br
on
ch
os
co
py
 (N
=1
) o
r e
nd
os
co
pi
c u
ltr
as
on
og
ra
ph
y (
N=
1)
. 
  
Re
gis
te
re
d
pa
tie
nt
s
N=
50
0
Pa
tie
nt
sb
io
ps
ie
d
N=
 4
50
No
tb
io
ps
ie
d
N=
 5
0
To
ta
l b
io
ps
ie
s
N=
 5
03
Se
qu
en
tia
lb
io
ps
ie
s 
N=
 5
3
Im
ag
e-
gu
id
ed
bi
op
sie
s
N=
46
9
No
n 
im
ag
e-
gu
id
ed
bi
op
sie
s
N=
34
Ch
ar
ac
te
ris
tic
s 
Im
ag
e-
gu
id
ed
 b
io
ps
ie
s 
N=
46
9 
Bi
op
sy
 ti
m
in
g 
- 
Ba
se
lin
e 
- 
On
-/
po
st
-tr
ea
tm
en
t 
 Bi
op
sy
 lo
ca
liz
at
io
n 
- 
Ab
do
m
in
al
: l
ive
r 
- 
Ab
do
m
in
al
: o
th
er
 
- 
Su
pe
rfi
cia
la  
- 
Th
or
ac
icb
 
- 
Bo
ne
 
 Im
ag
in
g m
od
al
ity
 
- 
CT
-sc
an
 
- 
Ul
tra
so
no
gr
ap
hy
 
- 
En
do
sc
op
yc
 
 41
9 
 
(8
9%
) 
50
  
(1
1%
) 
  18
5 
 
(3
9%
) 
94
  
(2
0%
) 
12
0 
 
(2
6%
) 
56
  
(1
2%
) 
14
  
(3
%)
 
  10
1 
 
(2
2%
) 
36
0 
 
(7
7%
) 
8 
 
(2
%)
 
Large-Scale Biobank of Fresh Frozen Tumor Tissue | 27
28 | Chapter 2 
 
 
Treatment Details 
Of all biopsied patients, 324 (72%) were subsequently treated with systemic therapy. The 
majority of these patients were treated with targeted agents (Table 3). 
 
Table 3. Treatment details of all biopsied patients. 
Details Subjects  
N=450 
Treatment 
Classical chemotherapy 
Phase I drug(s) 
Everolimus 
VEGF TKI (sunitinib / sorafenib / pazopanib) 
Monoclonal antibody 
Vemurafenib 
Anti-hormonal therapy  
Other TKI 
No treatment started 
 
83  (18%) 
76  (17%) 
51  (11%) 
37  (8%) 
26  (6%) 
23  (5%) 
16  (4%) 
12  (3%) 
126 (28%) 
Treatment duration (months) 
Observations  
Median (range)  
Median (IQR)  
 
Lost to follow up 
 
301 
1.91  (0.00-20.24) 
1.91  (0.92-3.88) 
 
23 
Response at first evaluation 
Complete response (CR) 
Partial response (PR) 
Stable disease (SD) 
Progressive disease (PD) 
Not evaluable 
Not done 
Lost to follow up 
 
1  (0%) 
39  (13%) 
129  (43%) 
110  (37%) 
2  (1%) 
12  (4%) 
8 (3%) 
Abbreviations: IQR, interquartile range; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial 
growth factor. 
 
Safety 
Adverse events occurred after 10 image-guided biopsy procedures (2.1%; Table 4). Four 
tients experienced grade 3 pain, one patient had grade 3 hypertension, and one patient 
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experienced grade 3 vasovagal reaction. Of the 41 patients who underwent percutaneous 
CT-guided lung biopsy, three patients (7.3%) suffered from pneumothorax, for which 
drainage was indicated (grade 3 in two patients and grade 2 in one patient). Grade 2 
pleural hemorrhage was observed once after a CT-guided liver biopsy of a metastatic 
lesion that was situated directly subdiaphragmatic. In this case, drainage was required, but 
treatment was not delayed. 
 
Table 4. Adverse events. 
Adverse event Grade  Related to 
biopsy 
Biopsied organ Duration of  
hospitalization 
Pain 3 Definite Abdomen (US-guided) NA 
Pain 3 Definite Liver (US-guided) Hours* 
Pain 3 Definite Para-vertebral mass 
(US-guided) 
NA 
Pain 3 Possible Liver (US-guided) Days 
Vasovagal reaction 3 Definite Liver (US-guided) NA 
Hypertension 3 Possible Abdomen (US-guided) Hours* 
Pneumothorax 3 Definite Lung (CT-guided) Days 
Pneumothorax 3 Definite Lung (CT-guided) Days 
Pneumothorax  2 Definite Lung (CT-guided) Days 
Pleural hemorrhage 2 Definite Liver (CT-guided) Days 
Abbreviations: CT, computed tomography; NA, not applicable; US, ultrasonography. 
*Two patients were admitted to the hospital for several hours after the biopsy procedure and were 
discharged on the same day. 
 
 
Tumor Cells and DNA Yield 
From 20 patients who underwent image-guided biopsies, no samples were sent in for 
analysis, because all material was used for standard-of-care treatment. In 363 of the 
remaining 449 image-guided biopsy-retrieved specimens (81%), we found a tumor cell 
percentage of 30% or more. Of the 86 tumor specimens with an insufficient percentage of 
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tumor cells, 40 did not contain tumor cells at all. A sufficient amount of DNA (i.e., 500 ng 
or more) was obtained from 331 of the 363 biopsy specimens containing ≥30% tumor 
cells. From 14 of these specimens, DNA had to be isolated a second time to retrieve the 
required amount of DNA. These 331 specimens (74% of the 449 image-guided biopsy-
retrieved specimens received at the central core facility) met our preset criteria to 
perform DNA sequencing. For all three centers individually, the proportion of samples that 
met the criteria was 70% or higher and did not differ significantly between the centers (p = 
.77; Chi-square test). 
 
DNA Sequencing 
At data cut-off for this analysis, the sequencing results from 73 biopsied specimens were 
available. DNA data could be retrieved from all specimens. On SOLiD (n554) we sequenced 
samples for the 1,977-gene panel until a minimum mean coverage of 1503 was reached 
(mean of 1853). For exome analysis on Illumina (n519) we sequenced reference samples 
at least ∼753 (mean of 953) and tumor ∼1503 (mean of 1853). The most frequently 
mutated genes were TP53, APC, and BRAF (Table 5). 
 
DISCUSSION 
With these results we have shown that it is feasible to set up large, multicenter logistics to 
biobank image-guided retrieved tumor biopsies. In several other retrospective studies, it 
has been shown that research-related biopsies are safe and feasible.25–28 Description of 
large biopsy series have generally reported on comparable frequencies of major 
complications.29–31 The incidence of pneumothorax requiring drainage after percutaneous 
lung biopsies (3 out of 41 biopsied patients) was similar to that described by El-Osta et 
al.32 (2 out of 42). Importantly, the additional value of our series is that we have also 
shown that it is feasible to extract sufficient DNA from the majority of the biopsy 
specimens to perform analyses such as NGS. Moreover, because all samples are processed 
at a central location within the CPCT, uniformity of the analyses is ensured. We could 
retrieve sufficient DNA for NGS from 74% of the image-guided retrieved biopsy specimens. 
Although this may be too low for a regular diagnostic test, we feel this hit rate justifies 
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tumor cells, 40 did not contain tumor cells at all. A sufficient amount of DNA (i.e., 500 ng 
or more) was obtained from 331 of the 363 biopsy specimens containing ≥30% tumor 
cells. From 14 of these specimens, DNA had to be isolated a second time to retrieve the 
required amount of DNA. These 331 specimens (74% of the 449 image-guided biopsy-
retrieved specimens received at the central core facility) met our preset criteria to 
perform DNA sequencing. For all three centers individually, the proportion of samples that 
met the criteria was 70% or higher and did not differ significantly between the centers (p = 
.77; Chi-square test). 
 
DNA Sequencing 
At data cut-off for this analysis, the sequencing results from 73 biopsied specimens were 
available. DNA data could be retrieved from all specimens. On SOLiD (n554) we sequenced 
samples for the 1,977-gene panel until a minimum mean coverage of 1503 was reached 
(mean of 1853). For exome analysis on Illumina (n519) we sequenced reference samples 
at least ∼753 (mean of 953) and tumor ∼1503 (mean of 1853). The most frequently 
mutated genes were TP53, APC, and BRAF (Table 5). 
 
DISCUSSION 
With these results we have shown that it is feasible to set up large, multicenter logistics to 
biobank image-guided retrieved tumor biopsies. In several other retrospective studies, it 
has been shown that research-related biopsies are safe and feasible.25–28 Description of 
large biopsy series have generally reported on comparable frequencies of major 
complications.29–31 The incidence of pneumothorax requiring drainage after percutaneous 
lung biopsies (3 out of 41 biopsied patients) was similar to that described by El-Osta et 
al.32 (2 out of 42). Importantly, the additional value of our series is that we have also 
shown that it is feasible to extract sufficient DNA from the majority of the biopsy 
specimens to perform analyses such as NGS. Moreover, because all samples are processed 
at a central location within the CPCT, uniformity of the analyses is ensured. We could 
retrieve sufficient DNA for NGS from 74% of the image-guided retrieved biopsy specimens. 
Although this may be too low for a regular diagnostic test, we feel this hit rate justifies 
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systematic tissue collection in this manner, because similar proportions have been 
reported in other series26 and because this hit rate is therefore likely to represent the true 
potential of image-guided tumor biopsies. For the specimens that did not meet the criteria 
for DNA sequencing, we found that 86 of the 118 specimens contained less than 30% 
tumor cells. Retrospectively, we cannot discern whether this low tumor cell percentage is 
due to issues with the biopsy procedure or due to intratumoral aspects, such as 
heterogeneity. As sequencing techniques advance, specimens with lower tumor cell 
percentage can probably be sequenced in the future, but especially in these specimens it 
will remain challenging to determine the clinical relevance of infrequent aberrations. The 
DNA sequencing data for the first 73 biopsy specimens are largely concordant with the 
results from the Cancer Genome Atlas (TCGA).33 Alterations in TP53, APC, KRAS, and 
PIK3CA were among the most frequently found genomic aberrations across all tumor 
types. The higher incidence of PTEN and VHL in the TCGA set and of BRAF in our set is 
likely to be caused by the difference in tumor types between the two sets: The TCGA set 
contains glioblastoma multiforme samples and many samples, relatively, from 
gynecological and kidney cancers, whereas our set contains a large number of melanoma 
samples. By sequencing germline DNA as a reference for the intratumoral findings, we 
were bound to detect hereditary mutations, as had been foretold almost a decade ago.34 
The way these findings have been handled in our consortium has been published 
separately.35 By establishing a multi-institutional pipeline for large-scale collection of fresh 
frozen tumor material, we have shown that it is possible for consortia to prospectively 
collect high-quality fresh frozen tumor tissue. In our collaboration, we have set up a 
unique framework in which tumor biopsies are obtained prior to standard-of-care 
systemic treatment and in which these biopsies are stored in a way that enables us to 
perform not only NGS, but also many other analyses on RNA, protein, epigenetic 
processes, or even metabolite concentrations if sufficient tissue remains. Because the 
biopsy specimens are obtained just before the start of the treatment, we are able to 
capture the most accurate status of genetic and metabolic processes within a tumor. The 
process of obtaining fresh frozen samples is seemingly simple but requires significant 
investment when introduced into the clinical setting. The effort we describe is meaningful 
if intended to serve as a discovery tool. Although many groups have shown that NGS and 
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other molecular techniques such as RNA sequencing are possible from formalin-fixed, paraffin-
embedded (FFPE) tissue samples,36 there are still discordances between RNA sequencing 
results from FFPE and fresh frozen tissue,37 and our experience is that NGS results from fresh 
frozen tissue are more consistent. However, the logistical process needed to implement our 
protocol in itself represents added value for discovery purposes and large-scale biobanking.  
 Patient accrual is one of the major issues in gathering biopsies in the context of a 
clinical study in which there is no direct benefit for an individual patient. Both the willingness 
of patients and the reluctance of the treating physician to ask their patients for research 
biopsies play a role here. This is a common phenomenon in the process of acquiring research 
biopsies and has recently been described elsewhere.38 Consequently, many of the early-phase 
clinical trials that include mandatory biopsies fail to report on biomarker analysis.39,40 Despite 
the scarcity of adequately collected tumor material, many tumor biopsies are still collected in 
small initiatives or by industry studies, looking predominantly at only RAS, RAF, or the ERBB 
family.41 An alternative would be to identify predictive markers in preclinical model systems, 
but here the major discrepancies between pharmacologic drug responses for identical cell lines 
in the two largest pharmacogenomics cell line studies suggest that preclinical studies often lack 
predictive power.42 Thus, current and future clinical research should be aimed at collecting 
tumor tissue and at correlating molecular data to clinical outcome to identify true predictive 
biomarkers. In this study we have shown that it is feasible to perform next-generation 
sequencing on fresh frozen biopsies for biomarker discovery in a multi-institutional setting. 
Additionally, we have confirmed that acquiring fresh frozen tumor biopsies under image 
guidance is safe in advanced cancer patients. 
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systematic tissue collection in this manner, because similar proportions have been 
reported in other series26 and because this hit rate is therefore likely to represent the true 
potential of image-guided tumor biopsies. For the specimens that did not meet the criteria 
for DNA sequencing, we found that 86 of the 118 specimens contained less than 30% 
tumor cells. Retrospectively, we cannot discern whether this low tumor cell percentage is 
due to issues with the biopsy procedure or due to intratumoral aspects, such as 
heterogeneity. As sequencing techniques advance, specimens with lower tumor cell 
percentage can probably be sequenced in the future, but especially in these specimens it 
will remain challenging to determine the clinical relevance of infrequent aberrations. The 
DNA sequencing data for the first 73 biopsy specimens are largely concordant with the 
results from the Cancer Genome Atlas (TCGA).33 Alterations in TP53, APC, KRAS, and 
PIK3CA were among the most frequently found genomic aberrations across all tumor 
types. The higher incidence of PTEN and VHL in the TCGA set and of BRAF in our set is 
likely to be caused by the difference in tumor types between the two sets: The TCGA set 
contains glioblastoma multiforme samples and many samples, relatively, from 
gynecological and kidney cancers, whereas our set contains a large number of melanoma 
samples. By sequencing germline DNA as a reference for the intratumoral findings, we 
were bound to detect hereditary mutations, as had been foretold almost a decade ago.34 
The way these findings have been handled in our consortium has been published 
separately.35 By establishing a multi-institutional pipeline for large-scale collection of fresh 
frozen tumor material, we have shown that it is possible for consortia to prospectively 
collect high-quality fresh frozen tumor tissue. In our collaboration, we have set up a 
unique framework in which tumor biopsies are obtained prior to standard-of-care 
systemic treatment and in which these biopsies are stored in a way that enables us to 
perform not only NGS, but also many other analyses on RNA, protein, epigenetic 
processes, or even metabolite concentrations if sufficient tissue remains. Because the 
biopsy specimens are obtained just before the start of the treatment, we are able to 
capture the most accurate status of genetic and metabolic processes within a tumor. The 
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investment when introduced into the clinical setting. The effort we describe is meaningful 
if intended to serve as a discovery tool. Although many groups have shown that NGS and 
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other molecular techniques such as RNA sequencing are possible from formalin-fixed, paraffin-
embedded (FFPE) tissue samples,36 there are still discordances between RNA sequencing 
results from FFPE and fresh frozen tissue,37 and our experience is that NGS results from fresh 
frozen tissue are more consistent. However, the logistical process needed to implement our 
protocol in itself represents added value for discovery purposes and large-scale biobanking.  
 Patient accrual is one of the major issues in gathering biopsies in the context of a 
clinical study in which there is no direct benefit for an individual patient. Both the willingness 
of patients and the reluctance of the treating physician to ask their patients for research 
biopsies play a role here. This is a common phenomenon in the process of acquiring research 
biopsies and has recently been described elsewhere.38 Consequently, many of the early-phase 
clinical trials that include mandatory biopsies fail to report on biomarker analysis.39,40 Despite 
the scarcity of adequately collected tumor material, many tumor biopsies are still collected in 
small initiatives or by industry studies, looking predominantly at only RAS, RAF, or the ERBB 
family.41 An alternative would be to identify predictive markers in preclinical model systems, 
but here the major discrepancies between pharmacologic drug responses for identical cell lines 
in the two largest pharmacogenomics cell line studies suggest that preclinical studies often lack 
predictive power.42 Thus, current and future clinical research should be aimed at collecting 
tumor tissue and at correlating molecular data to clinical outcome to identify true predictive 
biomarkers. In this study we have shown that it is feasible to perform next-generation 
sequencing on fresh frozen biopsies for biomarker discovery in a multi-institutional setting. 
Additionally, we have confirmed that acquiring fresh frozen tumor biopsies under image 
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Supplementary Table S1. SureSelect design CPCT capture kit > 1977 genes (update 
september 2011). 
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ADCK2 
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AKAP4 
AKT1 
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AKT3 
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ALKBH2 
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BIRC3 
BIRC5 
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BLM 
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BMP15 
BMP2 
BMP2K 
BMP4 
BMP5 
BMP6 
BMP7 
BMP8A 
BMP8B 
BMPR1A 
BMPR1B 
BMPR2 
BMX 
BOC 
BRAF 
BRCA1 
BRCA2 
BRD2 
BRD3 
BRD4 
BRDT 
BRIP1 
BRSK1 
BRSK2 
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BTK 
BTRC 
BUB1 
BUB1B 
BUB3 
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C13orf34 
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C16orf53 
C17orf106 
C8ORF4 
C9orf100 
C9orf96 
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CAB39L 
CABC1 
CACYBP 
CAD 
CALM1 
CALM2 
CALM3 
CALML3 
CALML5 
CALML6 
CAMK1 
CAMK1D 
CAMK1G 
CAMK2A 
CAMK2B 
CAMK2D 
CAMK2G 
CAMK4 
CAMKK1 
CAMKK2 
CAMKV 
CAMP 
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CAPN1 
CAPN2 
CARD9 
CARM1 
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CASP1 
CASP10 
CASP2 
CASP3 
CASP4 
CASP5 
CASP6 
CASP7 
CASP8 
CASP9 
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CBLB 
CBLC 
CCBE1 
CCDC6 
CCDC99 
CCNA1 
CCNA2 
CCNB1 
CCNB2 
CCNB3 
CCND1 
CCND2 
CCND3 
CCNE1 
CCNE2 
CCNG1 
CCNG2 
CCNH 
CCR3 
CCR7 
CCRK 
CD109 
CD14 
CD248 
CD40 
CD47 
CD82 
CDC14A 
CDC14B 
CDC16 
CDC20 
CDC23 
CDC25A 
CDC25B 
CDC25C 
CDC26 
CDC27 
CDC2L5 
CDC2L6 
CDC42 
CDC42BPA 
CDC42BPB 
CDC42BPG 
CDC45L 
CDC6 
CDC7 
CDC73 
CDCA8 
CDH1 
CDH20 
CDH3 
CDK1 
CDK10 
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CDK11A 
CDK17 
CDK2 
CDK4 
CDK5 
CDK6 
CDK7 
CDK8 
CDK9 
CDKL1 
CDKL2 
CDKL3 
CDKL4 
CDKL5 
CDKN1A 
CDKN1B 
CDKN1C 
CDKN2A 
CDKN2B 
CDKN2C 
CDKN2D 
CDON 
CDT1 
CEBPA 
CENPA 
CENPE 
CEP290 
CER1 
CERK 
CFL2 
CFLAR 
CHD3 
CHD5 
CHD8 
CHEK1 
CHEK2 
CHIC2 
CHL1 
CHRD 
CHRM1 
CHUK 
CIB2 
CIC 
CIR1 
CIT 
CITED1 
CKS1B 
CLDN1 
CLIP1 
CLK1 
CLK2 
CLK3 
CLK4 
CLSPN 
CLSTN1 
CLTC 
CLUAP1 
CNKSR1 
CNKSR2 
CNTN4 
CNTN6 
COL14A1 
COL1A1 
COL4A1 
COL4A2 
COL4A4 
COL4A6 
COMP 
COX7A2L 
CREB1 
CREB3L2 
CREBBP 
CRK 
CRKL 
CRKRS 
CRLF2 
CSF1 
CSF1R 
CSF2RA 
CSF2RB 
CSF3R 
CSK 
CSMD1 
CSMD3 
CSNK1A1 
CSNK1A1L 
CSNK1D 
CSNK1E 
CSNK1G1 
CSNK1G2 
CSNK1G3 
CSNK2A1 
CSNK2A2 
CSNK2B 
CTBP1 
CTBP2 
CTNNA1 
CTNNA2 
CTNNA3 
CTNNB1 
CTNNBIP1 
CUBN 
CUL1 
CUL2 
CXCL12 
CXCR4 
CXCR7 
CXXC4 
CYCS 
CYLD 
CYS1 
DAAM1 
DAAM2 
DAPK1 
DAPK2 
DAPK3 
DARC 
DAXX 
DBF4 
DCC 
DCLK1 
DCLK2 
DCLK3 
DCN 
DDB2 
DDIT3 
DDIT4 
DDR1 
DDR1 
DDR2 
DDX23 
DFFA 
DFFB 
DGKA 
DGKB 
DGKD 
DGKE 
DGKG 
DGKH 
DGKI 
DGKQ 
DGKZ 
DHH 
DIABLO 
DIP2C 
DKK1 
DKK2 
DKK3 
DKK4 
DLK1 
DLL1 
DLL3 
DLL4 
DMAP1 
DMPK 
DNAH11 
DNAH5 
DNAH9 
DNAI1 
DNLZ 
DOT1L 
DPP3 
DPP4 
DSCAML1 
DSTYK 
DTX1 
DTX2 
DTX3 
DTX3L 
DTX4 
DUSP1 
DUSP10 
DUSP14 
DUSP16 
DUSP2 
DUSP3 
DUSP4 
DUSP5 
DUSP6 
DUSP7 
DUSP8 
DUSP9 
DVL1 
DVL2 
DVL3 
DYRK1A 
DYRK1B 
DYRK2 
DYRK3 
DYRK4 
E2F1 
E2F2 
E2F3 
E2F4 
E2F5 
E2F6 
E2F7 
E2F8 
E4F1 
ECSIT 
EDA 
EEF2K 
EFNB1 
EFNB2 
EGF 
EGFL6 
EGFR 
EGLN1 
EGLN2 
EGLN3 
EGR1 
EHMT1 
EHMT2 
EI24 
EIF2AK1 
EIF2AK2 
EIF2AK3 
EIF2AK4 
EIF2B5 
EIF3J 
EIF4A2 
EIF4B 
EIF4E 
EIF4E1B 
EIF4E2 
EIF4EBP1 
ELF3 
ELF4 
ELK1 
ELK3 
ELK4 
EML4 
ENDOD1 
ENDOG 
EP300 
EPAS1 
EPCAM 
EPHA1 
EPHA10 
EPHA2 
EPHA3 
EPHA4 
EPHA5 
EPHA6 
EPHA7 
EPHA8 
EPHB1 
EPHB2 
EPHB3 
EPHB4 
EPHB6 
EPS8 
ERBB2 
ERBB3 
ERBB4 
ERC2 
ERCC1 
ERCC2 
ERCC3 
ERCC4 
ERCC5 
ERCC6 
ERCC6L 
EREG 
ERGIC3 
ERN1 
ERN2 
ERO1L 
ESCO2 
ESPL1 
ESR1 
ETFA 
ETS1 
EVL 
EWSR1 
EXO1 
EXOC4 
EXOC7 
EXOG 
EXT1 
EXT2 
EYA4 
EZH1 
EZH2 
FADD 
FAM123B 
FAM20C 
FANCA 
FANCC 
FANCD2 
FANCE 
FANCF 
FANCG 
FARP1 
FARP2 
FAS 
FASLG 
FASN 
FASTK 
FAT3 
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Supplementary Table S1. SureSelect design CPCT capture kit > 1977 genes (update 
september 2011). 
AAK1 
AATK 
ABCA1 
ABL1 
ABL2 
AC005726.6 
AC005756.1 
AC008735.15 
AC012652.1 
AC013461.1 
AC021106.1 
AC068353.1 
AC107883.1 
AC113191.2 
AC114947.1 
AC130454.2 
ACTR2 
ACVR1 
ACVR1B 
ACVR1C 
ACVR2A 
ACVR2B 
ACVRL1 
AD000671.3 
ADAM17 
ADAM29 
ADAMTS15 
ADAMTS18 
ADAMTSL3 
ADCK1 
ADCK2 
ADCK4 
ADCK5 
ADORA1 
ADRBK1 
ADRBK2 
AGK 
AIFM1 
AIFM2 
AIM1 
AIMP2 
AIP 
AKAP4 
AKT1 
AKT1S1 
AKT2 
AKT3 
AL117209.2 
ALK 
ALKBH1 
ALKBH2 
ALKBH3 
ALMS1 
ALPK1 
ALPK2 
ALPK3 
AMH 
AMHR2 
ANAPC1 
ANAPC10 
ANAPC11 
ANAPC13 
ANAPC2 
ANAPC4 
ANAPC5 
ANAPC7 
ANGPTL4 
ANK1 
ANK2 
ANKK1 
ANKRD29 
AP000654.1 
AP003355.2 
APAF1 
APC 
APC2 
APH1A 
APPL1 
AR 
ARAF 
AREG 
AREGB 
ARFRP1 
ARID1A 
ARIH2 
ARL13B 
ARL4C 
ARL6 
ARNT 
ARNT2 
ARPC3 
ARPC4 
ARPC5 
ARRB1 
ARRB2 
ASAP1 
ASCC1 
ASH1L 
ASH2L 
ASPSCR1 
ASXL1 
ATF1 
ATF2 
ATF4 
ATM 
ATP5S 
ATP8B1 
ATR 
ATRX 
AURKA 
AURKB 
AURKC 
AXIN1 
AXIN2 
AXL 
B9D1 
BACH1 
BAD 
BAG2 
BAI1 
BAI3 
BAIAP2 
BAP1 
BARD1 
BAX 
BBC3 
BBS2 
BBS4 
BBS5 
BBS7 
BBS9 
BCKDK 
BCL2 
BCL2L1 
BCL2L11 
BCL2L14 
BCL2L2 
BCL6 
BCL9 
BCR 
BDNF 
BID 
BIRC2 
BIRC3 
BIRC5 
BLK 
BLM 
BMP1 
BMP10 
BMP15 
BMP2 
BMP2K 
BMP4 
BMP5 
BMP6 
BMP7 
BMP8A 
BMP8B 
BMPR1A 
BMPR1B 
BMPR2 
BMX 
BOC 
BRAF 
BRCA1 
BRCA2 
BRD2 
BRD3 
BRD4 
BRDT 
BRIP1 
BRSK1 
BRSK2 
BTC 
BTK 
BTRC 
BUB1 
BUB1B 
BUB3 
C10orf104 
C10orf137 
C13orf34 
C14orf153 
C16orf53 
C17orf106 
C8ORF4 
C9orf100 
C9orf96 
CAB39 
CAB39L 
CABC1 
CACYBP 
CAD 
CALM1 
CALM2 
CALM3 
CALML3 
CALML5 
CALML6 
CAMK1 
CAMK1D 
CAMK1G 
CAMK2A 
CAMK2B 
CAMK2D 
CAMK2G 
CAMK4 
CAMKK1 
CAMKK2 
CAMKV 
CAMP 
CAPG 
CAPN1 
CAPN2 
CARD9 
CARM1 
CARS 
CASK 
CASP1 
CASP10 
CASP2 
CASP3 
CASP4 
CASP5 
CASP6 
CASP7 
CASP8 
CASP9 
CBL 
CBLB 
CBLC 
CCBE1 
CCDC6 
CCDC99 
CCNA1 
CCNA2 
CCNB1 
CCNB2 
CCNB3 
CCND1 
CCND2 
CCND3 
CCNE1 
CCNE2 
CCNG1 
CCNG2 
CCNH 
CCR3 
CCR7 
CCRK 
CD109 
CD14 
CD248 
CD40 
CD47 
CD82 
CDC14A 
CDC14B 
CDC16 
CDC20 
CDC23 
CDC25A 
CDC25B 
CDC25C 
CDC26 
CDC27 
CDC2L5 
CDC2L6 
CDC42 
CDC42BPA 
CDC42BPB 
CDC42BPG 
CDC45L 
CDC6 
CDC7 
CDC73 
CDCA8 
CDH1 
CDH20 
CDH3 
CDK1 
CDK10 
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CDK11A 
CDK17 
CDK2 
CDK4 
CDK5 
CDK6 
CDK7 
CDK8 
CDK9 
CDKL1 
CDKL2 
CDKL3 
CDKL4 
CDKL5 
CDKN1A 
CDKN1B 
CDKN1C 
CDKN2A 
CDKN2B 
CDKN2C 
CDKN2D 
CDON 
CDT1 
CEBPA 
CENPA 
CENPE 
CEP290 
CER1 
CERK 
CFL2 
CFLAR 
CHD3 
CHD5 
CHD8 
CHEK1 
CHEK2 
CHIC2 
CHL1 
CHRD 
CHRM1 
CHUK 
CIB2 
CIC 
CIR1 
CIT 
CITED1 
CKS1B 
CLDN1 
CLIP1 
CLK1 
CLK2 
CLK3 
CLK4 
CLSPN 
CLSTN1 
CLTC 
CLUAP1 
CNKSR1 
CNKSR2 
CNTN4 
CNTN6 
COL14A1 
COL1A1 
COL4A1 
COL4A2 
COL4A4 
COL4A6 
COMP 
COX7A2L 
CREB1 
CREB3L2 
CREBBP 
CRK 
CRKL 
CRKRS 
CRLF2 
CSF1 
CSF1R 
CSF2RA 
CSF2RB 
CSF3R 
CSK 
CSMD1 
CSMD3 
CSNK1A1 
CSNK1A1L 
CSNK1D 
CSNK1E 
CSNK1G1 
CSNK1G2 
CSNK1G3 
CSNK2A1 
CSNK2A2 
CSNK2B 
CTBP1 
CTBP2 
CTNNA1 
CTNNA2 
CTNNA3 
CTNNB1 
CTNNBIP1 
CUBN 
CUL1 
CUL2 
CXCL12 
CXCR4 
CXCR7 
CXXC4 
CYCS 
CYLD 
CYS1 
DAAM1 
DAAM2 
DAPK1 
DAPK2 
DAPK3 
DARC 
DAXX 
DBF4 
DCC 
DCLK1 
DCLK2 
DCLK3 
DCN 
DDB2 
DDIT3 
DDIT4 
DDR1 
DDR1 
DDR2 
DDX23 
DFFA 
DFFB 
DGKA 
DGKB 
DGKD 
DGKE 
DGKG 
DGKH 
DGKI 
DGKQ 
DGKZ 
DHH 
DIABLO 
DIP2C 
DKK1 
DKK2 
DKK3 
DKK4 
DLK1 
DLL1 
DLL3 
DLL4 
DMAP1 
DMPK 
DNAH11 
DNAH5 
DNAH9 
DNAI1 
DNLZ 
DOT1L 
DPP3 
DPP4 
DSCAML1 
DSTYK 
DTX1 
DTX2 
DTX3 
DTX3L 
DTX4 
DUSP1 
DUSP10 
DUSP14 
DUSP16 
DUSP2 
DUSP3 
DUSP4 
DUSP5 
DUSP6 
DUSP7 
DUSP8 
DUSP9 
DVL1 
DVL2 
DVL3 
DYRK1A 
DYRK1B 
DYRK2 
DYRK3 
DYRK4 
E2F1 
E2F2 
E2F3 
E2F4 
E2F5 
E2F6 
E2F7 
E2F8 
E4F1 
ECSIT 
EDA 
EEF2K 
EFNB1 
EFNB2 
EGF 
EGFL6 
EGFR 
EGLN1 
EGLN2 
EGLN3 
EGR1 
EHMT1 
EHMT2 
EI24 
EIF2AK1 
EIF2AK2 
EIF2AK3 
EIF2AK4 
EIF2B5 
EIF3J 
EIF4A2 
EIF4B 
EIF4E 
EIF4E1B 
EIF4E2 
EIF4EBP1 
ELF3 
ELF4 
ELK1 
ELK3 
ELK4 
EML4 
ENDOD1 
ENDOG 
EP300 
EPAS1 
EPCAM 
EPHA1 
EPHA10 
EPHA2 
EPHA3 
EPHA4 
EPHA5 
EPHA6 
EPHA7 
EPHA8 
EPHB1 
EPHB2 
EPHB3 
EPHB4 
EPHB6 
EPS8 
ERBB2 
ERBB3 
ERBB4 
ERC2 
ERCC1 
ERCC2 
ERCC3 
ERCC4 
ERCC5 
ERCC6 
ERCC6L 
EREG 
ERGIC3 
ERN1 
ERN2 
ERO1L 
ESCO2 
ESPL1 
ESR1 
ETFA 
ETS1 
EVL 
EWSR1 
EXO1 
EXOC4 
EXOC7 
EXOG 
EXT1 
EXT2 
EYA4 
EZH1 
EZH2 
FADD 
FAM123B 
FAM20C 
FANCA 
FANCC 
FANCD2 
FANCE 
FANCF 
FANCG 
FARP1 
FARP2 
FAS 
FASLG 
FASN 
FASTK 
FAT3 
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FBXL14 
FBXW11 
FBXW7 
FER 
FES 
FGF1 
FGF10 
FGF11 
FGF12 
FGF13 
FGF14 
FGF16 
FGF17 
FGF18 
FGF19 
FGF2 
FGF20 
FGF21 
FGF22 
FGF23 
FGF3 
FGF4 
FGF5 
FGF6 
FGF7 
FGF8 
FGF9 
FGFR1 
FGFR2 
FGFR3 
FGFR4 
FGR 
FH 
FIGF 
FKBP1A 
FLCN 
FLNA 
FLNB 
FLNC 
FLOT1 
FLOT2 
FLT1 
FLT3 
FLT3LG 
FLT4 
FN1 
FOS 
FOSL1 
FOXC1 
FOXC2 
FOXL2 
FOXM1 
FOXO1 
FOXO3 
FOXO4 
FRAT1 
FRAT2 
FRK 
FRZB 
FST 
FTO 
FYB 
FYN 
FZD1 
FZD10 
FZD2 
FZD3 
FZD4 
FZD5 
FZD6 
FZD7 
FZD8 
FZD9 
FZR1 
GAB1 
GABRA6 
GADD45A 
GADD45B 
GADD45G 
GAK 
GALNS 
GAS1 
GATA1 
GATA2 
GATA3 
GCK 
GDF5 
GDF6 
GDF7 
GDNF 
GLI1 
GLI2 
GLI3 
GMNN 
GMPS 
GNA12 
GNAQ 
GNAS 
GNG12 
GPR141 
GRAP2 
GRB10 
GRB2 
GRK1 
GRK4 
GRK5 
GRK6 
GRK7 
GSG2 
GSK3A 
GSK3B 
GSTP1 
GSX2 
GTSE1 
GUCY1A2 
GUCY2C 
GUCY2D 
GUCY2F 
GYS1 
GYS2 
H2AFX 
H2AFY2 
HABP4 
HAPLN1 
HAT1 
HAUS3 
HBEGF 
HBXIP 
HCK 
HDAC1 
HDAC10 
HDAC11 
HDAC2 
HDAC3 
HDAC4 
HDAC5 
HDAC6 
HDAC7 
HDAC8 
HDAC9 
HES1 
HES5 
HGF 
HHIP 
HIF1A 
HIF1AN 
HIF3A 
HIPK1 
HIPK2 
HIPK3 
HIPK4 
HIST1H1B 
HK1 
HK2 
HK3 
HNF1A 
HNF1B 
HNRNPH2 
HRAS 
HSF4 
HSP90AA1 
HSP90AB1 
HSP90B1 
HSPA1A 
HSPA1B 
HSPA1L 
HSPA2 
HSPA6 
HSPA8 
HSPB1 
HSPB8 
HUNK 
ICAM1 
ICAM2 
ICAM3 
ICAM4 
ICK 
ID1 
ID2 
ID3 
ID4 
IDH1 
IDH2 
IDUA 
IFNG 
IFT172 
IFT57 
IFT81 
IFT88 
IGF1 
IGF1R 
IGF2 
IGF2R 
IGFBP1 
IGFBP2 
IGFBP3 
IGFBP4 
IGFBP5 
IHH 
IKBKAP 
IKBKB 
IKBKE 
IKBKG 
IL12RB1 
IL18BP 
IL1R1 
IL1R2 
IL1RAP 
IL3RA 
IL6 
IL6ST 
IL8 
ILK 
INCENP 
INHBA 
INHBB 
INHBC 
INHBE 
INPP4A 
INPP5D 
INPP5K 
INPPL1 
INS 
INSR 
INSRR 
INVS 
IP6K1 
IP6K2 
IP6K3 
IPMK 
IPPK 
IQCB1 
IQGAP2 
IRAK1 
IRAK2 
IRAK3 
IRAK4 
IRF3 
IRS1 
IRS2 
IRS4 
ITCH 
ITGA2 
ITGA2B 
ITGA3 
ITGA6 
ITGAE 
ITGAV 
ITGB1 
ITK 
ITPK1 
ITPKA 
ITPKB 
ITPKC 
ITPR2 
JAG1 
JAG2 
JAK1 
JAK2 
JAK3 
JARID2 
JHDM1D 
JMJD1C 
JMJD4 
JMJD5 
JMJD6 
JMJD7-
PLA2G4B 
JMJD8 
JUN 
JUNB 
JUND 
JUP 
KALRN 
KAT2A 
KAT2B 
KAT5 
KCNE1 
KDM1A 
KDM1B 
KDM2A 
KDM2B 
KDM3A 
KDM3B 
KDM4A 
KDM4B 
KDM4C 
KDM4D 
KDM4DL 
KDM5A 
KDM5B 
KDM5C 
KDM5D 
KDM6A 
KDM6B 
KDR 
KIAA1468 
KIF11 
KIF15 
KIF1B 
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KIF2C 
KIF3A 
KIF3B 
KIFAP3 
KISS1 
KIT 
KITLG 
KLC3 
KLHL4 
KLK3 
KNTC1 
KRAS 
KREMEN1 
KREMEN2 
KRT20 
KRT71 
KRT73 
KRTCAP2 
KRTCAP3 
KSR1 
KSR2 
L3MBTL 
LAMA1 
LAMA2 
LAMA3 
LAMA4 
LAMA5 
LAMB1 
LAMB2 
LAMB3 
LAMB4 
LAMC1 
LAMC2 
LAMC3 
LATS1 
LATS2 
LCK 
LEF1 
LEFTY1 
LEFTY2 
LFNG 
LGR5 
LGR6 
LIMK1 
LIMK2 
LMTK2 
LMTK3 
LNX1 
LRDD 
LRP2 
LRP2BP 
LRP5 
LRP6 
LRRC50 
LRRC6 
LRRK1 
LRRK2 
LTBP1 
LTK 
LYN 
LZTS2 
MACC1 
MAD1L1 
MAD2L1 
MAD2L1BP 
MAD2L2 
MAK 
MAML1 
MAML2 
MAML3 
MAP2 
MAP2K1 
MAP2K2 
MAP2K3 
MAP2K4 
MAP2K5 
MAP2K6 
MAP2K7 
MAP3K1 
MAP3K10 
MAP3K11 
MAP3K12 
MAP3K13 
MAP3K14 
MAP3K15 
MAP3K2 
MAP3K3 
MAP3K4 
MAP3K5 
MAP3K6 
MAP3K7 
MAP3K7IP1 
MAP3K7IP2 
MAP3K8 
MAP3K9 
MAP4K1 
MAP4K2 
MAP4K3 
MAP4K4 
MAP4K5 
MAPK1 
MAPK10 
MAPK11 
MAPK12 
MAPK13 
MAPK14 
MAPK15 
MAPK3 
MAPK4 
MAPK6 
MAPK7 
MAPK8 
MAPK8IP1 
MAPK8IP2 
MAPK8IP3 
MAPK9 
MAPKAPK2 
MAPKAPK3 
MAPKAPK5 
MAPKSP1 
MAPRE1 
MAPRE3 
MAPT 
MARK1 
MARK2 
MARK3 
MARK4 
MAST1 
MAST2 
MAST3 
MAST4 
MASTL 
MATK 
MAX 
MBIP 
MCC 
MCF2L2 
MCL1 
MCM2 
MCM3 
MCM4 
MCM5 
MCM6 
MCM7 
MCM8 
MDM2 
MDM4 
MECOM 
MED12 
MED12L 
MEF2C 
MELK 
MEN1 
MERTK 
MET 
MFSD4 
MGMT 
MGST1 
MINK1 
MITF 
MKKS 
MKNK1 
MKNK2 
MKRN2 
MKS1 
MLH1 
MLH3 
MLKL 
MLL 
MLL2 
MLL3 
MLL5 
MLST8 
MMP1 
MMP2 
MMP7 
MMP9 
MOS 
MPL 
MRAS 
MRE11A 
MSH2 
MSH3 
MSH6 
MSN 
MST1 
MST1R 
MTAP 
MTOR 
MUC1 
MUSK 
MUTYH 
MVP 
MXD1 
MXI1 
MYC 
MYCBP2 
MYCL1 
MYCN 
MYCNOS 
MYD88 
MYLK 
MYLK2 
MYLK3 
MYLK4 
MYO18B 
MYO3A 
MYO3B 
MYST1 
MYST2 
MYST3 
MYST4 
MYT1 
NBN 
NCK1 
NCK2 
NCOA4 
NCOR1 
NCOR2 
NCSTN 
NDC80 
NDP 
NDUFV3 
NEDD9 
NEK1 
NEK10 
NEK11 
NEK2 
NEK3 
NEK4 
NEK5 
NEK6 
NEK7 
NEK8 
NEK9 
NF1 
NF2 
NFAT5 
NFATC1 
NFATC2 
NFATC3 
NFATC4 
NFKB1 
NFKB2 
NFKBIA 
NFKBIE 
NGF 
NKD1 
NKD2 
NKX2-1 
NKX3-1 
NLK 
NODAL 
NOG 
NOS2 
NOS3 
NOSIP 
NOSTRIN 
NOTCH1 
NOTCH2 
NOTCH2NL 
NOTCH3 
NOTCH4 
NPHP1 
NPHP3 
NPHP4 
NPM1 
NPR1 
NPR2 
NR4A1 
NRAS 
NRBP1 
NRBP2 
NRG1 
NRG2 
NRG3 
NRG4 
NRK 
NSD1 
NTF3 
NTF4 
NTHL1 
NTRK1 
NTRK2 
NTRK3 
NUAK1 
NUAK2 
NUF2 
NUMA1 
NUMB 
NUMBL 
NUP98 
OBSCN 
ODC1 
OFD1 
OGG1 
OPRM1 
ORC1L 
ORC2L 
ORC3L 
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FBXL14 
FBXW11 
FBXW7 
FER 
FES 
FGF1 
FGF10 
FGF11 
FGF12 
FGF13 
FGF14 
FGF16 
FGF17 
FGF18 
FGF19 
FGF2 
FGF20 
FGF21 
FGF22 
FGF23 
FGF3 
FGF4 
FGF5 
FGF6 
FGF7 
FGF8 
FGF9 
FGFR1 
FGFR2 
FGFR3 
FGFR4 
FGR 
FH 
FIGF 
FKBP1A 
FLCN 
FLNA 
FLNB 
FLNC 
FLOT1 
FLOT2 
FLT1 
FLT3 
FLT3LG 
FLT4 
FN1 
FOS 
FOSL1 
FOXC1 
FOXC2 
FOXL2 
FOXM1 
FOXO1 
FOXO3 
FOXO4 
FRAT1 
FRAT2 
FRK 
FRZB 
FST 
FTO 
FYB 
FYN 
FZD1 
FZD10 
FZD2 
FZD3 
FZD4 
FZD5 
FZD6 
FZD7 
FZD8 
FZD9 
FZR1 
GAB1 
GABRA6 
GADD45A 
GADD45B 
GADD45G 
GAK 
GALNS 
GAS1 
GATA1 
GATA2 
GATA3 
GCK 
GDF5 
GDF6 
GDF7 
GDNF 
GLI1 
GLI2 
GLI3 
GMNN 
GMPS 
GNA12 
GNAQ 
GNAS 
GNG12 
GPR141 
GRAP2 
GRB10 
GRB2 
GRK1 
GRK4 
GRK5 
GRK6 
GRK7 
GSG2 
GSK3A 
GSK3B 
GSTP1 
GSX2 
GTSE1 
GUCY1A2 
GUCY2C 
GUCY2D 
GUCY2F 
GYS1 
GYS2 
H2AFX 
H2AFY2 
HABP4 
HAPLN1 
HAT1 
HAUS3 
HBEGF 
HBXIP 
HCK 
HDAC1 
HDAC10 
HDAC11 
HDAC2 
HDAC3 
HDAC4 
HDAC5 
HDAC6 
HDAC7 
HDAC8 
HDAC9 
HES1 
HES5 
HGF 
HHIP 
HIF1A 
HIF1AN 
HIF3A 
HIPK1 
HIPK2 
HIPK3 
HIPK4 
HIST1H1B 
HK1 
HK2 
HK3 
HNF1A 
HNF1B 
HNRNPH2 
HRAS 
HSF4 
HSP90AA1 
HSP90AB1 
HSP90B1 
HSPA1A 
HSPA1B 
HSPA1L 
HSPA2 
HSPA6 
HSPA8 
HSPB1 
HSPB8 
HUNK 
ICAM1 
ICAM2 
ICAM3 
ICAM4 
ICK 
ID1 
ID2 
ID3 
ID4 
IDH1 
IDH2 
IDUA 
IFNG 
IFT172 
IFT57 
IFT81 
IFT88 
IGF1 
IGF1R 
IGF2 
IGF2R 
IGFBP1 
IGFBP2 
IGFBP3 
IGFBP4 
IGFBP5 
IHH 
IKBKAP 
IKBKB 
IKBKE 
IKBKG 
IL12RB1 
IL18BP 
IL1R1 
IL1R2 
IL1RAP 
IL3RA 
IL6 
IL6ST 
IL8 
ILK 
INCENP 
INHBA 
INHBB 
INHBC 
INHBE 
INPP4A 
INPP5D 
INPP5K 
INPPL1 
INS 
INSR 
INSRR 
INVS 
IP6K1 
IP6K2 
IP6K3 
IPMK 
IPPK 
IQCB1 
IQGAP2 
IRAK1 
IRAK2 
IRAK3 
IRAK4 
IRF3 
IRS1 
IRS2 
IRS4 
ITCH 
ITGA2 
ITGA2B 
ITGA3 
ITGA6 
ITGAE 
ITGAV 
ITGB1 
ITK 
ITPK1 
ITPKA 
ITPKB 
ITPKC 
ITPR2 
JAG1 
JAG2 
JAK1 
JAK2 
JAK3 
JARID2 
JHDM1D 
JMJD1C 
JMJD4 
JMJD5 
JMJD6 
JMJD7-
PLA2G4B 
JMJD8 
JUN 
JUNB 
JUND 
JUP 
KALRN 
KAT2A 
KAT2B 
KAT5 
KCNE1 
KDM1A 
KDM1B 
KDM2A 
KDM2B 
KDM3A 
KDM3B 
KDM4A 
KDM4B 
KDM4C 
KDM4D 
KDM4DL 
KDM5A 
KDM5B 
KDM5C 
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KDR 
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KIF15 
KIF1B 
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KIF2C 
KIF3A 
KIF3B 
KIFAP3 
KISS1 
KIT 
KITLG 
KLC3 
KLHL4 
KLK3 
KNTC1 
KRAS 
KREMEN1 
KREMEN2 
KRT20 
KRT71 
KRT73 
KRTCAP2 
KRTCAP3 
KSR1 
KSR2 
L3MBTL 
LAMA1 
LAMA2 
LAMA3 
LAMA4 
LAMA5 
LAMB1 
LAMB2 
LAMB3 
LAMB4 
LAMC1 
LAMC2 
LAMC3 
LATS1 
LATS2 
LCK 
LEF1 
LEFTY1 
LEFTY2 
LFNG 
LGR5 
LGR6 
LIMK1 
LIMK2 
LMTK2 
LMTK3 
LNX1 
LRDD 
LRP2 
LRP2BP 
LRP5 
LRP6 
LRRC50 
LRRC6 
LRRK1 
LRRK2 
LTBP1 
LTK 
LYN 
LZTS2 
MACC1 
MAD1L1 
MAD2L1 
MAD2L1BP 
MAD2L2 
MAK 
MAML1 
MAML2 
MAML3 
MAP2 
MAP2K1 
MAP2K2 
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MAP3K11 
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MAP3K14 
MAP3K15 
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MAP3K4 
MAP3K5 
MAP3K6 
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MAPK8 
MAPK8IP1 
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MAPK9 
MAPKAPK2 
MAPKAPK3 
MAPKAPK5 
MAPKSP1 
MAPRE1 
MAPRE3 
MAPT 
MARK1 
MARK2 
MARK3 
MARK4 
MAST1 
MAST2 
MAST3 
MAST4 
MASTL 
MATK 
MAX 
MBIP 
MCC 
MCF2L2 
MCL1 
MCM2 
MCM3 
MCM4 
MCM5 
MCM6 
MCM7 
MCM8 
MDM2 
MDM4 
MECOM 
MED12 
MED12L 
MEF2C 
MELK 
MEN1 
MERTK 
MET 
MFSD4 
MGMT 
MGST1 
MINK1 
MITF 
MKKS 
MKNK1 
MKNK2 
MKRN2 
MKS1 
MLH1 
MLH3 
MLKL 
MLL 
MLL2 
MLL3 
MLL5 
MLST8 
MMP1 
MMP2 
MMP7 
MMP9 
MOS 
MPL 
MRAS 
MRE11A 
MSH2 
MSH3 
MSH6 
MSN 
MST1 
MST1R 
MTAP 
MTOR 
MUC1 
MUSK 
MUTYH 
MVP 
MXD1 
MXI1 
MYC 
MYCBP2 
MYCL1 
MYCN 
MYCNOS 
MYD88 
MYLK 
MYLK2 
MYLK3 
MYLK4 
MYO18B 
MYO3A 
MYO3B 
MYST1 
MYST2 
MYST3 
MYST4 
MYT1 
NBN 
NCK1 
NCK2 
NCOA4 
NCOR1 
NCOR2 
NCSTN 
NDC80 
NDP 
NDUFV3 
NEDD9 
NEK1 
NEK10 
NEK11 
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NEK3 
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NEK5 
NEK6 
NEK7 
NEK8 
NEK9 
NF1 
NF2 
NFAT5 
NFATC1 
NFATC2 
NFATC3 
NFATC4 
NFKB1 
NFKB2 
NFKBIA 
NFKBIE 
NGF 
NKD1 
NKD2 
NKX2-1 
NKX3-1 
NLK 
NODAL 
NOG 
NOS2 
NOS3 
NOSIP 
NOSTRIN 
NOTCH1 
NOTCH2 
NOTCH2NL 
NOTCH3 
NOTCH4 
NPHP1 
NPHP3 
NPHP4 
NPM1 
NPR1 
NPR2 
NR4A1 
NRAS 
NRBP1 
NRBP2 
NRG1 
NRG2 
NRG3 
NRG4 
NRK 
NSD1 
NTF3 
NTF4 
NTHL1 
NTRK1 
NTRK2 
NTRK3 
NUAK1 
NUAK2 
NUF2 
NUMA1 
NUMB 
NUMBL 
NUP98 
OBSCN 
ODC1 
OFD1 
OGG1 
OPRM1 
ORC1L 
ORC2L 
ORC3L 
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ORC4L 
ORC5L 
ORC6L 
OSR1 
OXSR1 
P2RX7 
PAK1 
PAK2 
PAK3 
PAK4 
PAK6 
PAK7 
PALB2 
PAPD5 
PARD3 
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PARP11 
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PARP15 
PARP16 
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PASK 
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PBK 
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PCTK1 
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PDE3A 
PDE3B 
PDE4D 
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PDGFB 
PDGFRA 
PDGFRB 
PDGFRL 
PDIK1L 
PDK1 
PDK2 
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PDK4 
PDPK1 
PERP 
PFTK1 
PFTK2 
PGF 
PGPEP1 
PHF15 
PHF16 
PHF17 
PHF2 
PHF8 
PHIP 
PHKA1 
PHKA2 
PHKB 
PHKG1 
PHKG2 
PHLDB2 
PHOX2A 
PHOX2B 
PI4K2A 
PI4K2B 
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PI4KB 
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PIK3C2G 
PIK3C3 
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PIK3CB 
PIK3CD 
PIK3CG 
PIK3R1 
PIK3R2 
PIK3R3 
PIK3R4 
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PIK3R6 
PIKFYVE 
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PINK1 
PIP4K2C 
PIP5K1A 
PIP5K1B 
PIP5K1C 
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PIP5KL1 
PIPSL 
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PIWIL1 
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PKDCC 
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PKMYT1 
PKN1 
PKN2 
PKN3 
PKNOX1 
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PLCB1 
PLCB2 
PLCB3 
PLCB4 
PLCG1 
PLCG2 
PLCXD1 
PLCXD2 
PLCXD3 
PLCZ1 
PLD1 
PLD6 
PLK1 
PLK2 
PLK3 
PLK4 
PLXNB3 
PMAIP1 
PML 
PMS1 
PMS2 
PNCK 
POLS 
PORCN 
POU2F1 
PPA1 
PPA2 
PPARD 
PPARG 
PPARGC1A 
PPM1A 
PPM1B 
PPM1D 
PPP1CA 
PPP1CB 
PPP1CC 
PPP1R13B 
PPP1R3A 
PPP1R3B 
PPP1R3C 
PPP1R3D 
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PPP2CB 
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PPP2R5A 
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PPP2R5D 
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PPP3CA 
PPP3CB 
PPP3CC 
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PPP3R2 
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PRDM4 
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PRKACB 
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PRKAG2 
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PRKX 
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PROC 
PRPF4 
PRPF4B 
PSEN1 
PSEN2 
PSENEN 
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PSKH2 
PSMC4 
PSPH 
PTCH1 
PTCH2 
PTCRA 
PTEN 
PTGS2 
PTK2 
PTK2B 
PTK6 
PTK7 
PTN 
PTPN1 
PTPN11 
PTPN13 
PTPN14 
PTPN3 
PTPN5 
PTPN6 
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PTPRA 
PTPRD 
PTPRF 
PTPRG 
PTPRJ 
PTPRN2 
PTPRR 
PTPRS 
PTPRT 
PTPRU 
PTTG1 
PXK 
PXN 
PYGB 
PYGL 
PYGM 
PYGO1 
PYGO2 
RAB23 
RAC1 
RAC2 
RAC3 
RAD21 
RAD50 
RAD51 
RAD52 
RAD54L 
RAD9A 
RAD9B 
RAET1E 
RAET1L 
RAF1 
RAGE 
RALA 
RALB 
RALBP1 
RALGDS 
RANBP2 
RAP1A 
RAP1B 
RAP1GAP 
RAPGEF1 
RAPGEF2 
RAPGEF3 
RAPGEF4 
RARA 
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RASA1 
RASA2 
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RASGRF1 
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RASSF5 
RAVER2 
RAX2 
RB1 
RBBP4 
RBBP5 
RBBP8 
RBL1 
RBL2 
RBPJ 
RBPJL 
RBX1 
RCHY1 
REEP5 
REL 
RELA 
RELB 
RET 
RFC1 
RFC2 
RFC3 
RFC4 
RFC5 
RFNG 
RFWD2 
RFX2 
RHEB 
RHO 
RHOA 
RHOC 
RHOQ 
RICTOR 
RIOK1 
RIOK2 
RIOK3 
RIPK1 
RIPK2 
RIPK3 
RIPK4 
RMI1 
RNASEL 
RNF213 
RNF220 
ROCK1 
ROCK2 
ROR1 
ROR2 
ROS1 
RP11-
330H6.5 
RP11-
481A12.5 
RP5-862P8.2 
RPA1 
RPA2 
RPA3 
RPA4 
RPGR 
RPGRIP1 
RPGRIP1L 
RPRM 
RPS6 
RPS6KA1 
RPS6KA2 
RPS6KA3 
RPS6KA4 
RPS6KA5 
RPS6KA6 
RPS6KB1 
RPS6KB2 
RPS6KC1 
RPS6KL1 
RPTOR 
RRAS 
RRAS2 
RRM1 
RRM2 
RRM2B 
RSPO1 
RUNX1 
RUNX1T1 
RUVBL1 
RXRA 
RXRB 
RXRG 
RYK 
SBK1 
SBK2 
SCEL 
SCYL1 
SCYL2 
SCYL3 
SDCCAG1 
SDHB 
SDHD 
SEC31A 
SENP2 
SEPT9 
SERPINB5 
SERPINE1 
SESN1 
SESN2 
SESN3 
SETD1A 
SETD1B 
SETD2 
SETD3 
SETD4 
SETD5 
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SETD8 
SETDB1 
SETDB2 
SETMAR 
SFN 
SFRP1 
SFRP2 
SFRP4 
SFRP5 
SFRS6 
SGCB 
SGK1 
SGK2 
SGK3 
SGOL1 
SGOL2 
SH2B2 
SH2D2A 
SH2D7 
SHC1 
SHC2 
SHC3 
SHC4 
SHFM1 
SHH 
SHISA5 
SHOX 
SIAH1 
SIK1 
SIK2 
SIK3 
SIN3A 
SIN3B 
SIX4 
SKP1 
SKP2 
SLC26A1 
SLC29A1 
SLC2A1 
SLC2A4 
SLK 
SMAD1 
SMAD2 
SMAD3 
SMAD4 
SMAD5 
SMAD6 
SMAD7 
SMAD9 
SMARCA4 
SMARCB1 
SMARCD1 
SMARCE1 
SMC1A 
SMC1B 
SMC3 
SMG1 
SMO 
SMURF1 
SMURF2 
SMYD1 
SMYD2 
SMYD3 
SMYD4 
SMYD5 
SNAI1 
SNAI2 
SNRK 
SNTB1 
SNW1 
SNX25 
SNX4 
SOCS1 
SOCS2 
SOCS3 
SOCS4 
SORBS1 
SOS1 
SOS2 
SOST 
SOX17 
SP1 
SPAG5 
SPC24 
SPC25 
SPEG 
SPHK1 
SPHK2 
SPI1 
SPINK1 
SPINK2  
SPINK4  
SPINK5 
SPINK6 
SPINK7 
SPINK8 
SPINK9 
SPRED1 
SPTBN2 
SRC 
SREBF1 
SRF 
SRM 
SRMS 
SRPK1 
SRPK2 
SRPK3 
SSBP1 
SSBP2 
SSH1 
SSH2 
SSSCA1 
SSTR1 
SSTR2 
SSTR3 
SSTR4 
SSTR5 
ST13 
STAG1 
STAG2 
STAM 
STAT1 
STAT3 
STAT5A 
STAT5B 
STAT6 
STEAP3 
STK10 
STK11 
STK16 
STK17A 
STK17B 
STK19 
STK24 
STK25 
STK3 
STK31 
STK32A 
STK32B 
STK32C 
STK33 
STK35 
STK36 
STK38 
STK38L 
STK39 
STK4 
STK40 
STMN1 
STOML3 
STRADA 
STRADB 
STYK1 
SUFU 
SUV39H1 
SUV39H2 
SUV420H1 
SUV420H2 
SYK 
SYMPK 
TAF1 
TAF1L 
TAOK1 
TAOK2 
TAOK3 
TBCK 
TBK1 
TBL1X 
TBL1XR1 
TBL1Y 
TBX22 
TBX3 
TCEB1 
TCEB2 
TCEB3 
TCF3 
TCF4 
TCF7 
TCF7L1 
TCF7L2 
TEC 
TECTA 
TEK 
TESK1 
TESK2 
TEX14 
TFDP1 
TFDP2 
TFE3 
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ABSTRACT 
Background. Early signs of efficacy are critical in drug development. Response Evaluation 
Criteria in Solid Tumors (RECIST) are commonly used to determine the efficacy of anti-cancer 
therapy in clinical trials. RECIST, however, emphasizes the value of tumor shrinkage, while 
many targeted agents induce prolonged tumor growth arrest. This limits its use for the 
detection of treatment efficacy for these more cytostatic regimens. Therefore, we designed an 
individualized variant of a time to progression (TTP) end point based on prospective volumetric 
measurements and an intra-patient control, the TTP ratio.  
 
Patients and methods. Patients with any metastatic malignancy, without regular treatment 
options, were treated with the mTOR inhibitor everolimus. Treatment response was 
determined using both RECIST and the TTP ratio. The TTP ratio was defined as the volumetric 
pretreatment TTP divided by the volumetric on-treatment TTP. A patient was classified as a 
responder if the TTP ratio was <0.7. Consistency and reproducibility of volumetric 
measurements were determined.  
 
Results. Seventy-three patients were included of whom 59 started treatment. A TTP ratio could 
be established in 73% (n = 43) of the treated patients. The inter-observer agreement for 
volumetric progression was 0.78 (95% confidence interval 0.70–0.87) (Krippendorff's α-
coefficient). According to RECIST, 35 patients (59%) had stable disease (SD) and 1 patient 
demonstrated a partial response (PR), whereas only 21 patients (36%) met the prespecified 
criteria for treatment efficacy according to the TTP ratio. Treatment response according to 
both the TTP ratio and RECIST (SD + PR) correlated with overall survival (OS) [P(log-rank) < 
0.001]. The TTP ratio, however, was also able to differentiate which patients had a better OS 
within the RECIST SD group [P(log-rank) = 0.0496].  
 
Conclusion. The TTP ratio had a high inter-observer agreement, correlated with OS and 
identified which patients within the RECIST SD group had a longer OS.   
Time To Progression Ratio as an efficacy endpoint | 45 
 
INTRODUCTION 
Early signs of clinical activity are important in the decision to further develop new drugs. 
At present, Response Evaluation Criteria in Solid Tumors 1.1 (RECIST)-based parameters 
such as the response rate (RR) or progression-free survival (PFS) are standard to 
determine drug efficacy in early clinical trials.1 The introduction of targeted and 
immunomodulatory agents, however, has intensified the debate on the validity of these 
commonly used endpoints in clinical trials.2 Although RR reliably measures significant 
tumor progression and regression, it lacks the capability to detect growth rate reduction, 
which may be of great clinical value. This is an important limitation because targeted 
agents often exert a more cytostatic effect than chemotherapy, resulting in delayed 
growth rather than objective tumor regression.3 Patients with indolent growing tumors 
will end up in the stable disease (SD) group, obscuring the distinction between a slow 
natural course of disease and treatment effect. The value of PFS in single-arm studies is 
also adversely affected by inter-tumor variation in the natural growth rate. A drug-induced 
decrease in growth rate will not be detected without knowledge of the intrinsic growth 
rate. Using only RR or PFS as an efficacy end point in early-phase clinical trials may 
therefore lead to wrongful interpretation of the results with all untoward consequences.4  
These limitations of RECIST emphasize the need for a reliable parameter of 
clinical benefit that corrects for growth characteristics of the individual patient's tumor. 
Such a parameter will not only improve detection of drug efficacy but also support drug 
development in early clinical trials. Here, we introduce and evaluate a new personalized 
response parameter to measure the efficacy of targeted therapy: the time to progression 
(TTP) ratio (Figure 1). The TTP ratio prospectively compares volumetric tumor growth off 
and on treatment and therefore serves as an intra-patient control for natural tumor 
growth rate.  
 
METHODS 
Patients  
Patients with any advanced malignancy, who progressed on their previous treatment and 
had no regular systemic treatment options left, were eligible for inclusion. Key eligibility 
criteria included an age of 18 years or older; Eastern Cooperative Oncology Group (ECOG) 
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performance status of ≤2; volumetrically measurable disease; feasibility of histologic 
tumor biopsy; and adequate hepatic, renal and hematologic function.  
 
Study Regulatory Compliance  
The protocol (ClinicalTrials.gov identifier NCT01566279) was approved by the ethical 
review board of The Netherlands Cancer Institute and complied with the Declaration of 
Helsinki, Dutch law and Good Clinical Practice. All patients provided written informed 
consent before study-related procedures.  
 
 
Figure 1. TTP ratio.  
The TTP1 ratio is used to determine treatment efficacy in this study. If everolimus is beneficial for an 
individual patient, the time to progression under treatment (TTP2) is longer than the time to 
progression without treatment (TTP1). If the ratio of TTP1:TTP2 is <0.7, the patient is classified as a 
responder. In this figure, an example is given of a non-responder and responder. In the case of a 
>30% volumetric increase or new lesions on CT, the patient is classified as having progressive disease. 
The timing of CT evaluations has also been incorporated in this figure. The CT evaluation at 4 weeks 
in TTP2 will be done only if a patient is progressive at the first evaluation in TTP1. 
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Study Design  
The CPCT-03 study was an open-label, prospective, single-arm, multicenter intervention 
study. Study objectives included biomarker identification using RECIST and TTP ratio, 
evaluating the TTP ratio as a marker for treatment efficacy, and determining PFS, overall 
survival (OS) and Disease Control Rate (DCR) as defined by RECIST. Patients were accrued 
at the Netherlands Cancer Institute, UMC Utrecht Cancer Center and Erasmus MC Cancer 
Institute Rotterdam.  
 
Treatment  
All patients received everolimus 10 mg once daily, orally, on a continuous basis until 
disease progression according to RECIST. Dose reductions to 5 mg once daily and 5 mg 
every other day were allowed. A third dose reduction, or treatment interruption of more 
than 3 weeks, was not allowed.  
 
Efficacy Assessments  
After study inclusion, the time to an either ≥30% volumetric increase in target lesions or 
the development of new lesions was determined in a prospective manner, before the 
treatment with everolimus. This period was called time to progression 1 (TTP1) and 
represented the natural tumor growth rate. In TTP1, tumor assessments were carried out 
at baseline, 4 weeks after baseline and every 6 weeks subsequently. In the case of obvious 
clinical progression during TTP1, a computed tomography (CT) scan was carried out 
immediately. Subsequently, treatment with everolimus was started and patients were 
again followed until a ≥30% volumetric increase in target lesions or the development of 
new lesions. This was called time to progression 2 (TTP2) and represented the growth 
speed of the tumor under treatment. In TTP2, tumor assessments were carried out every 
8 weeks until progressive disease, according to RECIST, was observed. The only exception 
was patients who were already progressive in TTP1 at 4 weeks, they had their first on-
treatment scan at 4 weeks. The TTP ratio was calculated by dividing TTP1 by TTP2. A 
patient was classified as a responder if the TTP ratio was <0.7. The 0.7 cut-off for response 
was based on the PFS ratio of Von Hoff et al.5 Von Hoff et al. divided TTP2 by TTP1 (in 
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contrast to TTP1 by TTP2) and used a threshold of >1.33 for response, which corresponds 
to 0.75 for our TTP ratio. They determined TTP1 under the previous treatment, whereas 
here it is determined without treatment and the more stringent cut-off 0.7 was chosen.  
 
All tumor assessments were carried out using CT and sent to a central facility. Volumetric 
measurements were carried out using semiautomatic software (EncoreUnFoie, v5.0, 
Image Sciences, UMC Utrecht, the Netherlands, 2012). All CT scans were measured by at 
least two independent observers (GAC, FW, CGMG-H, IU) using the same set of target 
lesions. At study entry, volumetrically measurable target lesions were selected in 
adherence to RECIST guidelines.1 A lesion was considered volumetrically measurable if its 
borders could be delimited on every single CT scan slice. Volumetric measurements were 
carried out by manually contouring the lesion on all axial slices. Subsequently, the volume 
of each individual lesion was calculated automatically (Supplementary Figure S1). The 
percent change in volume was calculated for the sum of volumes. If there was no 
consensus on the presence or absence of volumetric progressive disease, a third observer 
was consulted. An increase of 30% since nadir or more in the cumulative volume of target 
lesions or appearance of new lesions was considered PD. The 30% cut-off was chosen 
based on the work of van Kessel et al.6, who found that for individual observers, 95% of all 
repeated lesion measurements fell within the limit of −28.6% and 30.4%. Patients were 
also evaluated according to the conventional RECIST during the TTP2 period. For all TTP 
ratio assessable patients, the PFS ratio as described by Von Hoff et al.5 was also 
determined to enable comparison with the TTP ratio. The PFS ratio uses TTP on the most 
recent line of treatment as an intra-patient control.  
 
Evaluability of Patients  
Patients were not evaluable for TTP ratio if they did not complete the TTP1 period or if 
they had a protocol violation, lost their volumetric measurability or stopped treatment 
due to reasons other than PD [with the exception of patients that had already passed the 
threshold of response (<0.7)]. Patients were evaluable for RECIST if treatment response 
was determined on at least one CT.  
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Statistical Analyses 
The majority of analyses were carried out using SPSS Statistics version 22 (IBM). Baseline 
data were reported with descriptive statistics. PFS and OS curves were constructed using 
the Kaplan–Meier technique, and analyzed using a log-rank test. Numbers of target lesions 
were compared using a paired t-test. A Spearman correlation was used to analyze the 
relation between TTP1 and TTP ratio, TTP1 and the wash-out period of the previous 
treatment, and baseline tumor volume and percentage change. Inter-observer variability 
was calculated using R version 3.2.0 (www.r-project.org) with Krippendorff's α-coefficient.  
 
 
Table 1. 
Demographic or clinical  
characteristic 
Patients  
(N) 
 
% 
No. of patients 73  
Sex  
Male 
 
29 
 
39.7 
Age, years  
Mean 
Range 
 
59 
31–79 
 
WHO PS 
0 
1 
2 
Missing 
 
21 
42 
2 
8 
 
28.8 
57.5 
2.7 
11.0 
Primary tumor 
Colorectal 
NET 
Esophageal 
Breast 
NSCLC 
Ovarian 
Bladder 
Sarcoma 
Cervical 
Head and neck 
Renal cell 
Unknown origin 
 
23 
9 
5 
4 
4 
3 
3 
3 
2 
2 
2 
2 
 
31.5 
12.3 
6.8 
5.5 
5.5 
4.1 
4.1 
4.1 
2.7 
2.7 
2.7 
2.7 
Demographic or clinical  
Characteristic 
Patients  
(N) 
 
% 
   
Time since initial  
diagnosis 
≤6 months 
>6 months to ≤2 years 
>2 to ≤5 years 
>5 years 
 
 
6 
27 
23 
17 
 
 
8.2 
37.0 
31.5 
23.3 
No. of organs involved 
1 
2 
>2 
Unknown 
 
13 
17 
38 
5 
 
17.8 
23.3 
52.1 
6.8 
Prior treatment 
Chemotherapy 
Targeted therapy 
Hormone therapy 
Immunotherapy 
Radiotherapy 
 
68 
27 
9 
0 
38 
 
93.1 
37.0 
12.3 
— 
52.1 
Abbreviations: NET, neuroendocrine tumor; 
NSCLC, non-small cell lung cancer; WHO PS, 
World Health Organisation Performance 
Score. 
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was determined on at least one CT.  
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Statistical Analyses 
The majority of analyses were carried out using SPSS Statistics version 22 (IBM). Baseline 
data were reported with descriptive statistics. PFS and OS curves were constructed using 
the Kaplan–Meier technique, and analyzed using a log-rank test. Numbers of target lesions 
were compared using a paired t-test. A Spearman correlation was used to analyze the 
relation between TTP1 and TTP ratio, TTP1 and the wash-out period of the previous 
treatment, and baseline tumor volume and percentage change. Inter-observer variability 
was calculated using R version 3.2.0 (www.r-project.org) with Krippendorff's α-coefficient.  
 
 
Table 1. 
Demographic or clinical  
characteristic 
Patients  
(N) 
 
% 
No. of patients 73  
Sex  
Male 
 
29 
 
39.7 
Age, years  
Mean 
Range 
 
59 
31–79 
 
WHO PS 
0 
1 
2 
Missing 
 
21 
42 
2 
8 
 
28.8 
57.5 
2.7 
11.0 
Primary tumor 
Colorectal 
NET 
Esophageal 
Breast 
NSCLC 
Ovarian 
Bladder 
Sarcoma 
Cervical 
Head and neck 
Renal cell 
Unknown origin 
 
23 
9 
5 
4 
4 
3 
3 
3 
2 
2 
2 
2 
 
31.5 
12.3 
6.8 
5.5 
5.5 
4.1 
4.1 
4.1 
2.7 
2.7 
2.7 
2.7 
Demographic or clinical  
Characteristic 
Patients  
(N) 
 
% 
   
Time since initial  
diagnosis 
≤6 months 
>6 months to ≤2 years 
>2 to ≤5 years 
>5 years 
 
 
6 
27 
23 
17 
 
 
8.2 
37.0 
31.5 
23.3 
No. of organs involved 
1 
2 
>2 
Unknown 
 
13 
17 
38 
5 
 
17.8 
23.3 
52.1 
6.8 
Prior treatment 
Chemotherapy 
Targeted therapy 
Hormone therapy 
Immunotherapy 
Radiotherapy 
 
68 
27 
9 
0 
38 
 
93.1 
37.0 
12.3 
— 
52.1 
Abbreviations: NET, neuroendocrine tumor; 
NSCLC, non-small cell lung cancer; WHO PS, 
World Health Organisation Performance 
Score. 
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RESULTS 
Study Population 
Seventy-three patients were included between 15 August 2012 and 23 April 2014 
(Supplementary Figure S2). Fifty-nine patients started treatment with everolimus. 
Reasons for drop-out during TTP1 included clinical deterioration (n = 8), initiation of other 
treatment (n = 2), toxicity from a previous treatment (n = 1), screen failure (n = 1) or 
withdrawal of informed consent (n = 1). Baseline patient characteristics are depicted in 
Table 1.  
 
TTP Ratio Versus RECIST  
To compare the TTP ratio and RECIST, we evaluated several factors, including number of 
target lesions, concordance of change and response classification. Forty-three (73%) 
patients reached TTP2 and were evaluable for efficacy using the TTP ratio. Fifty-one (86%) 
patients were evaluable using RECIST. Reasons for non-evaluability according to TTP ratio 
included protocol violation (n = 1), loss of volumetric measurability (n = 3) and stop of 
treatment due to reasons other than PD (n = 12). Patients were not evaluable for RECIST 
when treatment response was not determined (n = 8). Because not all lesions can be 
measured volumetrically, we compared the number of target lesions used for RECIST and 
volumetric measurements. Within patients evaluable for both methods, fewer lesions 
were selected as target lesions for volumetric measurements [mean 2.5 (±1.0 SD)] 
compared with RECIST [mean 3.0 (±1.2 SD)]. This difference was statistically significant (P 
< 0.001, paired t-test). Volumetric and RECIST measurements were concordant in 
measuring either tumor growth or regression in 79% of cases (Supplementary Figure S3).  
 
Using standard RECIST, most patients were classified as having SD (59%, Table 2). Twenty-
five percent of patients were classified as progressive (PD) and one patient had a partial 
response (PR). Using the TTP ratio, 36% of patients were classified as responders and 37% 
as non-responders. The RECIST SD cohort could be split in 20 TTP ratio responders and 8 
non-responders.  
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TTP Ratio As an Efficacy End Point 
To evaluate the consistency of measuring volumetric progressive disease, the inter-observer 
agreement was calculated using Krippendorff's α-coefficient. The inter-observer agreement 
was 0.78 [95% confidence interval (CI) 0.70–0.87] with 199 evaluated scans. Baseline tumor 
volume was not correlated to the percentage of change in target lesions (P = 0.413, Spearman). 
TTP1 was not correlated to TTP ratio (P = 0.551, Spearman) or the wash-out period of the 
previous treatment (P = 0.251, Spearman).  
 
 
 
 
 
Figure 2. Correlation of outcome measures 
to OS. (A) TTP ratio correlated with OS in the 
TTP ratio evaluable cohort, (B) PR and SD 
according to RECIST also correlated with OS 
in the TTP ratio evaluable cohort, (C) 
response according to TTP ratio within the SD 
cohort (n = 28) correlated to OS. 
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To explore the predictive value of outcome according to TTP ratio, we analyzed its relation with 
OS in the TTP ratio evaluable cohort (n = 43). Figure 2A shows OS of responders versus non-
responders according to TTP ratio. A significant difference in OS between responders [median 
12 months (95% CI 6.0–18.0)] and non-responders [median 4 months (95% CI 2.9–5.1)] was 
observed [P(log-rank) < 0.001]. There was also a significant difference in OS between the 
RECIST SD and PR patients versus the PD patients in the same cohort [P(log-rank) < 0.001, 
Figure 2B]. Because a large proportion of the RECIST SD population were TTP ratio responders, 
we carried out a separate analysis within the RECIST SD cohort to evaluate if TTP ratio response 
was correlated to OS within this subgroup (n = 28). The median OS was significantly longer in 
the TTP ratio responder group [median 11 months (95% CI 4.4–17.6)] than in the non-
responder group [median 5 months (95% CI 3.2–6.8)] [P(log-rank) = 0.0496, Figure 2C]. PFS 
ratio response also correlated to OS [P(log-rank) = 0.008]. However, in contrast to the TTP 
ratio, response according to PFS ratio was not correlated to OS in the RECIST SD cohort [P(log-
rank) = 0.311].  
 
Efficacy of Everolimus 
Within this study, we also evaluated the efficacy of everolimus according to both end 
points among different tumor types (Table 2). Individual TTP times and ratios are shown in 
Supplementary Figure S4. According to RECIST, high disease control rates (PR + SD) were 
observed for breast (75%) and esophageal (80%) cancer, including a PR for esophageal 
cancer. Both tumor types also had a high rate of responders according to the TTP ratio: 
60% for esophageal cancer and 75% for breast cancer.  
 
All TTP ratio evaluable breast cancers and esophageal adenocarcinomas had a short TTP1 
and a response according to the TTP ratio. The squamous cell esophageal carcinomas 
included a patient with a long TTP1 and response according to the TTP ratio (this patient 
also had a RECIST PR). The second patient was not evaluable for response according to the 
TTP ratio. RECIST response was SD. On CT, however, necrosis of the lung metastases was 
observed (Supplementary Figure S5).  
 
Time To Progression Ratio as an efficacy endpoint | 53 
 
The majority of patients stopped treatment due to PD (n = 35). Other reasons to stop 
treatment were adverse events (AEs) (n = 7); toxicity (n = 3); patient refusal (n = 1); clinical 
deterioration (n = 1); death (n = 1); other (n = 7). At the time of analysis, four patients 
were still on treatment. AEs are summarized in Table 3.  
 
Table 2. Efficacy of everolimus. 
 All patients  
(n = 59)  
Colorectal  
(n = 17)  
Neuro-
endocrine 
(n = 9)  
Esophageal 
(n = 5)  
Breast  
(n = 4)  
TTP ratio (n, %)  
Response (<0.7) 
Non-response (≥0.7) 
Unknown 
 
21 (36%) 
22 (37%) 
16 (27%) 
 
5 (29%) 
10 (59%) 
2 (12%) 
 
2 (22%) 
2 (22%) 
5 (56%) 
 
3 (60%) 
0 (—) 
2 (40%) 
 
3 (75%) 
0 (—) 
1 (25%) 
Best response (n, %)  
CR 
PR 
SD 
PD 
Unknown 
 
0 (—) 
1 (2%) 
35 (59%) 
15 (25%) 
8 (14%) 
 
0 (—) 
0 (—) 
8 (47%) 
8 (47%) 
1 (6%) 
 
0 (—) 
0 (—) 
6 (67%) 
1 (11%) 
2 (22%) 
 
0 (—) 
1 (20%) 
3 (60%) 
1 (20%) 
0 (—) 
 
0 (—) 
0 (—) 
3 (75%) 
0 (—) 
1 (25%) 
Disease control rate 36 (61%) 8 (47%) 6 (67%) 4 (80%) 4 (75%) 
PFS 
Events (n, %)  
Median, months 
95% CI 
 
45 (62%) 
2 
1.2–2.8 
 
14 (82%) 
2 
1.5–2.5 
 
3 (33%) 
15 
0–39.2 
 
4 (80%) 
3 
0.5–5.5 
 
3 (75%) 
1 
0–6.2 
OS 
Events (n, %)  
Median, months 
95% CI 
 
50 (85%) 
5 
4.3–5.7 
 
17 (100%) 
5 
4.0–6.0 
 
6 (67%) 
17 
0–34.5 
 
4 (80%) 
3 
0–6.2 
 
4 (100%) 
4 
0–9.9 
Abbreviations: CR, complete response; OS, overall survival; PD, progressive disease; PFS, progression 
free survival; PR, partial response; TTP ratio, time to progression ratio. 
 
Table 3. Adverse events. 
Adverse event All grades, N(%) Grade 3/4, N(%) 
Ƴ-GT increased 16 (26.7%) 1 (1.7%) 
AF increased 8 (13.3%) 1 (1.7%) 
Fatigue 6 (10%) 1 (1.7%) 
Anemia 5 (8.3%) 1 (1.7%) 
Dyspnea 5 (8.3%) 5 (8.3%) 
Hyperglycemia 5 (8.3%) 0 (-) 
Fever 4 (6.7%) 4 (6.7%) 
AST increased 3 (5%) 0 (-) 
Trombocytopenia 3 (5%) 0 (-) 
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DISCUSSION 
The results of our study suggest that the TTP ratio has additional value when determining 
the clinical benefit of targeted therapies in early-phase clinical studies. In this phase I 
population, both TTP ratio and RECIST correlated to OS. However, TTP ratio was also able 
to differentiate within the RECIST SD group which patients had a longer OS, which could 
be interpreted as a sign of clinical benefit. TTP ratio measurements were highly 
reproducible among observers in this study. If validated in other cohorts, this provides an 
opportunity to determine whether patients classified as having SD actually experienced 
clinical benefit, and gives more insight as to which patient groups benefit from treatment. 
Ultimately, we believe the TTP ratio could support drug development by improved 
detection of early signs of clinical activity.  
 
Furthermore, TTP ratio as an outcome measure was able to detect the efficacy of 
everolimus in breast and esophageal cancer. Previous studies show that everolimus 
combined with exemestane is active in breast cancer. However, the beneficial effect of 
everolimus for esophageal cancer patients has never been fully explored. Early phase 
studies by Werner et al.7 and Wainberg et al.8 report low RRs and a large SD population. 
Because it remains unclear if patients with SD actually benefit from treatment, further 
studies were discontinued. Our data, however, suggest that we were able to evaluate 
whether patients within the SD group indeed had a drug-attributable decrease in tumor 
growth rate. For all esophageal cancer patients in this study (n = 5), this was, in fact, the 
case. Despite their heavily pretreated status, these patients seemed to benefit from 
treatment with everolimus. Taking into account small patient numbers, these results may 
spark an interest to further investigate everolimus in esophageal cancer.  
 
Despite the advantages discussed above, using the TTP ratio as an end point in clinical 
studies also has several limitations. First, it has been a laborious effort to perform 
volumetric measurements (in duplicate) of each CT scan. Volumetric measurements are, 
and will remain, time-consuming procedures until robust and reliable fully automatic 
software is developed. Secondly, the wait-and-see period to assess natural growth rate 
initially raised concerns with physicians and patients. Eight patients (11%) were not able to 
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start treatment due to clinical deterioration during the waiting period. Percentagewise, 
this is comparable to the early drop-out rate in large phase I cohorts.9 In this regard, it is 
important to realize that participants in this study had no other treatment options besides 
best supportive care or phase I study participation, with a small chance of treatment 
success, possible suboptimal dosing and unknown toxicity profiles. A wait-and-see 
approach is also not necessarily disadvantageous. In this study, six patients had a TTP1 of 
>100 days. These patients had no strict indication to start treatment immediately and 
their quality of life was not negatively affected by treatment-related AEs during their 
waiting period. In addition, a first follow-up CT taking place at 4 weeks ensured early 
detection of highly progressive tumors with a low threshold to start treatment because a 
volumetric increase of 30% equals a much smaller increase in diameter.6 Altogether we 
feel that the aforementioned considerations legitimate the design of this study and 
exploratory end point. We cannot exclude the possibility of pseudoprogression in some 
patients. When adopting the TTP ratio to evaluate the efficacy of treatments that can 
result in pseudoprogression, we recommend a similar approach as the Immune-Related 
Response Criteria, namely performing a consecutive CT after 4 weeks to confirm PD.  
 
Previous studies have also recognized the limitations of on-treatment RECIST for targeted 
therapies and several alternative end points have been explored4,5,10,11 such as the tumor 
growth rate (TGR), by Ferté et al.,11 which compared tumor growth rate on-treatment and 
before treatment. They compared TGR and RECIST in a large cohort of renal cancer 
patients treated with sorafenib or everolimus and found that it facilitated detection of 
early signs of efficacy and was associated with PFS and OS. However, growth rate before 
treatment was determined retrospectively in the wash-out period, making it a less reliable 
end point. Another example is the PFS ratio by Von Hoff et al. where PFS according to 
RECIST was compared with PFS on the previous treatment.5 Although an intra-patient 
control is used, the success of the previous treatment is a major determinant of efficacy of 
the treatment of interest. Although PFS ratio also correlated to OS, PFS ratio was not able 
to differentiate within the RECIST SD group which patients had a longer OS. The TTP ratio, 
in contrast to the aforementioned examples, is thus far the only efficacy end point in 
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which natural growth rate (via intra-patient control) was prospectively determined and 
which correlated to OS in the RECIST SD group.  
 
To summarize, we believe that measuring clinical benefit according to TTP ratio is of 
additional value to standard RECIST measurements when determining the efficacy of 
targeted therapeutics in early-phase clinical studies as it (i) corrects for the natural growth 
rate of the tumor, (ii) corresponds well with OS in a phase I population of patients, (iii) is 
able to differentiate which patients had a longer OS within the SD cohort, (iv) shows high 
inter-observer agreement and (v) is able to identify potential patient groups (i.e. 
esophageal cancer) that might benefit from treatment. Our findings warrant further 
exploration and validation of this approach as it could greatly facilitate early detection of 
drug efficacy and thereby support drug development.  
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which natural growth rate (via intra-patient control) was prospectively determined and 
which correlated to OS in the RECIST SD group.  
 
To summarize, we believe that measuring clinical benefit according to TTP ratio is of 
additional value to standard RECIST measurements when determining the efficacy of 
targeted therapeutics in early-phase clinical studies as it (i) corrects for the natural growth 
rate of the tumor, (ii) corresponds well with OS in a phase I population of patients, (iii) is 
able to differentiate which patients had a longer OS within the SD cohort, (iv) shows high 
inter-observer agreement and (v) is able to identify potential patient groups (i.e. 
esophageal cancer) that might benefit from treatment. Our findings warrant further 
exploration and validation of this approach as it could greatly facilitate early detection of 
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SUPPLEMENTARY FIGURES 
Supplementary Figure 1. Semi-automated volumetric measurements. A) this figure demonstrates 
the delineation of the tumor on one CT slice. After delineating the tumor on every single CT slice, you 
get figure B and the volume is calculated automatically by the computer.    
 
 
 
Supplementary Figure 2. Evaluability of patients. This figure describes the evaluability of patients for 
the analyses included in this study. The flowchart demonstrates how many of the patients are 
evaluable for RECIST response and response according to the TTP ratio. A single patient can be 
evaluable in both cohorts. *Patients are non-evaluable for TTP ratio if they stopped treatment due to 
reasons other than PD, with the exception of patients that surpassed the threshold for response 
(<0.7) during follow-up. Abbreviations: IC, Informed Consent; PD, Progressive Disease; TTP1, Time To 
Progression 1; TTP2, Time To Progression 2.  
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Supplementary Figure 3. Waterfall plot volumetric and RECIST best response. This figure shows 
the best response as measured volumetrically (red bar) and by diameter (blue bar) for all patients 
that were evaluable for both outcomes. Absence of the blue bar means that no change has been 
detected. Using volumetric measurements, change in tumor size is more easily detected. Both 
outcome measures are highly concordant in reporting either a decrease or increase in tumor size.   
 
 
Supplementary Figure 4. Individual TTP1 & TTP2 periods and ratios. This figure portrays the time 
to progression pre-treatment (blue bar) and on-treatment (red bar) for individual patients in weeks 
on the left y-axis. The right y-axis and black stripes represent the TTP ratio.  
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Supplementary Figure 5. CT scan pre- and post-everolimus. A) pre-treatment scan, B) post-
treatment scan which shows substantial necrosis of the lung metastases.  
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Interindividual variability (IIV) in the pharmacokinetics of anticancer drugs is influenced by 
a wide variety of factors, including body composition, organ function, genetics, and 
environmental elements.1 Unfortunately, the body surface area (BSA)–based dosing 
strategy adjusts only for height and weight and is therefore unlikely to be sufficient to 
(safely) dose agents with a narrow therapeutic window. Moreover, this approach is 
conceptually invalid and should be replaced by better alternatives based on fundamental 
principles of clinical pharmacology. 
 
History 
Dose adjustments for BSA acquired their role in oncology in a rather controversial way. In 
1958, Donald Pinkel concluded that the maximum tolerable dose of a few cytostatic 
agents appeared to be quite comparable among different animal species, including 
humans (both young and adult) if corrected for BSA.2 The BSA range in his study was huge 
(from 0.0075 m2 in mice to 1.85 m2 in humans). In accordance with this finding and the 
hypothesis that the most important pharmacological processes are related to body size, 
the starting dose in oncology phase I studies was thereafter based on BSA.3 Something 
remarkable happened: this correction for BSA in early clinical trials was simply generalized 
to standard-of-care dosing of anticancer drugs in adults, without any additional evidence 
that this extrapolation was valid. In the decades that followed, the original 1916 formula 
by Du Bois and Du Bois4 was modified and simplified by others (i.e., Mosteller5 in 1987), 
but the principle remained the same. Even though this almost antique formula was based 
on the body compositions of (only) nine randomly chosen people, the correlation between 
all these formulas is strikingly high,1 making these formulas interchangeable. 
 
Evidence-based dosing? 
Although BSA-adjusted dosing has been widely utilized in oncology for decades, there has 
been extensive criticism of this approach. For many agents (e.g., 
epirubicin, cisplatin, and irinotecan), studies have demonstrated that this approach has 
little or no value in achieving the goal of reducing the IIV in exposure.6 For some drugs 
(e.g., paclitaxel), a correction for BSA may lead to reduced variability in clearance,6,7 and 
BSA is often a significant covariate in population pharmacokinetic models. However, 
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statistical significance is not necessarily associated with clinical relevance. To clarify this, 
we took a representative data set of 270 cancer patients treated with paclitaxel 
chemotherapy, with the pharmacokinetic parameters estimated from a population 
pharmacokinetic model.8 This modeling procedure is thought to deliver the most reliable 
pharmacokinetic data. Following current daily practice, all patients were dosed using BSA. 
If the BSA for these patients is plotted against paclitaxel clearance, the coefficient of 
variation is still over 30% (Figure 1). If we look at patients with a mean BSA of 1.8 m2, 
clearance may differ threefold within this subset. In addition, as shown earlier, BSA is not 
related to paclitaxel toxicity, especially myelosuppression.9 So, even for drugs like 
paclitaxel for which correction for BSA has the potential to reduce the IIV, the value of BSA 
in its dosing strategy is limited and should therefore be seriously questioned. In other 
words, despite its ability to lower the IIV of some drugs, BSA does not provide enough 
improvement in IIV to be used as the sole correction factor in dosing strategies. 
 
Another problem with BSA-based dosing is that it leads to a false sense of security. 
Calculating a dose on the basis of BSA will generate a very precise dose. For instance, for a 
patient 161 cm tall and weighing 54.7 kg who receives a drug dose of 75 mg/m2, a dose of 
117.31 mg (Mosteller5) will be displayed on the calculator. Although this dose is very 
precise, this precision is relevant only if it is also accurate. Unfortunately, the calculation 
of BSA is not as accurate as we would wish. In an obese population, it was found that the 
original formula underestimated BSA by 2.7% and 4.5% in males and females, 
respectively.10 Precision without accuracy has no medical value. 
 
Practical considerations for choosing a dosing strategy 
For newer drugs, particularly those given orally, the concept of BSA-based dosing has 
already been abandoned, and the starting dose is the same (fixed) for all patients. Because 
both BSA-adjusted dosing and fixed dosing are strategies with many imperfections, one 
should balance their workability. Fixed dosing comes with many practical advantages over 
BSA-adjusted dosing. First, the risk of prescription errors is smaller if there is only one 
dose to prescribe. A recent French study showed that prescription errors accounted for 
more than 90% of all errors in dosing chemotherapy, and that, if not discovered in time, 
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such errors may lead to serious overdosing issues, which in turn could cause potentially 
life-threatening damage.11 As a result of the current practice of electronically prescribing 
anticancer drugs, oncologists are no longer required to calculate a dose because it is 
automatically generated in many systems. However, this could potentially increase the 
risk of prescription errors because physicians may fail to recognize their own errors. 
Furthermore, administration of (oral) drugs by patients themselves is simplified by 
maintaining only one dose that applies to all patients. This could enhance compliance and 
will also lead to a reduction in (self-)administration errors. Moreover, it is not always easy 
to round doses to the nearest strength of available pills. Consequently, many patients are 
handed a dose of—for example—capecitabine that differs from the calculated dose 
according to their BSA. Deviating from the calculated dose introduces yet another error. 
 
 
Figure 1. Relationship between body surface area (x-axis) and the clearance of paclitaxel (based on 
unbound plasma concentrations) in 270 cancer patients (139 men and 131 women). Raw data were 
obtained from a recent clinical study.8 The mean clearance ±SD in this group was 488 l/h ± 149 l/h, 
and the coefficient of variation (CV) was 30.6%. Clearance was significantly higher in male patients 
(open circles) than in female patients (closed circles) (541 l/h ± 154 l/h; CV 28.5% vs. 432 l/h ± 141 
l/h; CV32.7%, respectively; P < 0.001). 
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Finally, several parties will benefit from a fixed-dosing strategy. The most obvious benefit 
concerns the preparation of parenteral drugs for administration, as single-dose vials could be 
used for all patients (absent any need for dose reduction). This would reduce preparation time 
and avoid the waste of partial vials. 
 
Some critics say fixed dosing is not realistic because patients with extremely low or high BSAs 
will be overdosed or underdosed if no correction is made for body size. Therefore, another 
interesting alternative dosing strategy for BSA was introduced by Plumridge and Sewell.12 They 
divided their patients into a few groups (based on a range of BSAs), and all patients within a 
group received the same dose (Figure 2). This dose was based on the mean BSA in that group. 
This dosing strategy, called dose banding, seems to combine the advantages of both fixed 
dosing and BSA-based dosing because only a limited number of standard doses (e.g., three or 
five) need to be available, and patients with extreme body-size measures will receive a dose 
more adjusted to their body size than the overall mean. A recent study with six cytostatic 
agents showed that the IIV for dose banding is comparable to that for BSA-based dosing.13 
 
 
Figure 2. Example of dose banding for paclitaxel, originally dosed at 175 mg/m2.  
The population has been divided into three (arbitrarily chosen) categories (BSA <1.60 m2, 1.60–2.00 
m2, and >2.00 m2). In each category, the dose is set on the BSA-adjusted dose for the mean BSA of 
that category. This leads, after rounding, to three fixed doses of 260, 315, and 370 mg, respectively 
(indicated by stars). Because the large majority of patients will fall into the middle category, only a 
small minority receive the low or high fixed dose. 
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Rational alternatives to BSA 
Figure 1 shows clearly that BSA-based dosing is a misconception for dosing paclitaxel 
chemotherapy. From this figure we also see that clearances differ significantly between 
men and women (despite the widely overlapping range); nonetheless, in clinical practice 
we do not distinguish men and women in dosing paclitaxel. If we are truly willing to 
improve our treatment by personalizing therapies, we should take the crucial step of 
implementing factors other than body size in our dosing regimens. These factors can be 
categorized as intrinsic (e.g., age, sex), genetic (e.g., variation in drug-metabolizing 
enzymes and transporters), and environmental (smoking, comedication, alternative 
medicine) and are likely to have a much larger influence on IIV than BSA does.1 Oral drugs 
are even less likely to be impacted by BSA, given the additional factors of adherence, 
concomitant food intake, increased risk of drug–drug interactions, and variability in 
absorption and first-pass metabolism. 
 
When looking for better and more rational options in dosing anticancer drugs, it is 
important to create a good starting dose. For some drugs, pharmacogenetic differences 
may help to prevent toxic doses for subgroups of patients (e.g., TPMT genotyping before 
dosing 6-mercaptopurine). However, any predictive test will have limited accuracy. 
Alternative phenotyping procedures are in development that might be more accurate than 
other approaches, with dosing of subsequent cycles based on observed plasma 
concentrations and toxicities. 
 
Implementation of alternative dosing strategies 
Dosing strategies remain a controversial issue in oncology. There are many opinions 
regarding the ideal way to maximize the likelihood of benefit while minimizing the risk of 
excessive toxicity. It is unlikely that BSA-based dosing will have the same role in the future 
that it has today. 
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Regrettably, despite the coming era of personalized medicine, the majority of the factors 
influencing the disposition of these agents are not yet taken into account by today's 
applied dosing strategies. From a practical, ethical, and financial point of view, randomized 
trials of dosing strategies are unlikely to be conducted. Therefore, we propose the 
following strategy:  
1. For marketed drugs, continue using BSA-based dosing if supported by data. If not, 
then dose banding is recommended, with adjustment for other important 
parameters (e.g., food, comedication, smoking, certain genotypes). 
2. For investigational drugs, BSA (and weight) should be utilized only if 
pharmacokinetically or clinically relevant. 
Application of this strategy might result in implementation of a more accurate way of 
dosing anticancer agents in the short term. Nevertheless, practical disadvantages should 
always be regarded carefully before implementation because the potential obstacles 
might otherwise outweigh the benefits of this strategy. 
 
One final thought: what if we were currently using another dosing strategy instead of BSA-
based dosing? Would the current evidence convince the vast majority of prescribers to 
switch to BSA-based dosing, or would it be viewed as not worth the effort? 
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excessive toxicity. It is unlikely that BSA-based dosing will have the same role in the future 
that it has today. 
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Regrettably, despite the coming era of personalized medicine, the majority of the factors 
influencing the disposition of these agents are not yet taken into account by today's 
applied dosing strategies. From a practical, ethical, and financial point of view, randomized 
trials of dosing strategies are unlikely to be conducted. Therefore, we propose the 
following strategy:  
1. For marketed drugs, continue using BSA-based dosing if supported by data. If not, 
then dose banding is recommended, with adjustment for other important 
parameters (e.g., food, comedication, smoking, certain genotypes). 
2. For investigational drugs, BSA (and weight) should be utilized only if 
pharmacokinetically or clinically relevant. 
Application of this strategy might result in implementation of a more accurate way of 
dosing anticancer agents in the short term. Nevertheless, practical disadvantages should 
always be regarded carefully before implementation because the potential obstacles 
might otherwise outweigh the benefits of this strategy. 
 
One final thought: what if we were currently using another dosing strategy instead of BSA-
based dosing? Would the current evidence convince the vast majority of prescribers to 
switch to BSA-based dosing, or would it be viewed as not worth the effort? 
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ABSTRACT 
Sorafenib undergoes extensive UGT1A9-mediated formation of sorafenib-β-D-glucuronide 
(SG). This metabolite can be extruded into bile by ABCC2 or follow a liver-to-blood 
shuttling loop via ABCC3-mediated efflux into the systemic circulation and subsequent 
uptake in neighboring hepatocytes by OATP1B-type transporters. We assessed SG uptake 
in OATP1B1, Oatp1b2 and/or ABCC2 transfected cells in the presence and absence of 
rifampin. The effect of rifampin on the pharmacokinetics of sorafenib and its metabolites 
was measured in Oatp1b2 knock-out (KO) and wildtype (WT) mice, as well as in 9 
sorafenib treated patients in a randomized cross-over trial. The in vitro transport of SG by 
human OATP1B1 and its murine equivalent Oatp1b2 was potently inhibited by rifampin. In 
mice, rifampin increased plasma levels of SG 15-fold, but not in Oatp1b2-KO animals. In 
human subjects on a chronic sorafenib regimen, rifampin acutely more than doubled 
exposure to SG (P<0.001). We show impaired OATP1B-type transport leads to systemic 
accumulation of SG. In view of the dominant role of SG in the enterohepatic recirculation 
of sorafenib, prolonged OATP1B inhibition by co-medication or by an inherited genetic 
predisposition may lead to reduced plasma levels of sorafenib, and consequently a 
diminished therapeutic efficacy. 
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INTRODUCTION 
The multikinase inhibitor sorafenib is used as a chemotherapeutic agent in the treatment 
of multiple malignant diseases, including cancers of the liver, kidney, and thyroid.1-3 The 
pharmacokinetic properties of sorafenib are characterized by up to 90% variation in oral 
exposure between patients receiving the same therapeutic regimen.4 The high degree of 
interindividual pharmacokinetic variability observed with sorafenib has important 
toxicological ramifications. For example, it was recently demonstrated that levels of 
sorafenib in plasma are correlated with the incidence of skin rash,5 with dose reduction 
and study withdrawal due to adverse effects 6, and with the development of severe 
adverse reactions.7 
The mechanisms underlying the unpredictable pharmacokinetic profile of 
sorafenib remain largely unexplained. After oral administration, sorafenib enters 
hepatocytes by incompletely defined mechanisms,8, 9 and then undergoes CYP3A4-
mediated oxidation10, 11 and UGT1A9-mediated glucuronidation.11 A mass balance study of 
oral sorafenib in humans has shown that 15% of the dose was eliminated as sorafenib-β-
D-glucuronide (SG), compared to less than 5% as oxidative metabolites. Interestingly, SG 
was not detectable in feces, which may be due to its instability in the presence of bacterial 
glucuronidases present in the gut.12 Therefore, it has been suggested that the actual 
contribution of glucuronidation to sorafenib elimination may have been underestimated 
in the mass balance study,9 and that, because of its effective secretion into bile,13 the 
appearance of SG in the systemic circulation represents an overshoot mechanism that 
poorly reflects the actual extent of its formation. These observations suggest that a critical 
determinant of sorafenib’s pharmacokinetic variability with possible consequences for 
clinical management may be associated with differential expression and function of SG 
transporters regulating its distribution and elimination.14 
After its formation, SG is secreted into the bile through a process mediated by the 
ATP-binding cassette efflux transporter ABCC2 (MRP2).13 Under normal physiologic 
conditions, a fraction of the hepatocellular SG is secreted back into the blood stream by 
ABCC3 (MRP3), from where it can be taken up again into downstream hepatocytes via the 
uptake carrier OATP1B1 (Oatp1b2 in mice) (Figure 1).13 This liver-to-blood shuttling loop 
called hepatocyte-hopping, may prevent saturation of ABCC2-mediated biliary secretion of 
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ABSTRACT 
Sorafenib undergoes extensive UGT1A9-mediated formation of sorafenib-β-D-glucuronide 
(SG). This metabolite can be extruded into bile by ABCC2 or follow a liver-to-blood 
shuttling loop via ABCC3-mediated efflux into the systemic circulation and subsequent 
uptake in neighboring hepatocytes by OATP1B-type transporters. We assessed SG uptake 
in OATP1B1, Oatp1b2 and/or ABCC2 transfected cells in the presence and absence of 
rifampin. The effect of rifampin on the pharmacokinetics of sorafenib and its metabolites 
was measured in Oatp1b2 knock-out (KO) and wildtype (WT) mice, as well as in 9 
sorafenib treated patients in a randomized cross-over trial. The in vitro transport of SG by 
human OATP1B1 and its murine equivalent Oatp1b2 was potently inhibited by rifampin. In 
mice, rifampin increased plasma levels of SG 15-fold, but not in Oatp1b2-KO animals. In 
human subjects on a chronic sorafenib regimen, rifampin acutely more than doubled 
exposure to SG (P<0.001). We show impaired OATP1B-type transport leads to systemic 
accumulation of SG. In view of the dominant role of SG in the enterohepatic recirculation 
of sorafenib, prolonged OATP1B inhibition by co-medication or by an inherited genetic 
predisposition may lead to reduced plasma levels of sorafenib, and consequently a 
diminished therapeutic efficacy. 
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INTRODUCTION 
The multikinase inhibitor sorafenib is used as a chemotherapeutic agent in the treatment 
of multiple malignant diseases, including cancers of the liver, kidney, and thyroid.1-3 The 
pharmacokinetic properties of sorafenib are characterized by up to 90% variation in oral 
exposure between patients receiving the same therapeutic regimen.4 The high degree of 
interindividual pharmacokinetic variability observed with sorafenib has important 
toxicological ramifications. For example, it was recently demonstrated that levels of 
sorafenib in plasma are correlated with the incidence of skin rash,5 with dose reduction 
and study withdrawal due to adverse effects 6, and with the development of severe 
adverse reactions.7 
The mechanisms underlying the unpredictable pharmacokinetic profile of 
sorafenib remain largely unexplained. After oral administration, sorafenib enters 
hepatocytes by incompletely defined mechanisms,8, 9 and then undergoes CYP3A4-
mediated oxidation10, 11 and UGT1A9-mediated glucuronidation.11 A mass balance study of 
oral sorafenib in humans has shown that 15% of the dose was eliminated as sorafenib-β-
D-glucuronide (SG), compared to less than 5% as oxidative metabolites. Interestingly, SG 
was not detectable in feces, which may be due to its instability in the presence of bacterial 
glucuronidases present in the gut.12 Therefore, it has been suggested that the actual 
contribution of glucuronidation to sorafenib elimination may have been underestimated 
in the mass balance study,9 and that, because of its effective secretion into bile,13 the 
appearance of SG in the systemic circulation represents an overshoot mechanism that 
poorly reflects the actual extent of its formation. These observations suggest that a critical 
determinant of sorafenib’s pharmacokinetic variability with possible consequences for 
clinical management may be associated with differential expression and function of SG 
transporters regulating its distribution and elimination.14 
After its formation, SG is secreted into the bile through a process mediated by the 
ATP-binding cassette efflux transporter ABCC2 (MRP2).13 Under normal physiologic 
conditions, a fraction of the hepatocellular SG is secreted back into the blood stream by 
ABCC3 (MRP3), from where it can be taken up again into downstream hepatocytes via the 
uptake carrier OATP1B1 (Oatp1b2 in mice) (Figure 1).13 This liver-to-blood shuttling loop 
called hepatocyte-hopping, may prevent saturation of ABCC2-mediated biliary secretion of 
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endogenous and xenobiotic glucuronides in upstream hepatocytes, thereby ensuring 
their efficient biliary elimination and hepatocyte detoxification. Once secreted into 
bile, SG enters the intestinal lumen where it serves as a substrate for a bacterial β-
glucuronidase that produces sorafenib, which subsequently undergoes intestinal 
absorption and then reenters the systemic circulation.13 In the current proof-of-
concept study, we tested the hypothesis that the hepatocyte hopping of SG can be 
interrupted by a clinical OATP1B1-mediated drug-drug interaction based on the 
expectation that inhibition of a hepatic uptake mechanism will lead to acute increases 
in levels of SG in plasma. 
 
METHODS 
Cell lines and chemicals 
A model of OATP1B1-expressing cells was created by transfecting HEK293 cells with 
the pIRES2-EGFP vector (Clontech) containing SLCO1B1 cDNA. Similarly, HEK293 cells 
were transfected with the pDream2.1/MCS vector (GenScript) containing Slco1b2 
cDNA. The HEK293 (ATCC® CRL¬1573™) cell line was obtained from ATCC (American 
Type Culture Collection).  This cell line was exclusively used to study drug transport, 
and was not authenticated by the authors. All stable cell lines were selected and 
maintained in DMEM supplemented with 10% FBS and G418 sulfate (500-1,000 
µg/mL; AG Scientific) at 37ºC under 5% CO2. 
Sorafenib and rifampin were obtained from Chemie Tek. General tritium-
labeled sorafenib (specific activity, >1 Ci/mmol; radiochemical purity, >97.1%) was 
custom made by Moravek Biochemicals, and [3H]estradiol-17β-D-glucuronide (E2G; 
specific activity, 50.1 Ci/mmol; radiochemical purity, 99.0%), a positive control 
substrate for OATP1B1 and Oatp1b2, was obtained from American Radiolabeled 
Chemicals.  
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endogenous and xenobiotic glucuronides in upstream hepatocytes, thereby ensuring 
their efficient biliary elimination and hepatocyte detoxification. Once secreted into 
bile, SG enters the intestinal lumen where it serves as a substrate for a bacterial β-
glucuronidase that produces sorafenib, which subsequently undergoes intestinal 
absorption and then reenters the systemic circulation.13 In the current proof-of-
concept study, we tested the hypothesis that the hepatocyte hopping of SG can be 
interrupted by a clinical OATP1B1-mediated drug-drug interaction based on the 
expectation that inhibition of a hepatic uptake mechanism will lead to acute increases 
in levels of SG in plasma. 
 
METHODS 
Cell lines and chemicals 
A model of OATP1B1-expressing cells was created by transfecting HEK293 cells with 
the pIRES2-EGFP vector (Clontech) containing SLCO1B1 cDNA. Similarly, HEK293 cells 
were transfected with the pDream2.1/MCS vector (GenScript) containing Slco1b2 
cDNA. The HEK293 (ATCC® CRL¬1573™) cell line was obtained from ATCC (American 
Type Culture Collection).  This cell line was exclusively used to study drug transport, 
and was not authenticated by the authors. All stable cell lines were selected and 
maintained in DMEM supplemented with 10% FBS and G418 sulfate (500-1,000 
µg/mL; AG Scientific) at 37ºC under 5% CO2. 
Sorafenib and rifampin were obtained from Chemie Tek. General tritium-
labeled sorafenib (specific activity, >1 Ci/mmol; radiochemical purity, >97.1%) was 
custom made by Moravek Biochemicals, and [3H]estradiol-17β-D-glucuronide (E2G; 
specific activity, 50.1 Ci/mmol; radiochemical purity, 99.0%), a positive control 
substrate for OATP1B1 and Oatp1b2, was obtained from American Radiolabeled 
Chemicals.  
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Uptake studies 
Cells were seeded in 6-well plates in phenol red-free DMEM media containing 10% 
FBS, and were incubated at 37oC for 24 hours. Cells were then washed with warm PBS 
and incubated with sorafenib or SG in phenol-free DMEM media (without FBS and 
supplements) at 37oC. Uptake and inhibition studies were performed as outlined in 
detail elsewhere.13 The experiment was terminated by placing cells on ice and 
washing twice with ice-cold PBS. Cells were collected and centrifuged at 1050 r.p.m. 
for 5 min at 4oC. The cell pellet was lysed in 1 N NaOH by vortex-mixing, incubated at 
4oC overnight, and then the solution was neutralized with 2 M HCl. Total protein was 
measured using a Pierce BCA Protein Assay Kit (Thermo Scientific) and total protein 
content was quantified using a Biotek µQuant microplate spectrophotometer. 
Intracellular drug concentrations were determined in the remaining cell lysate by 
liquid scintillation counting using a LS 6500 Multipurpose Scintillation Counter 
(Beckman). The experiments were performed in triplicate. Intracellular concentrations 
of SG were measured by liquid chromatography-tandem mass spectrometry (LC-
MS/MS), as described previously.11 
 
Transcellular transport 
MDCKII cells were transduced with pIRES2 construct containing CFP-ABCC2-V5, GFP-
OAT1B1-FLAG, or GFP-OATP1B1-FLAG/CFP-ABCC2-V5 (Figure 2). The MDCKII (ATCC® 
CRL¬2936™) cell line was obtained from ATCC (American Type Culture Collection).  
This cell line was exclusively used to study drug transport, and was not authenticated 
by the authors. Transport of SG (1 µM) was performed in 6-well plates (Corning), as 
described.11 Trans-epithelial electrical resistance was measured to confirm the 
integrity of cell monolayers. 
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Figure 2. Transcellular transport of SG in transfected MDCKII cells.  
MDCKII cells were stably transduced with pIRES2-GFP-OATP1B1-FLAG (A), pIRES2-CFP-ABCC2-V5 (B), 
or both (C).  Cells were stained with antibodies against FLAG (red; OATP1B1), V5 (green; ABCC2), or 
both.  Panels on top and left sides of the images represent x-z and y-z projections and represent slide 
to coverslip image where OATP1B1 is visualized on the basolateral membrane and ABCC2 on the 
apical membrane.  Basolateral-to apical transcellular transport of SG in these cells is shown for 
OATP1B1 (D), ABCC2 (E), or both (F) in the presence or absence of rifampin.  Cells were incubated 
with SG (1 µM) at t=0 then 50-µL aliquots were taken at 1, 2, 3, and 4 hours from the compartment 
opposite to where the drug was added.  Data are expressed as percent of the initial SG 
concentration, and symbols represent mean ± SE (error bars) of at least 3 replicate experiments. 
 
 
Immunofluorescence 
MDCKII cells transduced with CFP-ABCC2-V5 and/or GFP-SLCO1B1-FLAG were seeded at 
2×105 cells/well into 6-transwell plates. When they have reached about 90% confluence, 
cells were washed with ice-cold PBS, fixed with 4% paraformaldehyde-PBS, permeabilized 
with 0.1% TritonX-100-PBS and incubated in 3% BSA-PBS blocking buffer. Then, cells were 
stained with either anti-V5 (Sigma-Aldrich) or anti-FLAG M2 (Sigma-Aldrich) followed by 
staining with Alexa488 and Alex568 (Life Technologies), respectively, along with DAPI 
(Invitrogen) to stain the nuclei. Transwell membranes were cut out and placed on a slide, 
covered with a coverslip, and sealed. Imaging was done using a Marianas spinning disk 
confocal (SDC) imaging system (Intelligent Imaging Innovations/3i) based on AxioObserver 
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Z1 inverted microscope (Carl Zeiss MicroImaging). Images were acquired with Zeiss 
Plan-Apochromat 63× 1.4 NA DIC objective and Evolve 512 EMCCD camera 
(Photometrics) using SlideBook 5 software (3i). 
 
Murine pharmacokinetics 
Eight female mice knockout for Oatp1b2 [Oatp1b2(-/-)] and eight age-matched wild-
type mice on a DBA1/lacJ background were bred in-house. Mice were housed in a 
temperature-controlled environment with a 12-hour light cycle and given a standard 
diet and water ad libitum. Experiments were approved by the Institutional Animal 
Care and Use Committee.  
Sorafenib was formulated in 50% Cremophor EL (Sigma Aldrich) and 50% 
ethanol, and diluted 1:4 (vol/vol) with deionized water immediately before 
administration by oral gavage at a dose of 10 mg/kg. Mice were fasted for 3 hours 
before and during the study, with unrestricted access to drinking water. In four 
Oatp1b2(-/-) and in four wild-type mice, rifampin (20 mg/kg) was administered 
intravenously 5 minutes prior to the oral sorafenib administration. At select time 
points, blood samples (30 μL each) were taken from individual mice at 0.25, 0.5, and 
1.5 h from the submandibular vein using a lancet, and at 3, and 4.5 h from the retro-
orbital venous plexus using a capillary. A final blood draw was obtained at 7.5 h by a 
cardiac puncture using a syringe and needle. For sampling via retro-orbital bleeding, 
mice were anesthetized under 1-5% isoflurane through inhalation, and blood was 
collected using a heparinized capillary tube. The total blood volume collected during 
the procedure from each mouse was 150 μL. All blood samples were centrifuged at 
3000 × g for 5 min, and plasma was separated and stored at -80oC until analysis. At 
the terminal time points, liver samples were immediately collected and flash-frozen 
on dry ice. Liver specimens were stored at -80°C until further processing. Plasma and 
liver concentrations of sorafenib, sorafenib-N-oxide, and SG were determined by LC-
MS/MS, as described previously.11 Pharmacokinetic parameters were calculated using 
WinNonlin 6.3 software (Pharsight).  
Interaction of Rifampin with Sorafenib Disposition | 77 
 
Clinical studies 
Patients were enrolled and received standard of care treatment with sorafenib in an open-
label randomized cross-over trial. The principle inclusion criteria were: age ≥18 years, 
confirmed diagnosis of cancer, WHO performance score 0-1, and adequate organ function. 
Also, patients had to be on steady state of sorafenib, which we had defined as at least 14 
days treatment at the same sorafenib dose. The major exclusion criteria were prior liver 
transplantation, contra-indications for any of the study drugs, and use of any co-
medication or supplement that can interact with the study drugs. The sample size of the 
study was determined to be 9 in order to detect a difference of 239 ng/mL (25%) in steady 
state exposure to SG in the presence of rifampin, with a significance level of 0.05, power 
of 0.8, and an estimated SD of the difference between two measurements in one patient 
of 223 ng/mL (unpublished data). Between August 2013 and March 2015, 9 evaluable 
patients with hepatocellular carcinoma were included in the clinical study, of which 8 
were male and 1 was female. Their mean age was 71 years (range, 62-79) and all patients 
had WHO performance score 1. Patients were randomized by minimization using the web 
based application Trial Online Process (TOP). Patient characteristics were entered in TOP 
by one of the investigators and the patient’s trial number and randomization arm were 
then sent to all investigators in an automatic email from TOP. Four patients were 
randomized to receive rifampin during the first sampling period and 5 were randomized to 
rifampin during the second period. The administered sorafenib (Nexavar®; Bayer, the 
Netherlands) dose was 200 mg BID for 5 patients and 400 mg BID for 4 patients. The study 
was approved by the institutional review board (Protocol number, MEC 2013-194), and 
registered in the Dutch Trial Registry (www.trialregister.nl; number NTR4110). All patients 
provided written informed consent, and the study was conducted in accordance with 
Good Clinical Practice guidelines and the Declaration of Helsinki (59th WMA General 
Assembly, Seoul, Republic of Korea, October 2008).  
Subjects were admitted to the hospital for two separate days of blood sampling: 
once with prior rifampin administration and once without. Days of blood sampling were 
separated by a period of 9 days. Patients were randomized to receive rifampin either in 
advance of the first or the second sampling period. Rifampin was taken without food as 
600 mg tablets (Rifadin®; Sanofi-Aventis, the Netherlands) on the day before and on the 
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day of sampling at 8 AM, exactly one hour before sorafenib administration. Two and a half 
hours after sorafenib intake, midazolam (2.5 mg; Actavis, the Netherlands) was 
administrated intravenously as a probe for CYP3A4 activity.15 During both hospitalizations, 
blood samples (6 mL each) for the determination of sorafenib and metabolite levels were 
collected just before the administration of sorafenib, and 2, 4 and 7.5 hours after the 
administration of sorafenib. Samples were prepared by centrifugation at 1,200 g for 5 
minutes to obtain plasma, which was stored at -80°C until analysis. Concentrations of 
midazolam and its metabolites were measured in three plasma samples taken 2, 4 and 6 
hours after midazolam administration during both sample periods. The midazolam 
samples were centrifuged and stored as described above. WinNonlin 6.3 (Pharsight) was 
used for calculating pharmacokinetic parameters. 
Patients were seen in the outpatient clinic on a weekly basis for clinical 
examination, laboratory tests, and to evaluate possible side effects. Skin toxicity and 
diarrhea were managed according to local guidelines. Adverse events were registered 
according to the National Cancer Institute’s CTCAE version 4.03. During the study, dose 
changes of sorafenib and the use of co-medication that influences CYP3A4 function were 
not allowed. 
 
Statistical analysis 
Pharmacokinetic data are presented as geometric mean and 95% confidence interval. No 
statistical analyses have been performed on the cell line and murine experiments, since 
these experiments were replicated less than five times each and these results should 
therefore be regarded as exploratory. In patients that received sorafenib 200 mg BID, 
AUCs and absolute concentrations were corrected towards a 400 mg BID dose, i.e. all 
parameters were doubled, as sorafenib has been described to exhibit linear 
pharmacokinetics.16 Statistical analysis was performed using GraphPad Prism 5.0 
(GraphPad Software). Geometric means of the pharmacokinetic parameters were 
compared using two-sided paired t-tests, and P<0.05 was considered statistically 
significant.    
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RESULTS 
Influence of rifampin on SG transport in vitro 
Experiments were initially carried out with HEK293 cells expressing OATP1B1 or its 
murine equivalent Oatp1b2 using the recommended model substrate estradiol-17β-
glucuronide (E2G),17 and the clinically-relevant OATP1B-type transporter inhibitor 
rifampin.18 Following a 15-min incubation period, E2G uptake by human OATP1B1 and 
mouse Oatp1b2 was strongly inhibited by a pre-incubation with rifampin (30 µM) 
(Figure 3A-B). Since rifampin-mediated inhibition of OATP1B1 can be substrate-
dependent, with up to 12-fold variation in IC50 values,19 we next used SG as a test 
substrate in the same models. Similar to E2G, the intracellular uptake of SG by both 
OATP1B1 and Oatp1b2 was efficiently inhibited by rifampin (Figure 3A-B), and this 
process was dependent on the rifampin concentration (Figure 3C). The resulting IC50 
values of approximately 1 µM for both OATP1B1 and Oatp1b2 were similar to those 
reported previously for uptake inhibition by rifampin of other substrates.20 As 
measured plasma levels of rifampin after an oral dose of 600 mg reach >7 µM,21 the 
intrinsic likelihood of an OATP1B1-mediated pharmacokinetic drug-drug interaction 
between rifampin and SG is high. 
Because rifampin is also a known inhibitor of various ABC transporters,22 and 
can influence the transport of SG in inside-out vesicles expressing ABCC2,13 we next 
evaluated the influence of rifampin on the flux of SG in MDCKII cells engineered to 
overexpress OATP1B1, ABCC2, or both OATP1B1 and ABCC2 (Figure 2). Transfection of 
OATP1B1 (basolaterally localized) into MDCKII cells significantly increased the basal-
to-apical transport of SG, and this translocation was diminished in the presence of 
rifampin (Figure 2D). However, the basal-to-apical flux of SG was not substantially 
enhanced by co-transfection of ABCC2 (apically localized), and not further reduced by 
rifampin in cells expressing both OATP1B1 and ABCC2 (Figure 2D). This suggests that 
rifampin can be utilized for in vivo studies as a bona fide inhibitor of SG transport by 
OATP1B-type carriers. 
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Figure 3. Transport of SG by OATP1B-type transporters. 
Transport of estradiol-17β-glucuronide (E2G; 0.1 µM) and sorafenib-β-D-glucuronide (SG; 10 µM) in 
HEK293 cells engineered to overexpress OATP1B1 (a) or OATP1B2 (b) with or without rifampin (20 
µM). All results are normalized to the transport rate in OATP1B transfected cells without rifampin, 
i.e. the experiments with unrestricted OATP1B effect, which were 4.77 pmol/mg protein (OATP1B1) 
and 26.73 pmol/mg protein (OATP1B2) in 15 minutes for E2G, and  57.46 pmol/mg protein 
(OATP1B1) and 770.17 pmol/mg protein (OATP1B2) in 15 minutes for SG. (c) Inhibition of OATP1B1 
or OATP1B2-mediated transport of SG (10 µM) by different concentrations of rifampin (0-100 µM). 
Data are normalized to the relative uptake without rifampin, i.e. when the function of OATP1B is 
unrestricted, and represent the mean ± SE from 3-4 independent experiments (9-12 replicates). (d) 
Transcellular transport of SG in MDCKII cells expressing OATP1B1 and/or ABCC2. Cells were 
incubated with SG (1 µM), and 50-µl aliquots were taken at 1, 2, 3, and 4 hours from the 
compartment opposite to where the drug was added, in the presence or absence of rifampin (100 
µM). Data are expressed as transporter-mediated apparent permeability coefficient (Papp) for the 
basolateral to apical direction (B-to-A). Data represent the mean ± SE (at least 3 replicates). 
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Figure 4. Pharmacokinetics of sorafenib and SG in wild-type and Oatp1b2(-/-) mice. 
Plasma concentration-time profiles of SG (a) and sorafenib (d) in wild-type mice and Oatp1b2(-/-) 
mice in the presence and absence of rifampin pretreatment. Corresponding area under the plasma 
concentration-time curves (AUCs) of SG, sorafenib, and sorafenib-N-oxide (S-N-oxide) are shown in 
(b), (e), and (f). Sorafenib was administered orally at a dose of 10 mg/kg with or without 
pretreatment with rifampin (20 mg/kg). Livers were taken at 7.5 h after sorafenib administration 
(n=4 per group), with results expressed as the liver-to-plasma concentration ratio of SG (c). 
Concentrations in liver were normalized to corresponding concentrations in plasma. All data 
represent the geometric mean and the 95% confidence interval. 
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Figure 3. Transport of SG by OATP1B-type transporters. 
Transport of estradiol-17β-glucuronide (E2G; 0.1 µM) and sorafenib-β-D-glucuronide (SG; 10 µM) in 
HEK293 cells engineered to overexpress OATP1B1 (a) or OATP1B2 (b) with or without rifampin (20 
µM). All results are normalized to the transport rate in OATP1B transfected cells without rifampin, 
i.e. the experiments with unrestricted OATP1B effect, which were 4.77 pmol/mg protein (OATP1B1) 
and 26.73 pmol/mg protein (OATP1B2) in 15 minutes for E2G, and  57.46 pmol/mg protein 
(OATP1B1) and 770.17 pmol/mg protein (OATP1B2) in 15 minutes for SG. (c) Inhibition of OATP1B1 
or OATP1B2-mediated transport of SG (10 µM) by different concentrations of rifampin (0-100 µM). 
Data are normalized to the relative uptake without rifampin, i.e. when the function of OATP1B is 
unrestricted, and represent the mean ± SE from 3-4 independent experiments (9-12 replicates). (d) 
Transcellular transport of SG in MDCKII cells expressing OATP1B1 and/or ABCC2. Cells were 
incubated with SG (1 µM), and 50-µl aliquots were taken at 1, 2, 3, and 4 hours from the 
compartment opposite to where the drug was added, in the presence or absence of rifampin (100 
µM). Data are expressed as transporter-mediated apparent permeability coefficient (Papp) for the 
basolateral to apical direction (B-to-A). Data represent the mean ± SE (at least 3 replicates). 
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Figure 4. Pharmacokinetics of sorafenib and SG in wild-type and Oatp1b2(-/-) mice. 
Plasma concentration-time profiles of SG (a) and sorafenib (d) in wild-type mice and Oatp1b2(-/-) 
mice in the presence and absence of rifampin pretreatment. Corresponding area under the plasma 
concentration-time curves (AUCs) of SG, sorafenib, and sorafenib-N-oxide (S-N-oxide) are shown in 
(b), (e), and (f). Sorafenib was administered orally at a dose of 10 mg/kg with or without 
pretreatment with rifampin (20 mg/kg). Livers were taken at 7.5 h after sorafenib administration 
(n=4 per group), with results expressed as the liver-to-plasma concentration ratio of SG (c). 
Concentrations in liver were normalized to corresponding concentrations in plasma. All data 
represent the geometric mean and the 95% confidence interval. 
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Effects of rifampin on SG disposition in mice 
The in vivo role of rifampin (20 mg/kg) in the transport of SG was next evaluated in wild-
type mice and Oatp1b2-deficient [Oatp1b2(-/-)] littermates receiving a single oral dose of 
sorafenib (10 mg/kg). This experiment was based on the expectation that the systemic 
exposure to SG would increase by rifampin in an Oatp1b2-dependent manner, as 
predicted from our in vitro transport experiments. In line with our previous findings,9 
Oatp1b2-deficiency in mice was associated with a substantially increased systemic 
exposure to SG (Figure 4; Table 1).  
The liver-to-plasma ratio of SG was reduced by approximately 90% in wild-type 
mice pre-treated with rifampin, and similar to that observed in Oatp1b2(-/-) mice 
receiving sorafenib either alone or when given in combination with rifampin (Figure 4C). 
Oatp1b2-deficiency and/or rifampin pre-treatment did not substantially affect the plasma 
levels of sorafenib parent drug or of its primary oxidated metabolite sorafenib-N-oxide 
(Figure 4D-F). This observation is consistent with our previous finding that sorafenib itself 
is not a transported substrate of Oatp1b2,9 and with the contention that the applied single 
dose of rifampin is unlikely to have artificially influenced other enzymes and transporters 
of relevance to the disposition of sorafenib or SG. 
 
Effects of rifampin on SG disposition in humans 
We next assessed the influence of pre-treatment with rifampin (two daily oral doses of 
600 mg) on the pharmacokinetics of SG in human subjects receiving oral sorafenib at 
steady-state using an open-label randomized cross-over design. As predicted from the 
murine pharmacokinetic studies, we found that concomitant rifampin administration 
resulted in acute, statistically significant increases in the systemic exposure to SG (32,479 
ng×h/mL versus 14,646 ng×h/mL; P<0.001) (Figure 5A; Table 2), and this was independent 
of the randomization sequence (Figure 5B). 
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Effects of rifampin on SG disposition in mice 
The in vivo role of rifampin (20 mg/kg) in the transport of SG was next evaluated in wild-
type mice and Oatp1b2-deficient [Oatp1b2(-/-)] littermates receiving a single oral dose of 
sorafenib (10 mg/kg). This experiment was based on the expectation that the systemic 
exposure to SG would increase by rifampin in an Oatp1b2-dependent manner, as 
predicted from our in vitro transport experiments. In line with our previous findings,9 
Oatp1b2-deficiency in mice was associated with a substantially increased systemic 
exposure to SG (Figure 4; Table 1).  
The liver-to-plasma ratio of SG was reduced by approximately 90% in wild-type 
mice pre-treated with rifampin, and similar to that observed in Oatp1b2(-/-) mice 
receiving sorafenib either alone or when given in combination with rifampin (Figure 4C). 
Oatp1b2-deficiency and/or rifampin pre-treatment did not substantially affect the plasma 
levels of sorafenib parent drug or of its primary oxidated metabolite sorafenib-N-oxide 
(Figure 4D-F). This observation is consistent with our previous finding that sorafenib itself 
is not a transported substrate of Oatp1b2,9 and with the contention that the applied single 
dose of rifampin is unlikely to have artificially influenced other enzymes and transporters 
of relevance to the disposition of sorafenib or SG. 
 
Effects of rifampin on SG disposition in humans 
We next assessed the influence of pre-treatment with rifampin (two daily oral doses of 
600 mg) on the pharmacokinetics of SG in human subjects receiving oral sorafenib at 
steady-state using an open-label randomized cross-over design. As predicted from the 
murine pharmacokinetic studies, we found that concomitant rifampin administration 
resulted in acute, statistically significant increases in the systemic exposure to SG (32,479 
ng×h/mL versus 14,646 ng×h/mL; P<0.001) (Figure 5A; Table 2), and this was independent 
of the randomization sequence (Figure 5B). 
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Figure 5. Influence of rifampin on the pharmacokinetics of sorafenib in humans. 
Plasma concentration-time profiles of SG (a) and sorafenib (d) in patients with hepatocellular carcinoma in 
the presence and absence of rifampin pretreatment. The corresponding area under the plasma 
concentration-time curve (AUC) of SG is shown as a function of the randomization sequence of the cross-
over trial (b). The metabolic ratios for SG to sorafenib, 1’-hydroxy-midazolam (1’-OH-MDZ) to midazolam 
(MDZ) and sorafenib-N-oxide (S-N-oxide) to sorafenib are shown in (c), (e), and (f), respectively. All data 
represent the geometric mean and the 95% confidence interval. 
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Figure 5. Influence of rifampin on the pharmacokinetics of sorafenib in humans. 
Plasma concentration-time profiles of SG (a) and sorafenib (d) in patients with hepatocellular carcinoma in 
the presence and absence of rifampin pretreatment. The corresponding area under the plasma 
concentration-time curve (AUC) of SG is shown as a function of the randomization sequence of the cross-
over trial (b). The metabolic ratios for SG to sorafenib, 1’-hydroxy-midazolam (1’-OH-MDZ) to midazolam 
(MDZ) and sorafenib-N-oxide (S-N-oxide) to sorafenib are shown in (c), (e), and (f), respectively. All data 
represent the geometric mean and the 95% confidence interval. 
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The mean metabolic ratios of SG to sorafenib in the studied patient cohort were also 
significantly increased during rifampin administration (Figure 5C). No statistically 
significant differences were observed in the pharmacokinetic parameter estimates of 
sorafenib (Figure 5D). Although the mean ratio between 1’-hydroxymidazolam and 
midazolam, used as a measure of CYP3A4 activity changes,23 was approximately 2 times 
higher after rifampin intake (P=0.005; Figure 5E), the extent of sorafenib-N-oxide 
formation was not different between treatment cycles (Figure 5F). During the course of 
the clinical study, no toxicities were observed that could be attributed to rifampin or 
midazolam. In one patient, bilirubin levels in plasma were elevated from 14 to 29 μM (upper 
limit of normal, 16 μM) on the second day of rifampin intake, but bilirubin levels normalized to 
baseline within 2 days. 
 
DISCUSSION 
This study shows that acute inhibition of the hepatic uptake transporter OATP1B1 by 
rifampin results in a substantial pharmacokinetic interaction with SG at steady-state in 
human subjects receiving oral sorafenib. This finding not only emphasizes the need to 
consider hepatic handling of xenobiotic glucuronides in the design of pharmacokinetic 
drug-drug interaction studies of agents that undergo extensive Phase II conjugation, but 
also has potentially direct clinical relevance for the chemotherapeutic treatment with 
sorafenib. 
It was previously suggested based on in vitro microsomal studies that the most 
prominent pathway of sorafenib elimination consists of CYP3A4-mediated metabolism 
leading to the formation of sorafenib-N-oxide and several other metabolites.8 This finding 
suggested that sorafenib was potentially subject to a host of CYP3A4-mediated drug 
interactions with commonly co-prescribed medications.24 Here, the AUCs of the CYP3A4-
mediated metabolites of midazolam and sorafenib were nearly 2 times higher after 
rifampin, but – to a smaller extent – this was  also true for sorafenib. As the ratio of 
sorafenib-N-oxide to sorafenib did not change between both cycles, the interaction of 
rifampin on sorafenib-N-oxide formation does not seem to be relevant. Additionally, the 
prototypical CYP3A4 inhibitor ketoconazole has been demonstrated to have no influence 
on the pharmacokinetics of sorafenib in healthy male volunteers after single-dose 
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sorafenib administration, suggesting that the fraction of sorafenib that is metabolized by 
the Phase I oxidative pathway is low.12 However, although clinical data suggest that 
sorafenib glucuronidation accounts for only 15% of the dose, it is likely that this 
percentage is grossly underestimated,13 and may be increased further if the competing 
CYP3A4-mediated pathway is inhibited.12 The long-term clinical implications of such 
pharmacokinetic drug-drug interaction remain unstudied. 
The use of rifampin as an OATP1B1 inhibitor in our studies was based on 
considerations published elsewhere.18 The relatively strong impact of rifampin on SG 
levels in mice (>9-fold increase) compared with humans (~2-fold) likely reflects a 
differential direct influence of rifampin on the uptake of sorafenib itself into hepatocytes, 
which process is partially dependent on OATP1B-type transporters in humans but appears 
of less relevance in mice.9 In addition, SG is known to undergo substantial renal excretion 
in humans but not in mice,13 and the possible presence of a rifampin-insensitive escape 
mechanism in the kidney may result in shunting of SG to urine when OATP1B1 function in 
humans is impaired. 
It should also be pointed out that, although acute exposure to rifampin inhibits 
OATP1B1,25 extended daily administration of rifampin may induce enzymes and 
transporters of putative relevance to sorafenib. For example, exposure to rifampin for 5 
days or more dramatically increased the clearance of the CYP3A4 substrate drugs 
midazolam,26 alfentanil,27 and erythromycin.28 Several recent studies have evaluated the 
effects of acute and extended exposure to rifampin on CYP3A4 activity in the same 
individuals. For example, rifampin 600 mg given once daily for 1-2 doses (acute exposure) 
and for 6.5 days (extended exposure) changed the systemic exposure to bosentan, a dual 
OATP1B1 and CYP3A4 substrate drug, by +500% and -58%, respectively.29 If induction of 
enzymes occurs, it is likely that rifampin exposure for 5 days or more is required to cause a 
clinically-relevant, induced CYP3A4 phenotype. Because CYP3A4 induction seems to play 
only a modest role here, the present observations with sorafenib in conjunction with 
acute exposure to rifampin may not be extrapolated to the situation where the agent is 
co-administered with rifampin for an extended period of time or have relevance to a 
scenario in which other OATP1B1-interfering medications are co-prescribed with 
sorafenib. 
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Interestingly, administered at a dose of 600 mg once daily for 5 days with a single 
oral dose of sorafenib in healthy volunteers, rifampin was previously found to cause a 37% 
decrease in the mean systemic exposure to sorafenib.30 The causal connection of this 
observation with altered CYP3A4 activity, however, remains uncertain and other plausible 
mechanisms could contribute to the reported observations. For example, prolonged 
exposure to rifampin can significantly upregulate OATP1B1 and ABCC2 in primary 
hepatocytes,31 and can induce UGT1A9 mRNA and UGT1A9 activity in human subjects 
after 6 days of exposure to a once daily dose of 600 mg.32 Interestingly, prolonged 
treatment with rifampin may also affect the hepatic expression and function of the uptake 
transporter OCT1,33 which has been proposed as a possible hepatic uptake carrier of 
sorafenib.8, 34 However, this may not be of concern clinically, since recent studies in mice 
with a hepatic OCT1-deficiency indicate this transporter plays only a relatively minor role 
in the overall elimination of sorafenib.35 
The potential clinical ramifications of the hepatocyte-hopping phenomenon of SG 
and the impact of interference in this process with transporter inhibitors such as rifampin 
requires additional investigation. For example, it should be examined if excessive systemic 
accumulation of SG leads to adverse events, as is the case with morphine-6-glucuronide.36 
This is further emphasized by the fact that single nucleotide polymorphisms in SLCO1B1 
are associated with the risk of sorafenib toxicity.37 On the other hand, future research 
should be aimed at the consequences of reduced biliary SG excretion on the maintenance 
of systemic sorafenib exposure: sorafenib undergoes enterohepatic recirculation38 
following bacterial β-glucuronidase-mediated de-conjugation of SG within the intestinal 
lumen,39 and interference of this de-conjugation by neomycin treatment decreases the 
systemic exposure to sorafenib by more than 50% (Nexavar package insert). It can be 
envisaged that interference of the biliary excretion of SG by inhibition of OATP1B1-
mediated uptake into hepatocytes could potentially lead to diminished enterohepatic 
recycling of sorafenib and, ultimately, a reduced systemic exposure to the 
pharmacologically active species. A similar phenomenon has been recently reported for 
mycophenolate mofetil, an immune-suppressive drug that, like sorafenib, undergoes 
extensive glucuronidation. In this case, a cohort of renal transplant patients with an 
inherited genotype associated with decreased OATP1B1 function had reduced circulating 
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levels of the active moiety, mycophenolic acid, and a concomitant increase in the levels of 
its glucuronide metabolite, presumably due to a disturbance in enterohepatic cycling.40 
Although phenotypes similar to those reported for mycophenolate mofetil were not 
observed with sorafenib, it should be pointed out that our current study was neither 
designed nor statistically powered to observe effects of rifampin treatment on parent 
drug levels, despite the fact that we administered rifampin a day longer than 
recommended by the International Transporter Consortium18 in order to be able to 
observe the maximal effect on parent drug levels. It is also conceivable that direct 
inhibition of OATP1B1-mediated transport of sorafenib by rifampin in the studied patient 
population, in addition to an independent inhibitory effect of rifampin on SG transport by 
OATP1B1, could have masked an influence on enterohepatic recirculation. 
Overall, our findings signify an important contribution of OATP1B1 in the 
elimination of sorafenib in humans, whereby compromised OATP1B1 function leads to 
systemic SG accumulation, of which the clinical relevance needs to be assessed. The 
OATP1B1-related excretion of SG seems to take place via a sinusoidal liver-blood shuttling 
loop. As the design of this study was not suitable to detect the influence of OATP1B1 
inhibition on sorafenib exposure, the theory for lower systemic sorafenib exposure after 
prolonged OATP1B1 inhibition still cannot be rejected, with important potential 
ramifications illustrated by the established exposure-toxicity relationships. We expect that 
the current observations with sorafenib may have relevance to other kinase inhibitors 
undergoing Phase II conjugation through glucuronidation (Table 3). Therefore, the effects 
of prolonged OATP1B1 inhibiting factors, e.g. clarithromycin41 and ramipiril,20 on the 
pharmacokinetics of glucuronidated drugs should be assessed. Until then, we suggest that 
caution is warranted if such drugs have to be administered together with agents that 
potently inhibit OATP1B-type transporters.  
 
  
588 | Chapter 5 
 
 
Interestingly, administered at a dose of 600 mg once daily for 5 days with a single 
oral dose of sorafenib in healthy volunteers, rifampin was previously found to cause a 37% 
decrease in the mean systemic exposure to sorafenib.30 The causal connection of this 
observation with altered CYP3A4 activity, however, remains uncertain and other plausible 
mechanisms could contribute to the reported observations. For example, prolonged 
exposure to rifampin can significantly upregulate OATP1B1 and ABCC2 in primary 
hepatocytes,31 and can induce UGT1A9 mRNA and UGT1A9 activity in human subjects 
after 6 days of exposure to a once daily dose of 600 mg.32 Interestingly, prolonged 
treatment with rifampin may also affect the hepatic expression and function of the uptake 
transporter OCT1,33 which has been proposed as a possible hepatic uptake carrier of 
sorafenib.8, 34 However, this may not be of concern clinically, since recent studies in mice 
with a hepatic OCT1-deficiency indicate this transporter plays only a relatively minor role 
in the overall elimination of sorafenib.35 
The potential clinical ramifications of the hepatocyte-hopping phenomenon of SG 
and the impact of interference in this process with transporter inhibitors such as rifampin 
requires additional investigation. For example, it should be examined if excessive systemic 
accumulation of SG leads to adverse events, as is the case with morphine-6-glucuronide.36 
This is further emphasized by the fact that single nucleotide polymorphisms in SLCO1B1 
are associated with the risk of sorafenib toxicity.37 On the other hand, future research 
should be aimed at the consequences of reduced biliary SG excretion on the maintenance 
of systemic sorafenib exposure: sorafenib undergoes enterohepatic recirculation38 
following bacterial β-glucuronidase-mediated de-conjugation of SG within the intestinal 
lumen,39 and interference of this de-conjugation by neomycin treatment decreases the 
systemic exposure to sorafenib by more than 50% (Nexavar package insert). It can be 
envisaged that interference of the biliary excretion of SG by inhibition of OATP1B1-
mediated uptake into hepatocytes could potentially lead to diminished enterohepatic 
recycling of sorafenib and, ultimately, a reduced systemic exposure to the 
pharmacologically active species. A similar phenomenon has been recently reported for 
mycophenolate mofetil, an immune-suppressive drug that, like sorafenib, undergoes 
extensive glucuronidation. In this case, a cohort of renal transplant patients with an 
inherited genotype associated with decreased OATP1B1 function had reduced circulating 
Interaction of Rifampin with Sorafenib Disposition | 89 
 
levels of the active moiety, mycophenolic acid, and a concomitant increase in the levels of 
its glucuronide metabolite, presumably due to a disturbance in enterohepatic cycling.40 
Although phenotypes similar to those reported for mycophenolate mofetil were not 
observed with sorafenib, it should be pointed out that our current study was neither 
designed nor statistically powered to observe effects of rifampin treatment on parent 
drug levels, despite the fact that we administered rifampin a day longer than 
recommended by the International Transporter Consortium18 in order to be able to 
observe the maximal effect on parent drug levels. It is also conceivable that direct 
inhibition of OATP1B1-mediated transport of sorafenib by rifampin in the studied patient 
population, in addition to an independent inhibitory effect of rifampin on SG transport by 
OATP1B1, could have masked an influence on enterohepatic recirculation. 
Overall, our findings signify an important contribution of OATP1B1 in the 
elimination of sorafenib in humans, whereby compromised OATP1B1 function leads to 
systemic SG accumulation, of which the clinical relevance needs to be assessed. The 
OATP1B1-related excretion of SG seems to take place via a sinusoidal liver-blood shuttling 
loop. As the design of this study was not suitable to detect the influence of OATP1B1 
inhibition on sorafenib exposure, the theory for lower systemic sorafenib exposure after 
prolonged OATP1B1 inhibition still cannot be rejected, with important potential 
ramifications illustrated by the established exposure-toxicity relationships. We expect that 
the current observations with sorafenib may have relevance to other kinase inhibitors 
undergoing Phase II conjugation through glucuronidation (Table 3). Therefore, the effects 
of prolonged OATP1B1 inhibiting factors, e.g. clarithromycin41 and ramipiril,20 on the 
pharmacokinetics of glucuronidated drugs should be assessed. Until then, we suggest that 
caution is warranted if such drugs have to be administered together with agents that 
potently inhibit OATP1B-type transporters.  
 
  
90 | Chapter 5 
 
 
Table 3. Kinase inhibitors undergoing glucuronidation. 
Compound Target Enzyme(s) Ref. 
ASP015K JAK1/3 N/a 42 
Apatinib VEGFR2 UGT2B7, 1A4 43 
Axitinib VEGFR1-3 UGT1A1, 1A3, 1A9 44, 45 
BMS-690514 pan-ErbB UGT2B4, 2B7 46 
Briciclib Cyclin D1 N/a 47 
Cediranib VEGFR2 UGT1A4 48 
Dasatinib BCR/ABL N/a 49 
Flavopiridol CDK UGT1A9 50 
Flumatinib BCR/ABL N/a 51 
Fostamatinib SYP N/a 52 
JNJ-10198409 PDGFR N/a 53 
MDC-1016 RAS N/a 54 
NU7026 DNA-PKcs N/a 55 
OTS167 MELK UGT1A1, 1A3 56 
PKI-166 EGFR N/a 57 
Regorafenib Multikinase UGT1A9 14 
Ruxolitinib JAK1/2 N/a 58 
Sapitinib Pan-ErbB N/a 59 
Sorafenib Multikinase UGT1A9 11 
Tanzisertib JNK UGT1A1, 1A4, 1A10, 2B4 60, 61 
Trametinib MEK N/a 62 
Vandetanib VEGFR2 N/a 63 
Abbreviation: N/a, not available. 
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ABSTRACT 
Aim. Sorafenib-treated patients display a substantial variation in the incidence of toxicity. 
We aimed to investigate the association of genetic polymorphisms with observed toxicity 
on sorafenib.  
Patients & methods. We genotyped 114 patients that were treated with sorafenib at the 
Erasmus MC Cancer Institute, the Netherlands, for SLCO1B1, SLCO1B3, ABCC2, ABCG2, 
UGT1A1 and UGT1A9.  
Results. The UGT1A1 (rs8175347) polymorphism was associated with hyperbilirubinemia 
and treatment interruption. Polymorphisms in SLCO1B1 (rs2306283, rs4149056) were 
associated with diarrhea and thrombocytopenia, respectively. None of the investigated 
polymorphisms was associated with overall or progression-free survival in hepatocellular 
cancer patients.  
Conclusion. Polymorphisms in SLCO1B1 and UGT1A1 are associated with several different 
sorafenib side effects. 
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INTRODUCTION 
Sorafenib, a tyrosine kinase inhibitor (TKI), is currently approved for the treatment of 
unresectable or metastatic hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and 
iodine-refractory differentiated thyroid cancer.1-3 Like other TKIs, sorafenib shows a wide 
variation in toxicity, which cannot be predicted for individual patients. The most common 
sorafenib-induced adverse events include hand–foot skin reaction (HFSR), diarrhea, 
hypertension and liver function disorders. These adverse events may lead to dose 
reductions (26%) or treatment discontinuation (38%).1 In addition, these side effects have 
at least partly been related to sorafenib pharmacokinetics (PK), which show large inter-
individual variability on its own.4-6 
 
 
Figure 1. Important proteins regarding hepatic disposition and effect of sorafenib and its major 
metabolites.  
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unresectable or metastatic hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and 
iodine-refractory differentiated thyroid cancer.1-3 Like other TKIs, sorafenib shows a wide 
variation in toxicity, which cannot be predicted for individual patients. The most common 
sorafenib-induced adverse events include hand–foot skin reaction (HFSR), diarrhea, 
hypertension and liver function disorders. These adverse events may lead to dose 
reductions (26%) or treatment discontinuation (38%).1 In addition, these side effects have 
at least partly been related to sorafenib pharmacokinetics (PK), which show large inter-
individual variability on its own.4-6 
 
 
Figure 1. Important proteins regarding hepatic disposition and effect of sorafenib and its major 
metabolites.  
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Although little is known about factors that induce this inter-individual variability 
in sorafenib exposure, many pharmacokinetic processes have already been described in 
detail.7 Sorafenib is primarily metabolized in the liver and undergoes both UGT1A9-
mediated glucuronidation and CYP3A4-mediated oxidation.8 Different membrane 
transporters (e.g., OATP1B1, ABCC2; Figure 1) are responsible for hepatocellular uptake 
and efflux of sorafenib and its metabolites.7 Theoretically, differences in function of these 
proteins may lead to altered systemic sorafenib exposure, for example, due to co-
medication or genetic variation. Systemic sorafenib exposure is known to correlate with 
certain toxicities, such as hypertension and HFSR.5,9 Moreover, multiple studies have 
identified SNPs in a variety of genes to be associated with sorafenib toxicity. OATP1B1 and 
OATP1B3, major influx transporters for both sorafenib and sorafenib-glucuronide, have 
predominantly been investigated in patients treated with irinotecan, which is 
glucuronidated and distributed by OATP1B (SLCO1B) in a similar fashion as sorafenib. 
Homozygous polymorphisms in SLCO1B1 388A>G have been associated with longer 
progression-free survival (PFS) in irinotecan treated non-small cell lung cancer patients 
and also with more grade 3 diarrhea.10,11 Another polymorphism, SLCO1B1 521T>C, leads 
to decreased transporter activity and consequently to increased exposure of the 
irinotecan metabolite SN-38, which might explain the higher incidence of neutropenia in 
patients with this polymorphism.10,11 SNPs in SLCO1B3 have been investigated scarcely, 
but the 334T>G polymorphism has been associated with decreased plasma concentrations 
of mycophenolic acid, which has a similar pattern of hepatobiliary disposition as 
sorafenib.12 The efflux transporters ABCC2 and ABCG2 are involved in the biliary secretion 
of several anticancer drugs. For sorafenib, patients with the ABCC2 -24CC genotype were 
at higher risk of skin rash than those with the computed tomography (CT) genotype.13 
Besides, reduced risk of neutropenia and diarrhea was associated with ABCC2 -24CT for 
irinotecan.11 Reports on PFS in patients with the -24TT genotype showed contradictory 
results.11,14 For imatinib, neither trough levels nor response were found to be affected by 
this SNP.15 The ABCG2 421C>A polymorphism has been associated with increased risk of 
developing diarrhea and higher 5-year PFS rate for a variety of TKIs.16,17 UGT1A9 is 
involved in the metabolism of sorafenib and patients with the -2152C>T polymorphism 
have a higher risk of diarrhea.19 UGT1A1 is not identified in sorafenib metabolism, but its 
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function is inhibited by sorafenib. Patients with at least one UGT1A1 -53TA6>TA7 allele 
(UGT1A1*28) have increased plasma bilirubin concentrations.19 For irinotecan, UGT1A1 -
53TA7 carriers have an increased risk of neutropenia and diarrhea and a reduced PFS.11,20–
21 
Here, we aimed to investigate whether these pharmacogenetic polymorphisms 
are correlated with the observed clinical toxicity of sorafenib in a relatively large cohort of 
patients exposed to this TKI. 
 
PATIENTS & METHODS 
Study design  
In this retrospective study, we analyzed 114 patients treated with sorafenib between 2006 
and 2016 at the Erasmus MC Cancer Institute. We included patients from whom whole 
blood for DNA analysis was collected (local ethics board study number MEC 02.1002). 
Patient charts were reviewed to record demographic and clinical information, in other 
words, age, gender, ethnicity, Eastern Cooperative Oncology Group (ECOG)-performance 
status, tumor type, prior treatment and sorafenib dose changes. 
 
Adverse events were registered during the entire treatment period and graded according 
to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-
CTCAE) v4.0. HFSR, diarrhea, hyperbilirubinemia, cytopenias, increased liver enzymes, 
rash, hypertension and any toxicity were recorded as end point if ≥grade 3, except for 
HFSR, which was also recorded if ≥grade 2. Additionally, the maximum bilirubin level 
during the first 2 months of treatment was compared with total bilirubin at baseline and 
acute hyperbilirubinemia was defined as a ≥100% increase in blood bilirubin 
concentrations during these 2 months. In case of treatment interruption, dose reduction 
or treatment discontinuation, all details were recorded. 
 
PFS was defined as time from start of sorafenib treatment to date of radiological or clear 
clinical progression. Patients who did not have progressive disease, were censored for PFS 
at the time of last follow-up, at start of next treatment or at date of death. Overall survival 
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(OS) was defined as time from start of sorafenib treatment to date of death, or date at 
which patients were last known to be alive. 
 
SNP selection  
We identified eight potentially functional polymorphisms in six genes involved in the PK of 
sorafenib. These polymorphisms were selected based on previously reported research 
into clinically relevant associations. The genes and the selected polymorphisms are listed 
in Table 1. Although CYP3A4 is involved in sorafenib metabolism, CYP3A4 polymorphisms 
were not included, because the only clinically relevant SNP, in other words, CYP3A4*22 
(rs35599367), leads to impaired protein function and CYP3A4 inhibition has previously 
been shown not to influence sorafenib exposure.22–25 
 
DNA isolation  
Four hundred microliters of whole-blood specimens collected in EDTA tubes were 
extracted on the MagNAPure Compact instrument (Roche Diagnostics GmbH, Germany) 
using the Nucleic Acid Isolation Kit I (Roche Diagnostics GmbH, Germany) and a final 
elution volume of 200 μl. 
 
Table 1. Investigated single nucleotide polymorphisms. 
Gene Rs-number Variant Allele WW WM MM MAF 
SLCO1B1 rs2306283 
rs4149056 
388A>G 
521T>C 
*1B 
*5 
39 
85 
51 
25 
24 
4 
43% 
14% 
SLCO1B3 rs4149117 334T>G  5 32 77 18% 
ABCC2 rs717620 -24C>T  82 30 2 15% 
ABCG2 rs2231142 421C>A  95 17 2 9% 
UGT1A1 rs8175347 -53TA6>TA7 *28 53 46* 14 33% 
UGT1A9 rs17868320 
rs6714486 
-2152C>T 
-275T>A 
 104 
103 
10 
11 
0 
0 
4% 
5% 
*One patient harbored a TA5/TA6 genotype, which was categorized as a heterozygous variant. 
Abbreviations: MAF, minor allele frequency; MM, mutant - mutant; WM, wild type - mutant; WW, 
wild type - wild type. 
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Taqman genotyping  
The SLCO1B1 388A>G and 521T>C, SLCO1B3 334T>G, ABCC2 -24C>T, ABCG2 421C>A, 
UGT1A9 -2152C>T and -275T>A genotyping was done using predesigned Drug Metabolism 
Enzymes Taqman allelic discrimination assays on the Life Technologies Taqman 7500 
system (Applied Biosystems, Life Technologies Europe BV, Bleiswijk, The Netherlands). The 
assay IDs are listed in Table 1. Each assay consisted of two allele-specific minor groove 
binding probes, labeled with the fluorescent dyes VIC and FAM. PCRs were performed in a 
reaction volume of 10 μl, containing assay-specific primers, allele-specific Taqman minor 
groove binding probes, Abgene Absolute QPCR Rox Mix (Thermo Scientific, Life 
Technologies Europe BV, Bleiswijk, The Netherlands) and genomic DNA (20 ng). The 
thermal profile consists of 40 cycles of denaturation at 95°C for 20 s and annealing at 92°C 
for 3 s and extension at 60°C for 30 s. Genotypes were scored by measuring allele-specific 
fluorescence using the 7500 software v2.3 for allelic discrimination (Applied Biosystems). 
 
LightCycler  
The real-time PCR assay was developed on the LightCycler 2.0 instrument (Roche 
Diagnostics GmbH, Mannheim, Germany). The primers and fluorescence resonance energy 
transfer hybridization probes were analyte-specific reagents from Roche Molecular 
Diagnostics targeting the UGT1A1 gene. The PCR assay was performed using the LC 
FastStart DNA master hybridization probe kit (Roche Diagnostics GmbH). The total volume 
per reaction mixture was 21 μl (20 μl of master mix plus 1 μl of extracted nucleic acid 10 
ng/μl). PCR amplification with real-time detection was performed using the following 
cycling parameters: one-template denaturing cycle at 95°C for 10 min, followed by 45 
amplification cycles at 95°C for 0 s, 60°C for 10 s and 72°C for 15 s. Following amplification, 
a melting curve analysis was performed by measuring the fluorescent signal during the 
following cycling parameters: 95°C for 30 s, 45°C for 30 s and 70°C for 0 s, with a transition 
of 0.2°C/s. Following a second melting curve analysis was performed by measuring the 
fluorescent signal during the following cycling parameters: 95°C for 30 s, 45°C for 30 s and 
70°C for 0 s, with a transition of 0.1°C/s. Finally a cooling down step was performed at 
40°C for 30 min. Positive results were detected at 640 nm and using the melting curve-Tm 
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calling analysis. Wild-type TA6 peaked at about 55°C. Heterozygous TA (6)/TA (7) patients 
peaked at about 55 and 59°C, and the variant TA7 peaked at about 59°C. 
 
Statistical analysis  
The distribution of genotypes was tested for Hardy–Weinberg equilibrium using the Chi-
square test. Polymorphisms with a minor allele frequency <1% were not analyzed. 
Polymorphisms within a single gene were tested for linkage disequilibrium (LD) in the 
European population in reference haplotypes from Phase III of the 1000 Genomes Project 
using LDlink.26 The limit for LD was set at R2 > 0.8. In Utah Residents from north and west 
Europe (CEU population), the polymorphisms in UGT1A9 met the criteria for LD (R2 = 0.94) 
and the polymorphisms in SLCO1B1 were not correlated (R2 = 0.14). Therefore, the 
polymorphisms in UGT1A9 were further analyzed as haplotype. The selected 
polymorphisms and haplotype were fitted and the most appropriate model was selected. 
As for the dominant and recessive model, the polymorphisms and haplotype were tested 
against the toxicity end points using the Chi-square test or Fisher's exact test, while logistic 
regression analysis was applied for the multiplicative and additive model27 If an end point 
occurred in more than 20 patients, candidate genetic variables with p ≤ 0.1 were selected 
for the multiple logistic regression analysis with toxicity as depending variable. All 
multivariable analyses corrected for age, gender and ECOG performance status. PFS and 
OS were estimated in patients with HCC by the Kaplan–Meier method, and the log-rank 
test was used for univariable survival analysis. If all groups in the model contained more 
than ten patients, multivariable survival analysis was considered. All statistical analyses 
were performed using SPSS version 21 software (SPSS, IL, USA). A two-sided p < 0.05 was 
considered significant. In view of the exploratory nature of this study, no correction for 
multiple testing was applied. 
 
RESULTS 
Patients & treatment  
Between 2006 and 2016, 114 sorafenib-treated patients provided blood samples for 
pharmacogenetic analysis. Baseline patient characteristics are depicted in Table 2. Fifty-
five patients (48%) started sorafenib at 400 mg b.i.d., 57 patients (50%) started at 200 mg 
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b.i.d. and two patients (2%) started at 600 mg. In the latter two groups, the dose was 
increased to 400 mg b.i.d. by adding 200 mg to the daily dose every 2 weeks, if deemed 
safe and feasible. Any drug-related toxicity ≥grade 3 occurred in 76 patients (67%): 39 
patients had elevated liver enzymes (34%), 14 had hyperbilirubinemia (12%), ten had 
hypertension (9%), nine had diarrhea (8%), nine had HFSR (8%), nine had rash (8%) and 
nine had thrombocytopenia (8%). Grade 2 HFSR occurred in 36 patient (32%). Dose at start 
of treatment (200 vs 400 mg b.i.d.) was not significantly associated with incidence of 
toxicity ≥grade 3, although hyperbilirubinemia was observed significantly more frequent in 
the group started at 200 mg b.i.d. (p = 0.016, Fisher's exact test). At data cut-off on 1 
March 2016, eight patients were still treated with sorafenib, whereas the other patients 
had stopped treatment due to progressive disease (PD; n = 63; 55%), toxicity (n = 33; 
29%), both PD and toxicity (n = 8; 7%) or other reasons (n = 2; 2%). During treatment, in 50 
patients both dose reduction and interruption was pursued (44%), dose reduction alone 
was pursued in 13 patients (11%) and dose interruption alone in eight patients (7%). 
 
 
Table 2. Baseline patient characteristics. 
 Characteristics Patients (n=114) 
Gender 
Male 
Female 
 
89 (78%) 
25 (22%) 
Age (years) 
mean (± SD) 
 
63 (± 11) 
Primary tumor 
Hepatocellular carcinoma (HCC) 
Renal cell cancer (RCC) 
Desmoid fibromatosis 
 
99 (87%) 
14 (12%) 
1 (1%) 
WHO-score 
0 
1 
2 
 
20 (18%) 
90 (79%) 
4 (4%) 
Ethnicity 
Caucasian 
Black 
Asian 
Combination 
 
104 (91%) 
3 (3%) 
5 (4%) 
2 (2%) 
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Association of pharmacogenetic polymorphisms with toxicity  
The results of the genotyping analyses are depicted in Table 1. The polymorphisms that 
met our preset criteria for association with the end points in univariable analysis were 
entered in the multivariable logistic regression (Table 3). For any toxicity ≥grade 3, no 
association was found with the polymorphisms in multivariable analysis. This was also the 
case for elevated liver enzymes. Hyperbilirubinemia, thrombocytopenia, diarrhea and rash 
occurred in less than 20 patients and were therefore not considered for multivariable 
analysis. Hypertension, HFSR ≥grade 3 and HFSR ≥grade 2 were not associated with any of 
the polymorphisms in univariable analysis. The presence of at least one mutant UGT1A1 
allele was associated with 3.4-fold higher odds of interrupting treatment (p = 0.002), 
whereas the homozygous variant was associated with over fivefold higher odds of acute 
hyperbilirubinemia (p = 0.016). In univariable analysis, polymorphisms in SLCO1B1 were 
also related to the incidence toxicity: at least one mutant allele at codon 388 was 
associated with almost eightfold lower odds of developing diarrhea (p = 0.007) and at 
least one C allele at codon 521 was associated with 4.2-fold higher odds of 
thrombocytopenia (p = 0.045). Between HCC patients and the other patients the incidence 
of acute hyperbilirubinemia (41 vs 40%, respectively; p = 0.917), of hyperbilirubinemia (14 
vs 0%, respectively; p = 0.209) and of thrombocytopenia (9 vs 0%, respectively; p = 0.224) 
did not differ significantly. Other liver enzymes were elevated more frequently in HCC 
patients (38%) than in patients with RCC or desmoid fibromatosis (7%; p = 0.018). 
 
Association of pharmacogenetic polymorphisms with survival  
None of the SNPs were associated to PFS for HCC in univariable analysis. For OS, the 
recessive ABCC2 and ABCG2 models seemed associated, but both models had only two 
patients in the homozygous affected group and were therefore excluded. 
 
DISCUSSION 
In this study, we have found new associations between genetic polymorphisms in genes 
encoding for drug transporters and various kinds of well-recognized sorafenib toxicity. 
Earlier genotyping efforts in sorafenib-treated patients have predominantly focused on 
genes related to pharmacodynamics, for example, VEGF and VEGFR2 .9,28–29 Up till now, 
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genetic polymorphisms in ABCC2, UGT1A1 and UGT1A9 have been associated with 
sorafenib-induced toxicity.13,18–19 In our population, the significant association between 
polymorphisms in ABCC2 and UGT1A9 and toxicity could not be confirmed, but we did find 
that patients carrying a homozygous UGT1A1 -53 TA7 repeat (rs8175347) were at an 
increased odds for a more than twofold – and therefore clinically relevant – increase of 
bilirubin concentrations during the first 2 months of treatment. Any toxicity ≥grade 3 also 
occurred twice as often in patients with at least one mutant UGT1A1 -53 allele, although 
this was not statistically significant (p = 0.088). Furthermore, patients with at least one 
mutant allele at this position had their treatment interrupted significantly more often in 
our series, which is likely to be caused (partly) by the higher incidence of acute 
hyperbilirubinemia. This phenomenon was described in a case report, in which a 
sorafenib-treated patient with one mutant allele had a marked unconjugated 
hyperbilirubinemia.30 This has also been described before for several other drugs, like 
atazanavir and nilotinib.31,32 Unfortunately, we were unable to differentiate conjugated 
from unconjugated hyperbilirubinemia due to the retrospective character of this study. As 
systemic accumulation of unconjugated bilirubin is essentially benign, it may be useful for 
clinicians to be aware of UGT1A1*28 status in order to adequately consider sorafenib 
therapy in case of hyperbilirubinemia. 
 
Diarrhea and thrombocytopenia occurred significantly more often in patients with at least 
one mutant allele in SLCO1B1. The presence of a mutant G allele at codon 388 
(rs2306283), which leads to OATP1B1 activation,33 was associated with much lower odds 
of diarrhea than the wild-type genotype. On the other hand, patients with at least one 
mutant C allele at codon 521 (rs4149056), which is known to reduce OATP1B1 activity,33 
had significantly higher odds of developing thrombocytopenia. The OATP1B1 transporter, 
encoded for by SLCO1B1, is known to mediate hepatic transport of sorafenib-glucuronide,7 
but is possibly also involved in transport of unconjugated sorafenib.34 Our findings suggest 
that systemic concentrations of sorafenib or its glucuronide are highly dependent of 
OATP1B1 activity. Higher OATP1B1 activity and the subsequent higher hepatic clearance 
of the drug, for example, for *1B, leads to lower systemic exposure and therefore less 
toxicity (diarrhea) and vice versa for *5 and thrombocytopenia. As for the unconjugated 
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genetic polymorphisms in ABCC2, UGT1A1 and UGT1A9 have been associated with 
sorafenib-induced toxicity.13,18–19 In our population, the significant association between 
polymorphisms in ABCC2 and UGT1A9 and toxicity could not be confirmed, but we did find 
that patients carrying a homozygous UGT1A1 -53 TA7 repeat (rs8175347) were at an 
increased odds for a more than twofold – and therefore clinically relevant – increase of 
bilirubin concentrations during the first 2 months of treatment. Any toxicity ≥grade 3 also 
occurred twice as often in patients with at least one mutant UGT1A1 -53 allele, although 
this was not statistically significant (p = 0.088). Furthermore, patients with at least one 
mutant allele at this position had their treatment interrupted significantly more often in 
our series, which is likely to be caused (partly) by the higher incidence of acute 
hyperbilirubinemia. This phenomenon was described in a case report, in which a 
sorafenib-treated patient with one mutant allele had a marked unconjugated 
hyperbilirubinemia.30 This has also been described before for several other drugs, like 
atazanavir and nilotinib.31,32 Unfortunately, we were unable to differentiate conjugated 
from unconjugated hyperbilirubinemia due to the retrospective character of this study. As 
systemic accumulation of unconjugated bilirubin is essentially benign, it may be useful for 
clinicians to be aware of UGT1A1*28 status in order to adequately consider sorafenib 
therapy in case of hyperbilirubinemia. 
 
Diarrhea and thrombocytopenia occurred significantly more often in patients with at least 
one mutant allele in SLCO1B1. The presence of a mutant G allele at codon 388 
(rs2306283), which leads to OATP1B1 activation,33 was associated with much lower odds 
of diarrhea than the wild-type genotype. On the other hand, patients with at least one 
mutant C allele at codon 521 (rs4149056), which is known to reduce OATP1B1 activity,33 
had significantly higher odds of developing thrombocytopenia. The OATP1B1 transporter, 
encoded for by SLCO1B1, is known to mediate hepatic transport of sorafenib-glucuronide,7 
but is possibly also involved in transport of unconjugated sorafenib.34 Our findings suggest 
that systemic concentrations of sorafenib or its glucuronide are highly dependent of 
OATP1B1 activity. Higher OATP1B1 activity and the subsequent higher hepatic clearance 
of the drug, for example, for *1B, leads to lower systemic exposure and therefore less 
toxicity (diarrhea) and vice versa for *5 and thrombocytopenia. As for the unconjugated 
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bilirubin, we do not have pharmacokinetic data from these patients at our disposal and 
therefore cannot substantiate this theory with pharmacokinetic evidence. Still, our 
findings are similar to those in studies with other drugs like irinotecan10,11 or pravastatin.35 
Hence the scenario sketched above may not only be plausible, but also relevant since 
OATP1B1 function can also be altered by co-medication.8 
 
To provide definite proof of these retrospective observations, a prospective study, 
including PK and additional unconjugated bilirubin analysis, should be pursued. We were 
limited in registering low grade toxicity, which was not reported structurally in the patient 
records. On the other hand, clinically relevant adverse events are reported in a 
standardized way and therefore it is unlikely that we have missed important toxicity in our 
dataset. Finally, some of the end points we used, in other words, thrombocytopenia, 
hyperbilirubinemia and elevated liver enzymes, can also manifest as a symptom of 
advanced HCC. In our population however, only the latter occurred significantly more 
often in HCC patients. Therefore, the potential bias caused by differences in primary 
tumor seems to be limited. 
 
 
Conclusion 
We have observed that genetic polymorphisms in SLCO1B1 (rs2306283 and rs4149056) 
are associated with sorafenib-induced toxicity. Future fundamental research has to be 
aimed at discovering whether sorafenib itself or its metabolite sorafenib-glucuronide is 
being accumulated and causes toxicity. Additionally, we have confirmed that UGT1A1*28 
(rs8175347) is associated with acute hyperbilirubinemia, which causes physicians to 
interrupt treatment significantly more frequent. 
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bilirubin, we do not have pharmacokinetic data from these patients at our disposal and 
therefore cannot substantiate this theory with pharmacokinetic evidence. Still, our 
findings are similar to those in studies with other drugs like irinotecan10,11 or pravastatin.35 
Hence the scenario sketched above may not only be plausible, but also relevant since 
OATP1B1 function can also be altered by co-medication.8 
 
To provide definite proof of these retrospective observations, a prospective study, 
including PK and additional unconjugated bilirubin analysis, should be pursued. We were 
limited in registering low grade toxicity, which was not reported structurally in the patient 
records. On the other hand, clinically relevant adverse events are reported in a 
standardized way and therefore it is unlikely that we have missed important toxicity in our 
dataset. Finally, some of the end points we used, in other words, thrombocytopenia, 
hyperbilirubinemia and elevated liver enzymes, can also manifest as a symptom of 
advanced HCC. In our population however, only the latter occurred significantly more 
often in HCC patients. Therefore, the potential bias caused by differences in primary 
tumor seems to be limited. 
 
 
Conclusion 
We have observed that genetic polymorphisms in SLCO1B1 (rs2306283 and rs4149056) 
are associated with sorafenib-induced toxicity. Future fundamental research has to be 
aimed at discovering whether sorafenib itself or its metabolite sorafenib-glucuronide is 
being accumulated and causes toxicity. Additionally, we have confirmed that UGT1A1*28 
(rs8175347) is associated with acute hyperbilirubinemia, which causes physicians to 
interrupt treatment significantly more frequent. 
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ABSTRACT 
Background. For imatinib, a relationship between systemic exposure and clinical outcome 
has been suggested. Importantly, imatinib concentrations are not stable and decrease 
over time, for which several mechanisms have been suggested. In this study, we 
investigated if a decrease in alpha-1 acid glycoprotein (AGP) is the main cause of the 
lowering in imatinib exposure over time. 
Methods. We prospectively measured imatinib trough concentration (Cmin) values in 28 
patients with gastrointestinal stromal tumours, at 1, 3 and 12 months after the start of 
imatinib treatment. At the same time points, AGP levels were measured. 
Results. Overall, imatinib Cmin and AGP levels were correlated (R2 = 0.656; P < 0.001). 
However, AGP levels did not fluctuate significantly over time, nor did the change in AGP 
levels correlate with the change in the imatinib Cmin. 
Conclusion. We showed that systemic AGP levels are not likely to be a key player in the 
decrease in systemic imatinib exposure over time. As long as intra-individual changes in 
imatinib exposure remain unexplained, researchers should standardize the sampling times 
for imatinib in order to be able to assess the clinical applicability of therapeutic drug 
monitoring. 
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BACKGROUND 
Imatinib is one of the first tyrosine kinase inhibitors (TKIs) for which therapeutic drug 
monitoring (TDM) is deemed suitable in the treatment of both chronic myeloid leukaemia 
(CML) and gastrointestinal stromal tumours (GISTs). In CML, higher imatinib exposure has 
been found in patients with a treatment response,1-4 and imatinib trough concentration 
(Cmin) values above 1000 ng/mL have been found to be predictive of higher response 
rates.1,2 For GIST, the target imatinib Cmin has been established in a phase II study, in which 
patients with an imatinib Cmin in the lowest quartile (i.e. below 1100 ng/mL) had 
significantly worse progression-free survival (PFS), and it was suggested that this 
concentration should serve as a target Cmin.5 Studies conducted in the context of routine 
care have shown that more than half of imatinib-treated patients do not reach that Cmin.6–8 
In these studies performed in daily practice, the Cmin was measured more than 3 months 
after the start of treatment, whereas in the study describing the threshold of 1100 ng/mL, 
the imatinib Cmin was established after 4 weeks of treatment. Meanwhile, it has been 
shown that imatinib clearance increases—and systemic concentrations therefore 
decrease—during the first 3 months of treatment.9,10 Hence, it could be expected upfront 
that an even larger proportion of patients than the 25 % in the phase II study would have a 
Cmin below 1100 ng/mL when it was determined later than 3 months after the start of 
treatment, and doubts have been raised as to whether this threshold set at a time when 
systemic exposure has not yet stabilized is indeed the appropriate target imatinib Cmin in 
patients with GIST.11 Accordingly, in one of the more recent retrospective studies in GIST 
patients, a threshold of 760 ng/mL led to better prediction of the outcome.8 In the same 
study population, however, the median PFS was longer for patients with a Cmin >1100 
ng/mL than for those with a Cmin >760 ng/mL (67 versus 56 months).8 
Several mechanisms have been suggested to account for the reduction in 
systemic imatinib concentrations over time, the first being decreased absorption.9 
Alternatively, Chatelut et al.12 proposed that systemic imatinib exposure decreases 
because of increased clearance rather than because of decreased absorption. As imatinib 
is predominantly bound to the acute-phase protein alpha-1 acid glycoprotein (AGP),13-15 a 
reduction in AGP over time would lead to less protein-bound imatinib and therefore a 
larger proportion of free imatinib that could be metabolized or excreted.12 According to 
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larger proportion of free imatinib that could be metabolized or excreted.12 According to 
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this theory, it is assumed that a decrease in the tumour burden leads to a reduced 
inflammatory syndrome, which in turn causes lowering of AGP levels. The finding that 
changes in AGP levels over time correlate well with changes in imatinib concentrations 
seems to back this mechanism.16 However, these data were analysed in retrospect and, 
more importantly, they were not collected in a structured manner, as imatinib 
concentrations and AGP levels were measured at separate time points. Additionally, AGP 
levels and imatinib concentrations were not assessed synchronously in that study. To 
firmly establish the influence of AGP levels on blood imatinib concentrations, this study 
aimed to prospectively assess the correlation between imatinib Cmin values and AGP levels. 
 
METHODS 
Patients 
Adult patients with GIST in whom commencement of imatinib treatment was planned 
were eligible for inclusion in this study. The exclusion criteria were prior imatinib 
treatment within 3 months prior to the start of the study, major surgery within 2 weeks 
prior to the start of the study, use of potent cytochrome P450 (CYP) 3A inhibitors or 
inducers, and inability to give or understand informed consent. The study protocol was 
approved by the local institutional review board (protocol number MEC13-203). All 
procedures performed in this study were in accordance with the ethical standards of the 
institutional and/or national research committee and with the 1964 Helsinki Declaration 
and its later amendments or comparable ethical standards. Written informed consent was 
obtained from all individual participants included in the study. 
 
Study Procedures 
Pharmacokinetic sampling was performed at 1, 3 and 12 months after the start of imatinib 
treatment. At each time point, two blood samples were collected in addition to the 
standard-of-care blood draw at scheduled outpatient visits. The first sample was collected 
in a glass tube containing lithium heparin as an anticoagulant, and was used to quantify 
the concentrations of imatinib and its main metabolite, CGP74588. This sample was 
processed to plasma within 30 minutes by centrifugation for 15 min at 2500×g (4 °C). 
Next, the plasma was transferred to polypropylene tubes and stored at −70 °C unl the 
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time of analysis at the Laboratory of Translational Pharmacology, Erasmus MC Cancer 
Institute (Rotterdam, the Netherlands). The methods used for quantification of imatinib 
and CGP74588 concentrations have been described previously.17 The second sample was 
collected in a serum-separating tube and processed to serum. Serum AGP levels were 
measured using an immunoturbidimetric assay on a Cobas Integra 800 (Roche Diagnostics 
GmbH, Mannheim, Germany) in accordance with the instructions of the manufacturer. 
Briefly, serum AGP was agglutinated with a polyclonal goat-antihuman AGP antibody. The 
amount of agglutination of the antigen–antibody complex was measured turbidimetrically. 
 
Statistical Considerations 
At least 24 patients had to be included to identify a rho value of 0.55 in a two-sided test 
with alpha = 0.05 and power = 0.8. Correlation was tested using Pearson’s correlation, 
equality of two means was tested using t tests and equality of more than two means was 
tested using one-way analysis of variance (ANOVA). P values <0.05 were considered 
statistically significant. Descriptive statistics were performed using IBM SPSS Statistics 
version 21 software (SPSS, Chicago, IL, USA). All other statistical analyses were performed 
using GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA, USA). 
 
RESULTS 
Baseline 
Between April 2013 and March 2015, 35 patients signed informed consent and were 
included in the study. Four patients were not evaluable because they stopped imatinib 
treatment within 3 months and therefore did not provide repetitive pharmacokinetic 
samples. In another three patients, only one Cmin value was available because the patients 
had taken imatinib prior to the other sampling time points or because they had an 
imatinib concentration below the limit of quantification (<20.0 ng/mL). The baseline 
characteristics of the 28 evaluable patients are depicted in Table 1. Eight of the evaluable 
patients stopped treatment before the final sampling time point because of progressive 
disease (n = 3), cessation of neoadjuvant treatment (n = 4) or toxicity (n = 1). 
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approved by the local institutional review board (protocol number MEC13-203). All 
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institutional and/or national research committee and with the 1964 Helsinki Declaration 
and its later amendments or comparable ethical standards. Written informed consent was 
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Study Procedures 
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time of analysis at the Laboratory of Translational Pharmacology, Erasmus MC Cancer 
Institute (Rotterdam, the Netherlands). The methods used for quantification of imatinib 
and CGP74588 concentrations have been described previously.17 The second sample was 
collected in a serum-separating tube and processed to serum. Serum AGP levels were 
measured using an immunoturbidimetric assay on a Cobas Integra 800 (Roche Diagnostics 
GmbH, Mannheim, Germany) in accordance with the instructions of the manufacturer. 
Briefly, serum AGP was agglutinated with a polyclonal goat-antihuman AGP antibody. The 
amount of agglutination of the antigen–antibody complex was measured turbidimetrically. 
 
Statistical Considerations 
At least 24 patients had to be included to identify a rho value of 0.55 in a two-sided test 
with alpha = 0.05 and power = 0.8. Correlation was tested using Pearson’s correlation, 
equality of two means was tested using t tests and equality of more than two means was 
tested using one-way analysis of variance (ANOVA). P values <0.05 were considered 
statistically significant. Descriptive statistics were performed using IBM SPSS Statistics 
version 21 software (SPSS, Chicago, IL, USA). All other statistical analyses were performed 
using GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA, USA). 
 
RESULTS 
Baseline 
Between April 2013 and March 2015, 35 patients signed informed consent and were 
included in the study. Four patients were not evaluable because they stopped imatinib 
treatment within 3 months and therefore did not provide repetitive pharmacokinetic 
samples. In another three patients, only one Cmin value was available because the patients 
had taken imatinib prior to the other sampling time points or because they had an 
imatinib concentration below the limit of quantification (<20.0 ng/mL). The baseline 
characteristics of the 28 evaluable patients are depicted in Table 1. Eight of the evaluable 
patients stopped treatment before the final sampling time point because of progressive 
disease (n = 3), cessation of neoadjuvant treatment (n = 4) or toxicity (n = 1). 
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AGP Levels and Imatinib Concentrations 
A total of 73 imatinib trough concentration samples were obtained. In 69 cases, a blood 
sample for measurement of the AGP level was collected synchronically. The mean values 
of AGP, imatinib and CGP74588 at each time point are depicted in Table 2. At any of the 
three time points, the AGP levels in the five patients treated in the adjuvant setting did 
not differ significantly from those in the patients treated in the neoadjuvant or palliative 
settings (Figure 1a). 
 
 
 
Table 1. Baseline patient characteristics. 
Characteristics  Patients (n=28) 
Age at start Years 69 (36-85) 
Gender 
 
- Male 
- Female 
16 (57%) 
12 (43%) 
WHO performance - 0 
- 1 
- 2 
- Unknown 
12 (43%) 
13 (46%) 
1 (4%) 
2 (7%) 
c-KIT mutation - Wildtype 
- Exon 9 
- Exon 11 
- Exon 13 
- Unknown 
5 (18%) 
6 (21%) 
12 (43%) 
3 (11%) 
2 (7%) 
Treatment setting - Neoadjuvant 
- Adjuvant 
- Palliative 
11 (39%) 
5 (18%) 
12 (43%) 
Dose at start - 300 mg QD 
- 400 mg QD 
- 800 mg QD 
1 (4%) 
26 (93%) 
1 (4%) 
All values are presented as n (%) or as mean (SD). 
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Figure 1. (a) Geometric means of the AGP concentrations at 30 days (white bars), 90 days (striped 
bars), and 365 days (dotted bars) from treatment start, for each treatment setting. (b) Geometric 
means of imatinib trough concentrations (black bars) and AGP (white bars) at each of the time 
points. The error bars represent the 95% confidence intervals. 
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AGP Versus Imatinib 
Overall, AGP levels were significantly correlated with imatinib concentrations (R2 = 0.656; P < 
0.001; Figure 2) and with the sum of imatinib and CGP74588 concentrations (R2 = 0.667; P < 
0.001). The correlation between imatinib concentrations and AGP levels was less strong in the 
25 samples that were taken at the first time point after 30 days (R2 = 0.526; P < 0.001; Figure 3) 
in comparison with the correlations assessed at the two later time points. The absolute 
difference in AGP levels between time points 1 and 2 was also significantly correlated with the 
absolute difference in imatinib concentrations between time points 1 and 2 (R2 = 0.381; P = 
0.002) and between time points 1 and 3 (R2 = 0.355; P = 0.03). The relative differences in AGP 
levels and imatinib concentrations between time points were not significantly correlated. The 
geometric mean AGP levels did not differ significantly between the three time points (P = 
0.141; Figure 1b). 
 
 
Table 2. Analyses of the samples obtained at the different time points. 
 Time point 1 
(n=25) 
Time point 2 
(n=25) 
Time point 3 
(n=19) 
Total 
(n=69) 
Actual time since  
start imatinib (days) 
30 (3) 97 (30) 364 (20)  
     
AGP  
(g/L) 
0.97  
(0.85-1.10) 
0.81  
(0.69-0.94) 
0.89  
(0.78-1.00) 
0.89  
(0.82-0.96) 
Imatinib  
(ng/mL) 
1,457  
(1,155-1,838) 
1,305  
(1,001-1,702) 
1,193  
(967-1,472) 
1,325  
(1,158-1,516) 
CGP74588 (ng/mL) 308  
(247-384) 
265  
(205-343) 
231 
(179-299) 
270  
(235-309) 
Imatinib + CGP74588  
(ng/mL) 
1,777  
(1,420-2,224) 
1,578  
(1,217-2,047) 
1,439  
(1,165-1,777) 
1,606  
(1,407-1,833) 
     
Correlation between  
imatinib and AGP 
0.526  
(p<0.001) 
0.839  
(p<0.001) 
0.411  
(p=0.003) 
0.656  
(p<0.001) 
The three time points represent the 3 moments at which sampling was scheduled according to 
protocol, i.e. 30 days, 90 days, and 365 days after start of treatment. Correlations are depicted as r2 
(p-value). Units of time are presented as mean (SD). All other values are presented as geometric 
mean (95% confidence interval).  
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Figure 2. Correlation between imatinib and AGP in all samples (n=69). 
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Figure 3. Correlation between imatinib and AGP at day 30 (n=25). 
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DISCUSSION 
In this prospective setting, imatinib pharmacokinetics were closely correlated with 
systemic AGP levels when all samples obtained at the three different time points were 
considered together (R2 = 0.656; P < 0.001). Although—at first sight—this appeared to be 
in line with the hypothesis that the increase in imatinib clearance is due to reduced 
systemic AGP levels,14,16 the differences in AGP levels and imatinib Cmin values between the 
time points were less strongly correlated. Moreover, the argument that AGP decreases 
during treatment and thereby contributes to increased imatinib clearance over time12 did 
not seem to hold true, as we did not find substantial reductions in AGP levels during 
treatment (P = 0.141; Figure 1). Patients treated in the adjuvant setting even had a 
gradual increase in AGP levels, which contradicted the theory that AGP levels are initially 
elevated because of an inflammatory syndrome directly after tumour surgery and decline 
over time when the surgery effects resolve.12 Even though the decrease in imatinib 
concentrations was not as large as those published previously, the implication of our 
current findings is that the role of systemic AGP levels in the reduced systemic imatinib 
exposure over time is relatively small and that other factors, e.g. reduced bioavailability, 
likely have larger influences on systemic exposure. Still, AGP might seriously interfere with 
imatinib exposure in vivo, as extravascular AGP affects imatinib pharmacokinetics beyond 
the systemic circulation,15 and preclinical research has shown that the pharmacodynamic 
effects of imatinib are reduced in the presence of AGP.18-20 Nonetheless, it remains 
questionable whether these extravascular effects can be used to determine the optimal 
dose for individual patients. 
 
Unfortunately, the available evidence for individualized imatinib dosing in GIST patients is 
currently not robust, hampering assessment of the clinical relevance of TDM in GIST. 
Imatinib Cmin values measured at different time points during treatment have previously 
been related to the clinical outcome.5,8 Also, as mentioned previously, because of the 
decrease in systemic imatinib concentrations over time, target Cmin values after 1 month 
cannot be extrapolated into a dosing algorithm for the entire treatment period. Although 
it has been proposed that TDM be performed only after imatinib pharmacokinetics have 
stabilized after 3 months of treatment,11 whether or not an individual with GIST receives 
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the proper treatment and dose would ideally become visible much earlier during 
treatment. For example, by using fludeoxyglucose (18F) [18F-FDG] positron emission 
tomography [PET] as early as a few days after the start of treatment, it is possible to know 
whether or not a GIST patient is responding to treatment.21 Either way, TDM in imatinib 
treatment can reach its full potential only when sampling times are standardized between 
research groups.22 The sampling schedule employed in the current study could serve as a 
blueprint for larger studies because it incorporated Cmin values at 1 month and at later 
time points, enabling assessment of long-term pharmacokinetic targets, which could 
subsequently be compared with the established target at 1 month. Alternatively, long-
term pharmacokinetic targets could be derived from the target Cmin at 1 month, using a 
formula that corrects for the parameters that contribute to the decrease in imatinib 
exposure. However, as the biological mechanism of this decreased exposure seems to be 
complex and multifactorial, the latter option to determine long-term pharmacokinetic 
targets is not likely to be computed soon. In parallel, other challenges in making TDM 
clinically usable will be to integrate the dosing range (300–800 mg daily) and the possible 
options in the case of insufficient concentrations (dose escalation or a treatment switch), 
but these are secondary to standardization of the sampling time points. Last, but certainly 
not least, it remains to be proven that imatinib TDM in GIST really translates into a better 
outcome in terms of either less toxicity or better anti-tumour effects. 
 
Conclusion 
We found that systemic AGP levels are not likely to be a key player in the decrease of 
systemic imatinib exposure over time. We believe that TDM is a very potent tool to 
improve personalized imatinib treatment, but it can flourish only if researchers ensure 
that their results are obtained in a standardized way. 
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ABSTRACT 
Purpose. Pazopanib is a tyrosine kinase inhibitor approved for the treatment of renal cell 
carcinoma and soft tissue sarcoma. Retrospective analyses have shown that an increased 
median PFS and tumor shrinkage appears in patients with higher plasma trough levels 
(Cmin). Therefore, patients with low Cmin might benefit from pharmacokinetically-guided 
individualized dosing.  
Experimental Design. We conducted a prospective multicenter trial in 30 patients with 
advanced solid tumors. Pazopanib Cmin was measured weekly by LC-MS/MS. At week 3, 5 
and 7 the pazopanib dose was increased if the measured Cmin was <20 mg/L and toxicity 
was < grade 3.  
Results. In total, 17 patients had at least one Cmin <20 mg/L at week 3, 5 and 7. Of these, 
10 were successfully treated with a pharmacokinetically-guided dose escalation, leading to 
daily dosages ranging from 1000 to 1800 mg daily. Cmin in these patients increased 
significantly from 13.2 (38.0%) mg/L (mean (CV%)) to 22.9 mg/L (44.9%). Thirteen patients 
had all Cmin levels {greater than or equal to}20 mg/L. Of these, nine patients with a high 
Cmin of 51.3 mg/L (45.1%) experienced {greater than or equal to} grade 3 toxicity and 
subsequently required a dose reduction to 600 or 400 mg daily, yet in these patients Cmin 
remained above the threshold at 28.2 mg/L (25.3%).  
Conclusions. A pharmacokinetically-guided individualized dosing algorithm was 
successfully applied and evaluated. The dosing algorithm led to patients being treated at 
dosages ranging from 400 to 1800 mg daily. Further studies are needed to show a benefit 
of individualized dosing on clinical outcomes such as progression free survival. 
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INTRODUCTION 
Pazopanib is a tyrosine kinase inhibitor targeting VEGFR-1,2,3, PDGFR α/β, FGFR and c-Kit.1 
Pazopanib increased progression free survival (PFS) from 4.2 to 9.2 months in renal cell 
carcinoma (RCC) and from 1.6 to 4.6 months in soft tissue sarcoma (STS) compared to 
placebo.2,3  
A retrospective analysis in 177 RCC patients by Suttle et al. showed an increased 
tumor shrinkage and longer PFS in patients with plasma trough levels (Cmin) ≥20.5 mg/L 
compared to patients with a Cmin below this threshold (4). Median PFS was found to be 50.2 
weeks in patients with higher pazopanib Cmin versus 19.6 weeks in patients with lower Cmin. 
Median tumor shrinkage was 37.9% in the high versus 6.9% in the low exposure group. No 
further increase in PFS or tumor shrinkage was found above a pazopanib plasma concentration 
of 20.5 mg/L. 
This threshold for efficacy seems to be in accordance with preclinical data showing 
optimal VEGFR2 inhibition by pazopanib in vivo at a concentration ≥17.5 mg/L (40 μmol/L) in 
mouse models.5 Additionally, in the phase I trial hypertension, a pharmacodynamic biomarker 
for response to anti-angiogenic agents, correlated with C24h values above 15 mg/L at day 22.6 
Plasma concentrations were also correlated with radiographic response in a phase II study of 
patients with progressive, radioiodine-refractory, metastatic differentiated thyroid cancers 
treated with pazopanib.7 The above indicates that efficacy of pazopanib is strongly associated 
with pharmacokinetic (PK) exposure in many tumor types. Pazopanib PK shows significant 
inter-individual variability in plasma exposure6,8,9 and may be affected by various factors, such 
as concomitant medication (e.g. drugs increasing gastric pH or inhibiting/inducing CYP3A4), 
intake of food, patient compliance and (exact) time of tablet ingestion and blood sampling.9–12  
Despite the large variability in exposure, pazopanib is currently still administered at a 
fixed dose of 800 mg daily. This may however result in suboptimal treatment in a subset of 
patients who have a low Cmin. In a retrospective analysis performed by the manufacturer of 
pazopanib, 20% of patients had a Cmin below 20.5 mg/L and might have had benefit from an 
increased dose.4 The feasibility of PK-guided dosing has already been shown in prospective 
clinical trials for tamoxifen13 and another tyrosine kinase inhibitor with similar properties, 
sunitinib.14 Therefore, we now conducted a prospective feasibility trial to investigate whether 
the dose of pazopanib could be safely increased in patients who have a low Cmin on the fixed 
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800 mg dose of pazopanib and whether this led to increased drug exposure, without 
intolerable toxicity. 
 
MATERIALS AND METHODS 
Patient population 
Cancer patients for whom pazopanib was considered standard of care, or for whom no 
remaining standard treatment options were available, were eligible for enrollment. Patients 
also had to be at least 18 years of age, had to have a WHO performance score of 0 or 1, needed 
to have evaluable disease according to RECIST 1.1 and also had to have an adequate organ 
function at baseline defined as: absolute neutrophil count ≥ 1.5x109/L, hemoglobin ≥ 5.6 
mmol/L, platelets ≥ 100x109/L, prothrombin time or international normalized ratio ≤ 1.2x ULN, 
activated partial thromboplastin time ≤ 1.2x ULN, total bilirubin ≤ 1.5x ULN, alanine amino 
transferase and aspartate aminotransferase ≤ 2.5x ULN, serum creatinine ≤ 133 μmol/L or, if 
>133 μmol/L a calculated creatinine clearance of 30 to 50 mL/min, urinary protein (on dipstick) 
<2 + or <1 gram in 24-hour urine. 
Exclusion criteria were: corrected QT interval (QTc) > 480 milliseconds, history of any 
relevant cardiovascular conditions, cerebrovascular accidents, transient ischemic attack, 
pulmonary embolisms or untreated deep venous thrombosis (DVT) within the past 6 months, 
poorly controlled hypertension (defined as systolic blood pressure (SBP) of ≥140 mmHg or 
diastolic blood pressure (DBP) of ≥ 90mmHg), clinically significant gastrointestinal 
abnormalities that might increase the risk for gastrointestinal bleeding, major surgery or 
trauma within 28 days prior to first pazopanib dose, evidence of active bleeding or bleeding 
diathesis, known endobronchial lesions and/or lesions infiltrating major pulmonary vessels, 
recent hemoptysis within 8 weeks before the first dose, any anti-cancer therapy within 14 days 
or five half-lives of the previous anti-cancer drug (whichever was longer) prior to first 
pazopanib dose, any ongoing toxicity from prior anti-cancer therapy that was grade >1 and/or 
that was progressing in severity, except for alopecia. 
 
Pharmacokinetically guided dosing 
All patients started at the approved pazopanib dose of 800 mg once daily (QD). Plasma samples 
for Cmin measurements were collected weekly in the first 8 weeks of pazopanib treatment and 
every 4 weeks thereafter. Pazopanib concentrations were measured using a validated LC-
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MS/MS assay. A 10 μL plasma aliquot was used, to which 500 μL of methanol containing 
13C,2H3-pazopanib as internal standard and 500 μL of 10 mM ammonium hydroxide in water 
were added. This solution was then centrifuged at 15.000 rpm and 5 μL of the supernatant was 
injected into the LC-MS/MS system (LC-system from Agilent Technologies (Santa Clara, CA) and 
API3000 MS by AB Sciex (Framingham, MA). Elution was performed using an isocratic gradient 
of 45% 10 mM ammonium hydroxide in water and 55% methanol on a Gemini C18 column, 2.0 
x 50 mm, 5 μm by Phenomenex (Torrance, CA). This assay was validated and fulfilled all 
requirements of the FDA and EMA guidelines for bioanalytical method validation. Cmin results 
were reported to the treating physician within 1 week. 
At week 3, day 1 (Day 15); week 5, day 1 (Day 29) and week 7, day 1 (Day 43), the 
dose could be adapted, based on the measured Cmin collected a week earlier and observed 
toxicity was graded according to the National Cancer Institute’s Common Terminology Criteria 
for Adverse Events (NCI-CTCAE v4.02). The target exposure for efficacy used during this trial 
was a Cmin ≥20.0 mg/L. Patients with a Cmin <15.0 mg/L received a dose increase of 400 mg daily 
in the absence of ≥ grade 2 toxicity or 200 mg daily when experiencing grade 2 toxicity, but not 
≥ grade 3 adverse events (AEs). Patients with a Cmin of 15.0-19.9 mg/L received a 200 mg dose 
increase if toxicity was below grade 3. No patients would be treated above the prespecified 
dose limit of 2,000 mg QD, as this was the highest dose previously tested in humans.6 In case of 
severe (≥ grade 3) treatment related toxicity the dose was lowered by 1 dose level, or to the 
previous dose level in case of an earlier dose increment. 
 
Safety assessments 
Recording of AEs, physical examination, hematology and blood chemistry assessments were 
performed weekly during the first 8 weeks and monthly thereafter. The incidence, severity, 
start and end dates of all serious AEs (SAEs) and of non-serious AEs related to pazopanib were 
recorded. 
 
Efficacy assessments 
CT-scan and/or MRI-scans were performed every 8 weeks after initiation of therapy until 
documented disease progression according to the Response Evaluation Criteria in Solid Tumors 
(RECIST) version 1.1. Data on best response and time to progression was collected. 
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Statistical methods 
All statistical analyses were performed in R version 3.2.2.15 For exposure-response relationships 
the mean of all measured Cmin levels for each patient during the entire treatment period (from 
start of treatment to discontinuation) was used as the measure of pazopanib exposure. For the 
purpose of exposure-toxicity relationships, the Cmin measurement closest to the first 
presentation of the toxicity was used. Unless otherwise specified, hypotheses were tested 
using a two-sided independent sample t-test. P-values <0.05 were considered significant. 
 
Study Conduct and registry 
This trial was conducted in accordance with the World Medical Organization declaration of 
Helsinki, compliant with Good Clinical Practice and approved by the Medical Ethics Committee 
of the each participating medical centers. All patients provided written informed consent 
before enrollment. This trial was registered in the EudraCT database (2013-001567-24) and the 
Netherlands Trial Registry (NTR3967). 
 
RESULTS 
Patient population 
A total of 30 patients were included from September 2013 until March 2014 in 3 Dutch cancer 
centers. Characteristics of included patients are shown in Table 1. Tumor types of included 
patients were soft tissue sarcoma (n=7), colorectal carcinoma (n=6), cancer of unknown 
primary (n=4), neuroendocrine carcinoma (n=2), thymus carcinoid, hepatocellular carcinoma, 
ovarian carcinoma, mesothelioma, esophageal carcinoma, meningeoma, perivascular epithelial 
tumor, renal cell carcinoma, choroidal melanoma, endometrial carcinoma and 
cholangiocarcinoma (all n=1). All patients received at least one dose of pazopanib, underwent 
at least one Cmin measurement and were eligible for PK evaluation. Median study follow up was 
34 weeks. 
 
Pharmacokinetic guided dosing 
Based on treatment outcome patients were divided into four groups, see Figure 1. Patients 
who had at least one Cmin below 20.0 mg/L at day 15, 29 or 43 were appointed group 1, 
patients who had all these Cmin measurement above the target were appointed group 2. 
Patients who did not experience any toxicity requiring a dose reduction or interruption during 
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the dose escalation period (the first 8 weeks of treatment) were classified as group a (no 
severe toxicity), those who did were classed as group b (severe toxicity). Based on this 
classification the distribution of patients was 10 in group 1a (eligible for a dose escalation), 
7 in 1b (no dose escalation possible due to toxicity), 4 in group 2a (adequate Cmin, no 
toxicity) and 9 in group 2b (adequate Cmin, severe toxicity) (Figure 1). A full overview of 
treatment outcomes (Cmin measurements, dose received and percentage of patients above 
the Cmin target) is provided in Table 2. Plots of the Cmin over time per treatment outcome 
group are shown in Figure 2. 
 
Table 1. Demographics of included patients.  
Characteristic Patients (n=30) 
Gender (n (%)) 
Male 
Female 
 
14       (53) 
16       (47) 
Age  (median (range))         58      (33– 88) 
Steady state Cmin (mg/L) at  
800 mg dose (W2D1) (mean (CV %)) 
 
30.0   (71.9) 
Performance status (n (%)) 
0 
1 
 
7  (23) 
23  (77) 
Previous lines of systemic therapy  
(median (range)) 
 
Type (n(%)) 
Chemotherapy 
Targeted therapy 
Endocrine therapy 
2  (1-5) 
 
 
 
24  (80) 
7  (23) 
3  (10) 
Primary tumor (n (%)) 
Soft tissue sarcoma 
Colorectal carcinoma 
Cancer of unknown primary 
Neuroendocrine carcinoma 
Miscellaneous* 
  
7 (23) 
6 (20) 
4      (13) 
2      (6) 
11    (33) 
* Hepatocellular carcinoma, ovarian carcinoma, mesothelioma, esophageal carcinoma, 
meningeoma, perivascular epithelial tumor, renal cell carcinoma, choroidal melanoma, endometrial 
carcinoma, cholangiocarcinoma and thymus carcinoid (all n=1). 
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Pharmacokinetic guided dosing 
Based on treatment outcome patients were divided into four groups, see Figure 1. Patients 
who had at least one Cmin below 20.0 mg/L at day 15, 29 or 43 were appointed group 1, 
patients who had all these Cmin measurement above the target were appointed group 2. 
Patients who did not experience any toxicity requiring a dose reduction or interruption during 
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the dose escalation period (the first 8 weeks of treatment) were classified as group a (no 
severe toxicity), those who did were classed as group b (severe toxicity). Based on this 
classification the distribution of patients was 10 in group 1a (eligible for a dose escalation), 
7 in 1b (no dose escalation possible due to toxicity), 4 in group 2a (adequate Cmin, no 
toxicity) and 9 in group 2b (adequate Cmin, severe toxicity) (Figure 1). A full overview of 
treatment outcomes (Cmin measurements, dose received and percentage of patients above 
the Cmin target) is provided in Table 2. Plots of the Cmin over time per treatment outcome 
group are shown in Figure 2. 
 
Table 1. Demographics of included patients.  
Characteristic Patients (n=30) 
Gender (n (%)) 
Male 
Female 
 
14       (53) 
16       (47) 
Age  (median (range))         58      (33– 88) 
Steady state Cmin (mg/L) at  
800 mg dose (W2D1) (mean (CV %)) 
 
30.0   (71.9) 
Performance status (n (%)) 
0 
1 
 
7  (23) 
23  (77) 
Previous lines of systemic therapy  
(median (range)) 
 
Type (n(%)) 
Chemotherapy 
Targeted therapy 
Endocrine therapy 
2  (1-5) 
 
 
 
24  (80) 
7  (23) 
3  (10) 
Primary tumor (n (%)) 
Soft tissue sarcoma 
Colorectal carcinoma 
Cancer of unknown primary 
Neuroendocrine carcinoma 
Miscellaneous* 
  
7 (23) 
6 (20) 
4      (13) 
2      (6) 
11    (33) 
* Hepatocellular carcinoma, ovarian carcinoma, mesothelioma, esophageal carcinoma, 
meningeoma, perivascular epithelial tumor, renal cell carcinoma, choroidal melanoma, endometrial 
carcinoma, cholangiocarcinoma and thymus carcinoid (all n=1). 
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Figure 1a. Trial outcome flowchart. Toxicity for the purposes of this chart is defined as any adverse 
event requiring a dose interruption or reduction in the first 8 weeks of treatment. Cmin below or 
above the target of ≥20.0 mg/L is based on samples from week 2, 4 or 6 as per protocol dose 
escalations were based on these samples.  
 
 
Figure 1b. Percent change in dose from baseline (steady state at W2D1) to the end of the dose 
algorithm period (Last dose change (W7D1) and corresponding steady state Cmin W8D1). Grey bars 
represent % change in pazopanib dose (mg QD) white bars represent % change in pazopanib Cmin 
(mg/L). Each patient is represented by adjacent bars, plotted per treatment outcome group, only 
patients evaluable at both week 2 and week 8 are shown. 
Patients included
(N=30)
Patients with at least 
one Cmin < 20 mg/L
(N=17)
Patients successfully 
treated with PK-guided 
dose escalation
(N=10)
Patients with Cmin > 20mg/L 
and toxicity ≥ grade 3
(N=9)
Patients with Cmin > 20mg/L 
and toxicity < grade 3
(N=4)
Patients unable to be 
escalated due to toxicity
(N=7)
Group 
2b
Group 
1b
Group 
2a
Group 
1a
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Table 2. Pazopanib Cmin, percentage of patients above target and dose per treatment outcome group‡. 
Outcome Group 1a Group 1b Group 2a Group 2b Total 
 TOX - TOX + TOX - TOX + n = 30 
 Cmin <20.0 mg/L Cmin <20.0 mg/L Cmin ≥20.0 mg/L Cmin ≥20.0 mg/L 
 n = 10 n = 7 n = 4 n = 9 
Mean pazopanib Cmin (mg/L (CV %)) 
W2D1 13.2 (38.0) 19.7 (56.6) 37.4 (19.4) 51.3 (45.1) 30.0 (71.9) 
W4D1 15.5 (52.8) 16.2 (39.6) 31.8 (8.1) 39.4 (29.5) 24.8 (54.8) 
W6D1 19.7 (27.4) 13.3 (39.6) 26.8 (29.2) 33.2 (30.5) 22.8 (43.2) 
W8D1 22.9 (44.9) 18.9 (40.5) 25.9 (18.8) 28.2 (25.3) 24.1 (33.9) 
% of pts above the target Cmin of ≥20.0 mg/L† 
W2D1 10.0 42.8 100.0 100 56.7 
W4D1 20.0 14.3 100.0 88.6 50.0 
W6D1 40.0  14.3 100.0 66.6 50.0 
W8D1 40.0 28.6 100.0 55.6 50.0 
Mean daily pazopanib Dose (mg) 
W3D1 1040 933 800 725 893 
W5D1 1280 1000 800 667 1000 
W7D1 1378 950 800 633 1009 
*40% of patients in group 1a achieved the target in week 8. During study follow up, 7 patients in group 1a (70%) achieved target  
exposure of > 20.0 mg/L within 3 months since start of treatment.  
†Patients for whom no Cmin was available or who discontinued treatment are scored as below the target 
‡Toxicity for the purposes of grouping is deﬁned as any adverse event requiring a dose interrupon or reducon in the ﬁrst 8 weeks  
of treatment. Cmin below or above the target of ≥20.0 mg/L is based on samples from week 2, 4 or 6. 
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Group1a: Group 1a (patients with low drug exposure, and no severe toxicity) consisted of 
10 patients who were sustainably treated at an increased dose. The Cmin in this group 
increased from 13.2 (CV 38.0%) mg/L in week 2 to 22.9 (CV 44.9%) mg/L in week 8 
(p=0.02). Only two patients did not show an increase in Cmin after the dose escalation. Four 
patients reached the target at the end of the dose escalation period (week 8) and 7 
patients reached the target exposure of ≥20 mg/L within 3 months of treatment. After the 
last dose escalation (day 43), patients in group 1a were treated at a 
Figure 2. Pazopanib exposure over time per outcome group (mean Cmin ± standard deviation). The 
dotted line indicates the threshold of 20 mg/L. Cmin did not change in group 1b (p=0.89). In group 2a 
and 2b Cmin declined significantly (p=0.04 and 0.04 respectively). Group 1a showed a significant 
increase in Cmin from 13.2 mg/L to 22.9 mg/L (p=0.02). 
 
Individualized pazopanib dosing | 135 
 
mean dose of 1,378 mg, ranging from 1,000 to 1,800 mg. One patient was treated with 
1,800 mg QD for over 33 weeks, with acceptable (<grade 3) toxicity.  
Group 1b: Patients in group 1b (patients with low drug exposure, but with toxicity 
requiring a dose interruption or reduction, n=7) had a stable Cmin during the dose 
escalation phase. In this group, one patient could not have a dose escalation because of 
toxicity (ASAT/ALAT increase) at the prespecified dose escalation moments. Another 
patient required a dose interruption but could later continue treatment on 800 mg QD. 
Five patients experienced toxicity after an initial escalation and required a subsequent 
dose reduction. Four of these five could hereafter be treated successfully until disease 
progression at a dose of 800 mg (n=3) or 1,000 mg (n=1) daily. One patient discontinued 
treatment due to toxicity after dose escalation (fatigue, grade 3).Their Cmin was 19.7 (CV 
56.6%) mg/L at week 2 and 18.9 (CV 40.5%) mg/L at week 8 (p=0.89). 
Group 2a: Four patients (group 2a, patients with high drug exposure, and no 
severe toxicity) could be treated on the fixed 800 mg dose with adequate Cmin without the 
need for a dose reduction or interruption in the first 8 weeks. Surprisingly, the Cmin 
decreased in these patients from 37.4 mg/L (CV 19.4%) at week 2 to 25.9 mg/L (CV 18.8%) 
at week 8 (p=0.04). 
Group 2b: Patients in group 2b (patients with a high drug exposure, but also 
severe toxicity, n=9) had a decrease in Cmin from week 2 to week 8 from 51.3 mg/L (CV 
45.1%) to 28.2 mg/L CV 25.3%) (p=0.04). The mean dose was reduced from 800 mg to 600 
mg in the same interval. 
Use of gastric acid reducing agents was discouraged but not prohibited during 
this trial. Of patients in the low exposure groups 9 (7 in group 1a and 2 in 1b) and in the 
high exposure groups 4 (all in 2b) used a PPI at any point during treatment. Patients were 
instructed to take the PPI concomitantly with pazopanib as recommended in the summary 
of product characteristics. 
 
Adverse events 
An overview of the observed AEs related to pazopanib with a frequency of ≥10% is shown 
in Table 3. The most common severe (≥ grade 3) AEs were hypertension, fatigue, 
ASAT/ALAT increase. 
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Less patients experienced ≥ grade 3 AEs in the low exposure groups (1a and 1b), 
with 41.2% of patients experiencing at least one ≥ grade 3 AE, compared to 76.9% in the 
high exposure groups (2a and b). The percentage of patients discontinuing due to toxicity 
was similar between the high and low exposure groups, 11.8% in 1a plus 1b and 15.4% in 
2a plus 2b. Of patients with a high exposure requiring a dose reduction (group 2b, n=9), all 
but 2 (both cases fatigue grade 3) could be successfully treated at a lower dose until 
disease progression. Overall, events causing the discontinuation were fatigue (n=3) and 
ASAT/ALAT increase (n=1). Remarkably, the Cmin at week 2 appeared higher in patients in 
group 1 experiencing toxicity (19.7 mg/L versus 13.2 mg/L (p=0.19), respectively) and the 
same trend was observed in group 2 (37.4 mg/L for patients without toxicity versus 51.3 
mg/L for patients with toxicity (p=0.27), respectively). 
Patients who experienced fatigue (n=3) or ASAT/ALAT increase (n=2) had a Cmin 
(at first presentation of grade 3 toxicity) 51.4 mg/L (range 21.4 - 98.1) and 8.9 mg/L (range 
7.3 - 10.5) respectively. Patients with grade 3 hypertension (n=11) had a Cmin at 
presentation of 37.3 mg/L (range 7.0 - 76.5) while that patients who experienced grade 2 
hypertension (n=10) was 27.8 mg/L (range 16.7 – 43.8). 
 
Efficacy 
From 27 patients at least one response evaluation was available. Of these, 3 patients had 
a partial response (perivascular epithelial tumor, renal cell carcinoma and soft tissue 
sarcoma, all n=1), 18 had stable disease, and 6 had progressive disease as best response. 
 
The mean of all measured Cmin levels per patient (from start of treatment to 
discontinuation) was calculated as a measure of exposure during pazopanib therapy for 
the purpose of exposure-response relationships. Overall, the average of the mean Cmin of 
each patient was 24.4 mg/L (CV 39.1%). In total, 19 patients had a mean Cmin above and 11 
below the target of 20 mg/L. A waterfall plot of the maximum decrease in tumor size from 
baseline is shown in Figure 3. All three patients who had a partial response had a mean 
Cmin above the 20 mg/L threshold (with an average of 27.6 mg/L (CV 14.4%). In non-
prespecified, exploratory analyses of all evaluable patients (n=27), tumor response was 
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associated with mean Cmin of pazopanib. An average change from baseline for patients 
above and below the PK threshold of -6.49% and +14.6% respectively, (p=0.01). In soft 
tissue sarcoma patients (n=7), mean change from baseline was -6.01% (n=5) for patients 
above the threshold and +13.5% for patients below (n=2)(p=0.28). In sarcoma patients PFS 
was 47.9 weeks (range 8 - 60, n=5) and 11.5 weeks (range 7 - 16, n=2) for patients below 
the PK threshold (p=0.06, log-rank test). 
 
 
 
Figure 3. Left panel: Waterfall plot showing the maximum change in tumor size from baseline in all 
evaluable patients (n = 27). Grey bars represent patients with a mean Cmin ≥20.0 mg/L (n=17), white 
bars represent patients with a Cmin <20.0 mg/L (n=10). Mean change from baseline for all evaluable 
patients (n=27) above and below the PK threshold was -6.49% and +14.6%, (p=0.01). Right Panel: 
Mean change from baseline in soft tissue sarcoma patients (n=7) above and below the PK threshold 
was -6.01% (n=5) and +13.5% (n=2), (p=0.28). 
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DISCUSSION 
We performed a prospective multicenter clinical trial to assess the safety and feasibility of 
PK-guided individualized dosing of pazopanib in 30 patients with advanced solid tumors. 
With the PK-guided dosing algorithm, 33.3% of all patients could be treated at a higher 
dose (1000 – 1800 mg daily) with acceptable toxicity (Figure 1). Most of these patients 
achieved the target Cmin of 20.0 mg/L within study follow up. Furthermore, overall 
variability in pazopanib Cmin was reduced from 71.9% before the dose escalation period to 
33.9% thereafter (Table 2). 
An equal number of patients discontinued treatment in the low Cmin versus the 
high Cmin group and only one patient discontinued treatment after a dose escalation. This 
suggests PK-guided increasing of the dose does not lead to more severe toxicity or higher 
rates of treatment discontinuation. Meanwhile, a reduction of the dose in case of very 
high systemic concentrations, may lead to less toxicity and still maintain therapeutic Cmin 
levels (group 2b, Figure 2). 
High pazopanib exposure seemed predictive of dose reductions for toxicity in 
patients not eligible for a dose escalation (group 2a en 2b). The Cmin at week 2 was higher 
(though not significantly) in the patients that would require a dose reduction (2b) than 
those who would not (2a), (mean of 51.3 versus 37.4 mg/L, table 2, Figure 2). This implies 
that patients are unlikely to tolerate a very high trough level for a longer period of time 
and could support strategies to prevent toxicity by implementing dose reduction in 
patients with Cmin >50 mg/L, although this is based on limited data. 
No clear relations between Cmin and specific grade ≥ 3 toxicities were found. The 
most common severe AE was hypertension. This is thought to be related to higher 
pazopanib exposure;6 our study found a mean Cmin at occurrence of hypertension 37.3 and 
27.8 mg/L in patients experiencing grade 3 (n=11) and 2 (n=10) hypertension respectively. 
But this was not significantly higher than the overall mean Cmin. It might be the case 
however, that another pharmacokinetic parameter (e.g. Cmax) may be more appropriate to 
study exposure-toxicity relationships than Cmin, the one used in the current trial. 
Two patients experienced severe hepatotoxicity, in one case leading to ASAT and 
ALAT values of over 13 times the upper limit of normal and discontinuation of treatment. 
This seemed unrelated to high exposure, as the mean Cmin of these patients (in the sample 
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DISCUSSION 
We performed a prospective multicenter clinical trial to assess the safety and feasibility of 
PK-guided individualized dosing of pazopanib in 30 patients with advanced solid tumors. 
With the PK-guided dosing algorithm, 33.3% of all patients could be treated at a higher 
dose (1000 – 1800 mg daily) with acceptable toxicity (Figure 1). Most of these patients 
achieved the target Cmin of 20.0 mg/L within study follow up. Furthermore, overall 
variability in pazopanib Cmin was reduced from 71.9% before the dose escalation period to 
33.9% thereafter (Table 2). 
An equal number of patients discontinued treatment in the low Cmin versus the 
high Cmin group and only one patient discontinued treatment after a dose escalation. This 
suggests PK-guided increasing of the dose does not lead to more severe toxicity or higher 
rates of treatment discontinuation. Meanwhile, a reduction of the dose in case of very 
high systemic concentrations, may lead to less toxicity and still maintain therapeutic Cmin 
levels (group 2b, Figure 2). 
High pazopanib exposure seemed predictive of dose reductions for toxicity in 
patients not eligible for a dose escalation (group 2a en 2b). The Cmin at week 2 was higher 
(though not significantly) in the patients that would require a dose reduction (2b) than 
those who would not (2a), (mean of 51.3 versus 37.4 mg/L, table 2, Figure 2). This implies 
that patients are unlikely to tolerate a very high trough level for a longer period of time 
and could support strategies to prevent toxicity by implementing dose reduction in 
patients with Cmin >50 mg/L, although this is based on limited data. 
No clear relations between Cmin and specific grade ≥ 3 toxicities were found. The 
most common severe AE was hypertension. This is thought to be related to higher 
pazopanib exposure;6 our study found a mean Cmin at occurrence of hypertension 37.3 and 
27.8 mg/L in patients experiencing grade 3 (n=11) and 2 (n=10) hypertension respectively. 
But this was not significantly higher than the overall mean Cmin. It might be the case 
however, that another pharmacokinetic parameter (e.g. Cmax) may be more appropriate to 
study exposure-toxicity relationships than Cmin, the one used in the current trial. 
Two patients experienced severe hepatotoxicity, in one case leading to ASAT and 
ALAT values of over 13 times the upper limit of normal and discontinuation of treatment. 
This seemed unrelated to high exposure, as the mean Cmin of these patients (in the sample 
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closest in time to occurrence) was only 8.9 mg/L. This finding is corroborated by a recent 
study suggesting the mechanism of pazopanib hepatotoxicity may be immunological and 
therefore unrelated to pazopanib PK or dose.16 
A significant reduction in pazopanib Cmin was seen in patients treated 
continuously at the 800 mg fixed dose (group 2a, Figure 2).Though in our trial this group 
consisted of only a small number of patients, the same effect was observed in a 
population pharmacokinetic analysis of previously published clinical trials.17 A time 
dependent decrease in exposure was also observed for another tyrosine kinase inhibitor, 
imatinib.18 For imatinib, upregulation of drug transporters or CYP3A4 have been suggested 
as possible explanations, which could also be the case for pazopanib as it is a known 
substrate of both. 
In addition to PK-guided dosing of pazopanib other dose individualization 
strategies could be explored. Pharmacodynamic biomarkers could be used for example, 
such as interleukin 12 (IL12) or soluble VEGFR2 (sVEGFR2).19 However given that for 
pazopanib the relation between Cmin and PFS was very significant at p=0.0038 and resulted 
in a remarkable median PFS difference of 32.4 weeks in RCC patients,4 Cmin might be a 
more appropriate biomarker for pazopanib than sVEGFR2 or IL12. 
Toxicity based dosing could also be proposed as a dose individualization approach 
and has been explored previously for erlotinib (using rash), sorafenib and axitinib (both 
using hypertension).20–22 A drawback of this strategy is that it, per definition, would lead to 
more toxicity. The PK-guided approach applied in this trial with pazopanib did not seem to 
lead to less tolerability. 
Another trial was performed to assess PK-guided dosing of pazopanib by De Wit 
et al.9 In that trial, pazopanib area under the curve (AUC0-24h) was used as the 
pharmacokinetic parameter to individualize dosing and a target window of 715-920 
mg∙h∙L-1 (corresponding to Cmin values of 20.5 – 46.0 mg/L) was specified. The primary 
endpoint of that study in 13 patients was a reduction in variability and, per protocol, only 
one dose change was allowed. AUC-guided dosing did not significantly reduce inter-
patient variability, probably due to intra-patient variability or sampling time issues. Based 
on this trial the authors concluded it may be more beneficial to target the Cmin threshold 
rather than an AUC window.4,9 In addition, dosing base on Cmin will also be more practical 
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to implement in routine care, as it requires just one instead of multiple samples. 
Moreover, as target inhibition is thought to be concentration dependent, dosing should 
strive to keep the drug concentration above a certain minimally efficacious concentration 
during the whole dose interval, which is most accurately reflected by Cmin. 
Most importantly, studies relating pazopanib exposure to response have used 
Cmin, rather than AUC, further strengthening the case for Cmin threshold monitoring.4,6 
Finally, self-sampling approaches facilitated by dried blood spot sampling may further 
enable the use of PK-guided dosing in routine care and several assays have already been 
developed for this purpose.23,24 
The number of patients who had a Cmin below the target at a moment of possible 
dose modification was 56.7%, which is markedly higher than the 20% found by Suttle et 
al.4 This may partly be explained by the combination of repeated measurements and 
relatively large intra-individual variability in Cmin. The large number of patients with low 
drug exposure may also partially be caused by use of proton pump inhibitors (PPI), which 
are known to decrease the pH-dependent absorption of pazopanib.25 9 patients in the low 
exposure groups (1a and 1b) used a PPI. The use of gastric-pH increasing agents was 
discouraged but not prohibited during this trial. On the other hand, it also shows that PK-
guided dosing may overcome the problem of pH-limited absorption of pazopanib in 
patients for whom treatment with PPIs is medically necessary. 
A drawback of the current study is that dose modification was limited to three 
pre-specified time points. If later dose increments would have been allowed, more 
patients in the low exposure group might have achieved the target threshold. Another 
limitation is that our study was performed in patients with a wide range of advanced solid 
tumors. Therefore, a satisfying analysis of the effect of individualized dosing on tumor 
response or PFS is impossible. Nonetheless, all patients who had a partial response had a 
Cmin above the 20.0 mg/L threshold and in a non-prespecified analysis, we found 
significant association between tumor response (measured as maximum change in tumor 
size from baseline) and pazopanib Cmin, which would provide further support for targeting 
a Cmin of ≥20.0 mg/L. Interestingly, in a subgroup analysis of STS patients (n=7), a trend 
toward increased response and longer PFS with higher Cmin was found. Yet, perhaps due to 
the small size of this subgroup, these results were not significant. 
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Moreover, as target inhibition is thought to be concentration dependent, dosing should 
strive to keep the drug concentration above a certain minimally efficacious concentration 
during the whole dose interval, which is most accurately reflected by Cmin. 
Most importantly, studies relating pazopanib exposure to response have used 
Cmin, rather than AUC, further strengthening the case for Cmin threshold monitoring.4,6 
Finally, self-sampling approaches facilitated by dried blood spot sampling may further 
enable the use of PK-guided dosing in routine care and several assays have already been 
developed for this purpose.23,24 
The number of patients who had a Cmin below the target at a moment of possible 
dose modification was 56.7%, which is markedly higher than the 20% found by Suttle et 
al.4 This may partly be explained by the combination of repeated measurements and 
relatively large intra-individual variability in Cmin. The large number of patients with low 
drug exposure may also partially be caused by use of proton pump inhibitors (PPI), which 
are known to decrease the pH-dependent absorption of pazopanib.25 9 patients in the low 
exposure groups (1a and 1b) used a PPI. The use of gastric-pH increasing agents was 
discouraged but not prohibited during this trial. On the other hand, it also shows that PK-
guided dosing may overcome the problem of pH-limited absorption of pazopanib in 
patients for whom treatment with PPIs is medically necessary. 
A drawback of the current study is that dose modification was limited to three 
pre-specified time points. If later dose increments would have been allowed, more 
patients in the low exposure group might have achieved the target threshold. Another 
limitation is that our study was performed in patients with a wide range of advanced solid 
tumors. Therefore, a satisfying analysis of the effect of individualized dosing on tumor 
response or PFS is impossible. Nonetheless, all patients who had a partial response had a 
Cmin above the 20.0 mg/L threshold and in a non-prespecified analysis, we found 
significant association between tumor response (measured as maximum change in tumor 
size from baseline) and pazopanib Cmin, which would provide further support for targeting 
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toward increased response and longer PFS with higher Cmin was found. Yet, perhaps due to 
the small size of this subgroup, these results were not significant. 
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The results of this trial merit further investigation of individualized pazopanib 
dosing in cancer patients. A similar design to the one that was previously used for axitinib 
dose titration in RCC patients could be explored.21,26 As the ideal form of for future studies 
would be a prospective randomized placebo controlled trial in either STS or RCC patients. 
 
CONCLUSION 
In summary, this prospective multicenter trial in patients with advanced solid tumors 
showed that pazopanib dose could safely be escalated in selected patients with a Cmin 
<20.0 mg/L and that pazopanib exposure increased significantly in patients whose dose 
was escalated based on a low Cmin. Moreover, a significant association between Cmin and 
tumor response was found. The outcomes of this trial support further investigation of 
individualized pazopanib dosing, using the here described dosing algorithm, ideally in a 
large prospective randomized clinical trial using PFS or overall survival as an endpoint. 
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The results of this trial merit further investigation of individualized pazopanib 
dosing in cancer patients. A similar design to the one that was previously used for axitinib 
dose titration in RCC patients could be explored.21,26 As the ideal form of for future studies 
would be a prospective randomized placebo controlled trial in either STS or RCC patients. 
 
CONCLUSION 
In summary, this prospective multicenter trial in patients with advanced solid tumors 
showed that pazopanib dose could safely be escalated in selected patients with a Cmin 
<20.0 mg/L and that pazopanib exposure increased significantly in patients whose dose 
was escalated based on a low Cmin. Moreover, a significant association between Cmin and 
tumor response was found. The outcomes of this trial support further investigation of 
individualized pazopanib dosing, using the here described dosing algorithm, ideally in a 
large prospective randomized clinical trial using PFS or overall survival as an endpoint. 
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ABSTRACT 
Background. Pazopanib is approved for the treatment of renal cell carcinoma and soft 
tissue sarcoma. Analyses show increased benefit in patients with plasma trough 
concentrations ≥20.5 μg/ml compared with patients with lower concentrations. 
Methods & results. We developed a DBS assay as a patient friendly approach to guide 
treatment. The method was validated according to US FDA and EMA guidelines and 
European Bioanalysis Forum recommendations. Influence of spot homogeneity, spot 
volume and hematocrit were shown to be within acceptable limits. Analysis of paired 
clinical samples showed a good correlation between the measured plasma and DBS 
concentrations (R2 of 0.872). 
Conclusion. The method was successfully validated, applied to paired clinical samples and 
is suitable for application to therapeutic drug monitoring of pazopanib. 
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BACKGROUND 
Pazopanib is an angiogenesis inhibitor targeting the VEGFR-1,2,3, PDGFR α/β, FGFR and 
the stem cell receptor/c-Kit.1 Pazopanib has shown efficacy in advanced renal cell 
carcinoma and soft tissue sarcoma in a fixed dose of 800 mg once daily.2,3 A recent 
retrospective analysis of a trial of 177 patients treated with pazopanib showed a markedly 
increased median progression free survival in patients with (steady-state) plasma trough 
concentrations (Cmin) ≥20.5 μg/mL compared with patients with lower Cmin (50.2 vs 19.6 
weeks).4 In addition, pazopanib shows large interindividual variability in plasma exposure, 
resulting in a subset of patients at risk of receiving less than optimal exposure.4–7 Given 
the established exposure–response relationship and large interindividual variability in 
exposure, patients might benefit from pharmacokinetically guided dosing, also known as 
therapeutic drug monitoring 
(TDM), based on a measured Cmin. A quantitative assay is needed to identify patients with 
a low Cmin that might benefit from treatment at a higher dose. Several assays to quantify 
pazopanib in (mouse and human) plasma have been described, both using diode array 
detection8 and LC–MS/MS.9–11 Last year, a review article by Wilhelm et al. discussed the 
application of DBS to support TDM.12. A DBS method would allow patients to take a 
sample themselves using a simple finger prick. Compared with plasma methods, DBS 
sampling could be more patient friendly and lead to increased sample stability, limited 
sample volume, convenient storage and shipping. Additionally DBS methods may be 
ideally suited to measure Cmin concentrations, because a blood sample can be obtained at 
the planned time point by the patients themselves and will not be dependent on the time 
of the visit to an out-patient clinic. This may be relevant for pazopanib as De Wit et al. 
found a strong correlation (R2 of 0.940) between the trough sample (exactly C24h) and 
pazopanib area under the curve.7 However, quantification in DBS samples may be more 
challenging for several reasons. Patients or nurses will need additional training to provide 
good quality samples and additional validation tests need to be performed, such as the 
influences of blood hematocrit, spot volume, punch carryover and blood spot 
homogeneity on analytical outcome.13 Moreover, a clinical validation study to investigate 
the relationship between the plasma and DBS concentrations is needed.14,15 But once a 
comprehensively validated method is available and patients and nurses are familiar with 
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the sampling technique, a DBS method will be optimally suited to pharmacokinetically 
guided dosing of pazopanib. Here, we describe the development, analytical and clinical 
validation of an LC–MS/MS method for the quantification of pazopanib in DBS. 
 
MATERIALS, METHODS & PATIENTS 
Chemicals & reagents 
Pazopanib hydrochloride and stable isotopically labeled internal standard (IS) 13C,2H3-
pazopanib hydrochloride, with purities as free base of 92.3 and 92.6%, respectively were 
supplied by GlaxoSmithKline (Zeist, The Netherlands). Formic acid and dimethyl sulfoxide 
were purchased from Merck (Darmstadt, Germany) and methanol (analytical grade) and 
water (LC–MS grade) from BioSolve Ltd (Valkenswaard, The Netherlands). Blank human 
whole K2EDTA blood was obtained from healthy volunteers and used for preparation of 
the quality control (QC) samples, calibration standards and matrix blanks. 
 
Stock solutions, calibration standards & quality control samples 
Stock solutions of pazopanib (2 mg/mL) were prepared in dimethyl sulfoxide. Working 
solutions were prepared by dilution from stocks with methanol. The IS stock solution (1 
mg/mL) was prepared in methanol. The IS working solution was prepared by further 
dilution with methanol to a concentration of 0.1 μg/mL. All stock and working solutions 
were stored at -20°C, the IS working solution at 2–8°C. Calibration standards and QC 
samples were prepared by spiking 30 μL of the working solutions to 570 μL of control 
whole blood. Concentrations of 1.00, 3.00, 15.0 and 37.5 μg/mL were used for the QC 
samples (LLOQ, low, mid and high concentrations, respectively). The concentrations for 
the calibration standards were: 1.00, 2.00, 5.00, 10.0, 20.0, 30.0, 40.0 and 50.0 μg/mL. 
From the blanks, calibration standards and QC samples a volume of 15 μL whole blood 
was spotted on the DBS cards. The blood spots were dried at ambient temperatures (20–
25°C) for at least 3 h after which the samples were stored at ambient temperature with 
desiccant in a sealed foil bag. Hematocrit values of calibration standards and QC samples 
were not standardized in each run. 
 
 
Quantification of pazopanib in DBS | 149 
 
Equipment & conditions 
Blood was spotted on Whatman™ 903 protein saver cards and punches from these cards were 
made using a Harris Uni-Core™ 3.0 mm puncher both purchased from GE Healthcare Europe 
GmbH (Diegem, Belgium). Samples were shaken using an L45 shaker by Labinco (Breda, The 
Netherlands). 
All LC–MS/MS experiments were performed using an 1100 series binary pump, 
degasser, column oven and autosampler from Agilent Technologies (Santa Clara, CA, USA) and 
an API3000 triple quadrupole equipped with Turbo ionspray interface operating in positive ion-
mode, on Analyst™ software for data analysis from Sciex (Framingham, MA, USA). Mass 
transitions of precursor and product ions and other MS parameters were optimized. Final 
settings were: tubro, nebulizer, curtain and collision gases 7 ll/min 7, 8 and 12 au, ion spray 
voltage 3000 V, ionization temperature 500°C, declustering potential 41 V, collision energy 43 
V, collision cell exit and entrance potential 24 V and 10 V. Quantification was performed using 
the m/z 438.2 → m/z 357.3 transition for pazopanib and m/z 442.2 → m/z 361.2 for 13C,2H3-
pazopanib (see Figure 1). 
 
Figure 1. Chemical structure and proposed mass transition of pazopanib and 13C,2H3-pazopanib. 
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Sample preparation 
Separation was performed on a Sunfire C18 Column, 2.1 × 50 mm, 5 μm from 
Waters (Milford, MA, USA) with a Gemini SecurityGuard, 2.0 × 4.0 mm guard column by 
Phenomenex (Torrance, CA, USA). The column oven was set at 55°C and the tray 
temperature of the autosampler at 5°C. Elution was achieved by using a gradient of 
methanol and 0.1% formic acid in water. The gradient started at a flow of 0.4 ml/min at a 
percentage of 27% methanol, after 1.5 min the gradient was increased to 80% methanol. 
At 2 min, the flow increased to 0.6 ml/min and at 2.5 min the percentage of methanol was 
returned to 27% for 1.5 min. The total runtime was 4 min. 
On the day of analysis a 3 mm diameter punch was taken from the blood spots 
and transferred to an eppendorf tube. A total of 50 μL of concentrated formic acid (99%) 
was added to the spot and the sample was vortex mixed and consequently shaken for 10 
min at 1250 rpm. Hereafter, 500 μL of methanol containing the IS (at a concentration of 
0.1 μg/mL) was added and the samples were again vortexed and shaken for 10 min at 
1250 rpm. After centrifugation at 23100 g, 300 μL of the supernatant was transferred to a 
clean vial containing 300 μL of water. These vials were then vortex mixed and 5 μL was 
injected into the LC–MS/MS system. 
For plasma samples, a 10 μl aliquot was used, to which 500 μL of IS containing 
methanol and 500 μL eluent was added. This solution was then centrifuged at 23100 rpm 
and 5 μL of the supernatant was analyzed by LC–MS/MS. 
 
Validation 
The method was validated in accordance with US FDA and EMA guidelines on bioanalytical 
method validation and Good Laboratory Practices.16,17 DBS-specific validation tests were 
performed, as recommended by the European Bioanalysis Forum.18,19 
 
Analytical validation 
Three separate validation runs were executed on separate days and the following 
validation parameters were assessed: LLOQ, calibration model, accuracy and precision, 
dilution integrity, selectivity, instrumentation carryover, matrix effect and recovery. 
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Linear regression was applied. Nonweighted, 1/x and 1/x2 weighted regression 
were evaluated (where x equals the peak area ratio). In every run at least 75% of the 
nonzero standards (including at least one LLOQ and ULOQ) should be within ±15% of the 
nominal value (or ±20% for the LLOQ), additionally for the LLOQ and ULOQ level at least 
50% should meet these criteria. Regression coefficients were calculated in each run. 
Accuracy and precision of the method were assessed by injecting five replicates 
of LLOQ, QC low, mid and high samples in three separate validation runs. Intra- and inter-
run accuracy was expressed as the bias in% and intra- and inter-run precision as the 
coefficient of variation (CV) in%. At each of the QC levels the bias should be within ±15% 
and the precision should not exceed 15%. 
The LLOQ was evaluated in each run using the signal-to-noise ratio expressed as 
the signal (peak height of the 1.00 μg/ml calibration standard) to the noise (peak height) 
of a blank sample. This ratio should be at least 5. 
Dilution integrity was calculated by analyzing five replicates of samples with a 
concentration of 100 μg/ml, diluted 10-times with a processed controlled matrix and 
comparing the measured concentration with the nominal concentration. This bias should 
be within ±15% and the precision should not exceed 15%. 
For selectivity, the effect of endogenous interferences and IS interference were 
determined. Six different batches of human whole blood were processed both as blanks 
and spiked at the LLOQ concentration to investigate possible endogenous interferences. 
Cross analyte interference was assessed by extracting pazopanib without the addition of 
the IS and by spiking IS separately to a double blank sample (a matrix sample; 3 mm punch 
from a blood spot without spiking analyte or IS) at the concentration used in the assay. 
The interference should be less than 20% of the response of the LLOQ of the analyte and 
less than 5% of the response of the IS. 
Instrumentation carryover was tested by injecting two double blank samples 
after injecting an ULOQ sample in each validation run and expressed as the peak area in 
the blanks as a percentage of the LLOQ peak area. Carryover was considered acceptable 
when the response in the first blank at the retention time of the analyte is less than 20% 
of the response of the LLOQ. 
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methanol and 0.1% formic acid in water. The gradient started at a flow of 0.4 ml/min at a 
percentage of 27% methanol, after 1.5 min the gradient was increased to 80% methanol. 
At 2 min, the flow increased to 0.6 ml/min and at 2.5 min the percentage of methanol was 
returned to 27% for 1.5 min. The total runtime was 4 min. 
On the day of analysis a 3 mm diameter punch was taken from the blood spots 
and transferred to an eppendorf tube. A total of 50 μL of concentrated formic acid (99%) 
was added to the spot and the sample was vortex mixed and consequently shaken for 10 
min at 1250 rpm. Hereafter, 500 μL of methanol containing the IS (at a concentration of 
0.1 μg/mL) was added and the samples were again vortexed and shaken for 10 min at 
1250 rpm. After centrifugation at 23100 g, 300 μL of the supernatant was transferred to a 
clean vial containing 300 μL of water. These vials were then vortex mixed and 5 μL was 
injected into the LC–MS/MS system. 
For plasma samples, a 10 μl aliquot was used, to which 500 μL of IS containing 
methanol and 500 μL eluent was added. This solution was then centrifuged at 23100 rpm 
and 5 μL of the supernatant was analyzed by LC–MS/MS. 
 
Validation 
The method was validated in accordance with US FDA and EMA guidelines on bioanalytical 
method validation and Good Laboratory Practices.16,17 DBS-specific validation tests were 
performed, as recommended by the European Bioanalysis Forum.18,19 
 
Analytical validation 
Three separate validation runs were executed on separate days and the following 
validation parameters were assessed: LLOQ, calibration model, accuracy and precision, 
dilution integrity, selectivity, instrumentation carryover, matrix effect and recovery. 
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Linear regression was applied. Nonweighted, 1/x and 1/x2 weighted regression 
were evaluated (where x equals the peak area ratio). In every run at least 75% of the 
nonzero standards (including at least one LLOQ and ULOQ) should be within ±15% of the 
nominal value (or ±20% for the LLOQ), additionally for the LLOQ and ULOQ level at least 
50% should meet these criteria. Regression coefficients were calculated in each run. 
Accuracy and precision of the method were assessed by injecting five replicates 
of LLOQ, QC low, mid and high samples in three separate validation runs. Intra- and inter-
run accuracy was expressed as the bias in% and intra- and inter-run precision as the 
coefficient of variation (CV) in%. At each of the QC levels the bias should be within ±15% 
and the precision should not exceed 15%. 
The LLOQ was evaluated in each run using the signal-to-noise ratio expressed as 
the signal (peak height of the 1.00 μg/ml calibration standard) to the noise (peak height) 
of a blank sample. This ratio should be at least 5. 
Dilution integrity was calculated by analyzing five replicates of samples with a 
concentration of 100 μg/ml, diluted 10-times with a processed controlled matrix and 
comparing the measured concentration with the nominal concentration. This bias should 
be within ±15% and the precision should not exceed 15%. 
For selectivity, the effect of endogenous interferences and IS interference were 
determined. Six different batches of human whole blood were processed both as blanks 
and spiked at the LLOQ concentration to investigate possible endogenous interferences. 
Cross analyte interference was assessed by extracting pazopanib without the addition of 
the IS and by spiking IS separately to a double blank sample (a matrix sample; 3 mm punch 
from a blood spot without spiking analyte or IS) at the concentration used in the assay. 
The interference should be less than 20% of the response of the LLOQ of the analyte and 
less than 5% of the response of the IS. 
Instrumentation carryover was tested by injecting two double blank samples 
after injecting an ULOQ sample in each validation run and expressed as the peak area in 
the blanks as a percentage of the LLOQ peak area. Carryover was considered acceptable 
when the response in the first blank at the retention time of the analyte is less than 20% 
of the response of the LLOQ. 
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The matrix factor (MF) was calculated by dividing the analyte and IS peak area in 
presence of matrix by the peak area of the analyte and IS in a neat solution, using six 
different batches of whole blood spiked at both the QC low and QC high concentration. 
The IS normalized MF was calculated by dividing the MF of pazopanib by the MF of the IS 
of which the CV was calculated. This CV was considered acceptable if it was less than 15%.  
The (sample pretreatment) recovery was determined by comparing peak area of 
pazopanib in processed validation samples to peak area of pazopanib area in presence of 
matrix, at QC low and high concentrations in triplicate. No specific requirement for 
recovery was predefined except that it should be reproducible. 
 
DBS-specific validation 
The influence of spot (in)homogeneity, spot volume, blood hematocrit and spot-to-spot 
carryover was investigated. The spot-to-spot carryover was tested by punching a double 
blank sample after an ULOQ sample. Carryover was considered acceptable as the response 
in this blank sample at the retention time of the analyte was ≤20% of the mean (n = 5) 
response at the LLOQ. 
The effect of (in)homogeneity within the blood spot was examined in triplicate by 
taking punches from the edge of the blood spot and comparing the measured 
concentration with the nominal concentration, at low and high QC concentrations. The 
effect of spot volume and blood hematocrit was investigated in triplicate at QC low and 
QC high concentrations, by spotting a range of volumes on the DBS cards (10, 15, 30 μL). 
The effect of the hematocrit was determined by preparing batches of whole blood with 
different hematocrit values in the range from nominally 35 to 50% (tested values: 34.1, 
42.4 and 49.7%). 
The effect of spot volume, inhomogeneity and hematocrit was considered 
acceptable if bias and precision were within ±15 and ≤15%, respectively. 
 
Stability 
Stability of processed samples stored at nominally 2–8°C and samples on the DBS cards at 
ambient temperature (in a foil bag with desiccant) was investigated in triplicate at both 
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low and high QC concentrations. Samples were considered stable if the bias was within ±15% 
of the nominal concentration and the CV was ≤15%.  
 
Clinical validation 
Paired DBS and (venous) plasma samples were obtained from patients with advanced solid 
tumors treated with pazopanib (n = 30) recruited from three centers (the Netherlands Cancer 
Institute, Amsterdam, Utrecht University Medical Center, Utrecht and Erasmus MC Cancer 
Institute, Rotterdam). Doses administered ranged from 400 mg to 1800 mg daily following 
protocol and within patient adjustments of the dose were possible.20 The trial was approved by 
the independent ethics committee of each participating hospital (Dutch Trial Registry; trial 
identifier NTR3967) and all patients provided written informed consent before enrollment. DBS 
samples were taken by a finger prick under the supervision of a study nurse and the obtained 
blood spots were dried at ambient temperatures for at least 3 h, after which the samples were 
stored with desiccant in a sealed foil bag and sent to the analytical laboratory. 
Weighted Deming fit was used to investigate the relationship between the plasma 
and DBS concentration. Using the observed slope and intercept the plasma concentration were 
calculated. Bland–Altman plots were made to investigate the bias between the calculated and 
measured plasma concentrations. These analyses were all performed in R (version 3.0.0).21 
An arbitrarily selected subset of DBS samples (n = 47) was measured in duplicate (two 
separate blood spots on the same card, obtained from the same patient at the same date and 
time) to investigate the variability during the spotting procedure in clinical practice. Another 
subset of DBS samples was measured in duplicate with one punch of 3 mm and another of 6 
mm (n = 51), to assess the effect of punch size in the clinical samples. In this separate analysis 
the calibration standards and QC samples were also analyzed using a 6 mm punch for the DBS.  
 
RESULTS & DISCUSSION 
Analytical validation results 
An overview of the validated parameters is shown in Table 1. Analytical performance data for 
pazopanib in DBS are shown in Table 2. All tested parameters met their predefined acceptance 
criteria. As 1/x weighted regression resulted in the lowest total bias this was selected for the 
calibration model. 
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The matrix factor (MF) was calculated by dividing the analyte and IS peak area in 
presence of matrix by the peak area of the analyte and IS in a neat solution, using six 
different batches of whole blood spiked at both the QC low and QC high concentration. 
The IS normalized MF was calculated by dividing the MF of pazopanib by the MF of the IS 
of which the CV was calculated. This CV was considered acceptable if it was less than 15%.  
The (sample pretreatment) recovery was determined by comparing peak area of 
pazopanib in processed validation samples to peak area of pazopanib area in presence of 
matrix, at QC low and high concentrations in triplicate. No specific requirement for 
recovery was predefined except that it should be reproducible. 
 
DBS-specific validation 
The influence of spot (in)homogeneity, spot volume, blood hematocrit and spot-to-spot 
carryover was investigated. The spot-to-spot carryover was tested by punching a double 
blank sample after an ULOQ sample. Carryover was considered acceptable as the response 
in this blank sample at the retention time of the analyte was ≤20% of the mean (n = 5) 
response at the LLOQ. 
The effect of (in)homogeneity within the blood spot was examined in triplicate by 
taking punches from the edge of the blood spot and comparing the measured 
concentration with the nominal concentration, at low and high QC concentrations. The 
effect of spot volume and blood hematocrit was investigated in triplicate at QC low and 
QC high concentrations, by spotting a range of volumes on the DBS cards (10, 15, 30 μL). 
The effect of the hematocrit was determined by preparing batches of whole blood with 
different hematocrit values in the range from nominally 35 to 50% (tested values: 34.1, 
42.4 and 49.7%). 
The effect of spot volume, inhomogeneity and hematocrit was considered 
acceptable if bias and precision were within ±15 and ≤15%, respectively. 
 
Stability 
Stability of processed samples stored at nominally 2–8°C and samples on the DBS cards at 
ambient temperature (in a foil bag with desiccant) was investigated in triplicate at both 
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low and high QC concentrations. Samples were considered stable if the bias was within ±15% 
of the nominal concentration and the CV was ≤15%.  
 
Clinical validation 
Paired DBS and (venous) plasma samples were obtained from patients with advanced solid 
tumors treated with pazopanib (n = 30) recruited from three centers (the Netherlands Cancer 
Institute, Amsterdam, Utrecht University Medical Center, Utrecht and Erasmus MC Cancer 
Institute, Rotterdam). Doses administered ranged from 400 mg to 1800 mg daily following 
protocol and within patient adjustments of the dose were possible.20 The trial was approved by 
the independent ethics committee of each participating hospital (Dutch Trial Registry; trial 
identifier NTR3967) and all patients provided written informed consent before enrollment. DBS 
samples were taken by a finger prick under the supervision of a study nurse and the obtained 
blood spots were dried at ambient temperatures for at least 3 h, after which the samples were 
stored with desiccant in a sealed foil bag and sent to the analytical laboratory. 
Weighted Deming fit was used to investigate the relationship between the plasma 
and DBS concentration. Using the observed slope and intercept the plasma concentration were 
calculated. Bland–Altman plots were made to investigate the bias between the calculated and 
measured plasma concentrations. These analyses were all performed in R (version 3.0.0).21 
An arbitrarily selected subset of DBS samples (n = 47) was measured in duplicate (two 
separate blood spots on the same card, obtained from the same patient at the same date and 
time) to investigate the variability during the spotting procedure in clinical practice. Another 
subset of DBS samples was measured in duplicate with one punch of 3 mm and another of 6 
mm (n = 51), to assess the effect of punch size in the clinical samples. In this separate analysis 
the calibration standards and QC samples were also analyzed using a 6 mm punch for the DBS.  
 
RESULTS & DISCUSSION 
Analytical validation results 
An overview of the validated parameters is shown in Table 1. Analytical performance data for 
pazopanib in DBS are shown in Table 2. All tested parameters met their predefined acceptance 
criteria. As 1/x weighted regression resulted in the lowest total bias this was selected for the 
calibration model. 
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Table 1. Summary of validation results. 
Parameter Result 
Calibration model Linear regression coefficients all >0.99 
Validated range  1.00–50.0 μg/mL 
Overall (in)accuracy  Bias ±4.0% 
Inter- and intra-run precision (CV)  ≤8.6% 
Lower limit of quantification (S/N)  >27 
Dilution integrity  Bias ±1.0%, CV 10.7% 
Selectivity (endogenous and cross analyte)  ≤0.6% 
Instrument carryover  0.6% of the LLOQ 
IS normalized matrix factor (mean, CV)  1.01, 1.6% (QC low), 0.980, 1.9% (QC high) 
Recovery  97.6% (QC low), 103.7% (QC high), CV ≤2.7% 
Spot-to-spot carry-over  6.4% of the LLOQ 
Blood spot homogeneity  Bias ±3.5%, CV ≤4.6% 
Effect of blood spot volume  Bias ±9.5%, CV ≤4.8% 
Effect of blood hematocrit  Bias ±14.2%, CV ≤10.2% 
Final extract stability (2–8°C)  168 days 
DBS stability (ambient temperatures)  398 days 
All tested parameters met their predefined criteria (predefined acceptance criteria are mentioned in 
the text). 
 
 
Table 2. Analytical performance data for pazopanib in DBS. 
Run  Nominal 
concentration  
(μg/mL) 
Mean measured 
concentration  
(μg/mL) 
(In)accuracy  
(%deviation) 
Precision  
(% CV)  
Replicates  
(n) 
1 1.01 1.09 8.1 5.6 5 
2 1.01 1.02 1.2 5.9 5 
3 1.01 1.00 -0.8 6.1 5 
Overall 1.01 1.04 2.8 3.7 15 
1 3.03 3.04 0.2 5.1 5 
2 3.03 2.95 -2.7 5.3 5 
3 3.03 3.20 5.7 7.1 5 
Overall 3.03 3.06 1.1 3.4 15 
1 15.1 15.9 5.0 3.0 5 
2 15.1 14.8 -2.3 8.6 5 
3 15.1 16.5 9.3 3.8 5 
Overall 15.1 15.7 4.0 5.0 15 
1 37.9 38.5 1.6 5.8 5 
2 37.9 36.6 -3.5 4.9 5 
3 37.9 40.3 6.4 3.2 5 
Overall 37.9 38.5 1.5 4.4 15 
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DBS-specific validation results 
The spot-to-spot carryover was 6.4% of the mean (n = 5) LLOQ level for pazopanib and 
0.0% for 13C,2H3-pazopanib. Spot (in)homogeneity resulted in a bias of 3.5 and 2.2% for 
low and high QC levels with CV percentages of 1.3 and 4.6, respectively. 
Data for the effect of spot volume are presented in Table 3. The biases for all 
tested volumes were ≤9.5% of the nominal concentration and the CV was  ≤4.8%, 
indicating that the influence of spot volume was within the requirements. 
Results for the influence of hematocrit are shown in Table 4. The calibration 
standards used in the analysis had a hematocrit value of 43.8%. The effect of the 
hematocrit was within the predefined limits as the mean measured concentration was 
≤14.2% of the nominal concentration, with a CV of ≤10.2%.  
 
Table 3. Effect of spot volume on the quantification of pazopanib (n = 3). 
Spot volume QC low bias (%) CV  
(%) 
QC high bias 
(%) 
CV  
(%) 
10 μL -9.0 4.7 -5.0 0.7 
20 μL 5.2 4.8 -0.7 1.8 
30 μL 9.5 3.1 5.5 1.9 
 
 
Table 4. Effect of blood hematocrit on the quantification of pazopanib (n = 3). 
Blood hematocrit QC low bias (%) CV  
(%) 
QC high bias 
(%) 
CV  
(%) 
34.1% -14.2 7.1 -10.0 10.2 
42.4% -4.2 4.4 -7.4 2.4 
49.7% 7.4 3.9 1.0 1.3 
 
Stability 
QC samples at low and high concentrations (n = 3), deviated ≤15% of the nominal 
concentration after being stored at ambient temperatures (in a foil bag with desiccant) at 
398 days. Therefore, pazopanib was considered to be stable for at least 398 days on the 
DBS cards. Processed samples stored at nominally 2–8°C deviated ≤15% of the nominal 
concentration and were therefore considered stable at nominally 2–8°C for at least 168 
days. 
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DBS-specific validation results 
The spot-to-spot carryover was 6.4% of the mean (n = 5) LLOQ level for pazopanib and 
0.0% for 13C,2H3-pazopanib. Spot (in)homogeneity resulted in a bias of 3.5 and 2.2% for 
low and high QC levels with CV percentages of 1.3 and 4.6, respectively. 
Data for the effect of spot volume are presented in Table 3. The biases for all 
tested volumes were ≤9.5% of the nominal concentration and the CV was  ≤4.8%, 
indicating that the influence of spot volume was within the requirements. 
Results for the influence of hematocrit are shown in Table 4. The calibration 
standards used in the analysis had a hematocrit value of 43.8%. The effect of the 
hematocrit was within the predefined limits as the mean measured concentration was 
≤14.2% of the nominal concentration, with a CV of ≤10.2%.  
 
Table 3. Effect of spot volume on the quantification of pazopanib (n = 3). 
Spot volume QC low bias (%) CV  
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Table 4. Effect of blood hematocrit on the quantification of pazopanib (n = 3). 
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Stability 
QC samples at low and high concentrations (n = 3), deviated ≤15% of the nominal 
concentration after being stored at ambient temperatures (in a foil bag with desiccant) at 
398 days. Therefore, pazopanib was considered to be stable for at least 398 days on the 
DBS cards. Processed samples stored at nominally 2–8°C deviated ≤15% of the nominal 
concentration and were therefore considered stable at nominally 2–8°C for at least 168 
days. 
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Clinical validation 
The method was applied to clinical samples taken approximately 24 h after the last dose 
(at steady state) from cancer patients treated with pazopanib. In total, 329 paired DBS and 
plasma samples were obtained from the 30 enrolled patients. Irregular, very large (larger 
than the printed ring on the DBS card), very small (smaller than the punch diameter) spots 
were excluded. Samples resulting in concentrations below the LLOQ15 were also excluded. 
In total, 221 spots were used for the analysis. As shown in Figure 2, a good correlation 
between the DBS and the plasma concentration was found (R2 of 0.872 with a slope of 
0.709 and an intercept of -0.182). 
The plasma concentration was back calculated based on the measured DBS 
concentration, using [pazopanibcalculated plasma] = ([pazopanibDBS] + 0.182) / 0.709. The 
plotted calculated versus measured plasma concentrations are shown in Figure 3. The  
difference between the calculated and measured plasma concentrations versus the 
measured plasma concentration is shown in a Bland–Altman plot in Figure 4. Back 
calculated plasma concentrations were within 20% of measured plasma concentrations for 
79.2% of the DBS samples. 
Correction for patient-specific hematocrit when calculating the plasma 
concentration (using the formula proposed by Kromdijk et al.14, [pazopanibcalculated plasma 
(hmtcrt corrected)] = [pazopanibDBS]/(1-hematocrit)*fraction bound to plasma protein) did not 
improve the correlation between the calculated and measured plasma concentrations 
compared with the empirically found Deming regression. The hematocrit values of the 
patients used for this sub analysis were within the validated range, the mean was 40%, 
ranging from 36 to 48%. 
When used to identify patients above or below the 20 μg/mL threshold the 
plasma and DBS methods were in agreement in 91.4% of the cases. A Bland–Altman plot 
of the difference between two spots taken at the same time as a function of the mean of 
the two measurements is given in Figure 5. The Bland–Altman plot showing the deviations 
of clinical samples punched with both a 3 and a 6 mm diameter punch is shown in Figure 
6. 
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Figure 2. Measured DBS concentration versus the measured plasma concentration (n= 
221). The solid black line represents the weighted Deming fit, the dotted black lines 
represent the 95% CI of the Deming fit, the green dotted line is the line of unity. 
 
 
 
Figure 3. Calculated plasma versus the measured plasma concentration (n = 221). 
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Figure 4. Bland–Altman plot showing the difference between the calculated and measured 
pazopanib plasma concentration (n = 221). The mean difference between the two methods 
was 0.08 μg/ml. 
 
Figure 5. Bland–Altman plot showing the difference between the measured pazopanib 
spots in the subset of samples of which two spots provided by the same patient at the 
same time were measured (n = 47). The mean difference between the two methods was -
0.105 μg/ml. 
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Figure 6. Bland–Altman plots showing the difference between the measured pazopanib 
spots in the subset of samples (n = 51) which were measured after a 3 mm punch (A) and a 
6 mm punch (B) from the DBS card. The mean difference was -0.09 and 0.44 μg/ml for the 
3 and 6 mm punched samples, respectively. 
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Our method was successfully developed to quantify pazopanib in DBS and 
validated in accordance with FDA and EMA guidelines on bioanalytical method validation 
and good laboratory practices.16,17 With a run time of only 4 min, the developed method is 
suitable for routine analyses of patient samples. Moreover processed samples were 
shown to be stable for at least 168 days, therefore calibration standards can be reused 
several times, reducing the time needed to perform an analytical run. 
Spot volume resulted in a small positive bias for large volumes and a small 
negative bias for small volumes (both within the predefined requirements). No clear 
mechanism for this effect has been reported. The same trend was found for the tyrosine 
kinase inhibitor vemurafenib22 and other compounds such as everolimus, tacrolimus and 
sirolimus.23 
Spot-to-spot carryover was shown to be only 6.4% of the LLOQ and will therefore 
have no relevant effect on the analytical outcome when applying this method. 
The influence of spot homogeneity was assessed in the laboratory and showed a 
bias within ±3.5 and a CV of ≤4.6%. In practice however it is likely that this effect will be 
larger, as samples provided by patients will be less uniform than those made using a 
pipette. 
During the DBS-specific validation experiments, hematocrit values from 35 to 
50% were tested and the bias and variability were within predefined limits. Low 
hematocrit values resulted in a negative bias, while high hematocrit resulted in a positive 
bias. This might be explained by the higher viscosity with higher hematocrit and, 
consequently, less spreading on paper. The effect of hematocrit seems to be dependent 
on the analyte tested. For example, a trend similar to that of pazopanib was found for 
vemurafenib, everolimus and sirolimus, no clear trend was observed for tamoxifen, 
endoxifen, tacrolimus and an opposite trend was found for cyclosporine A.22–24 
A good correlation was observed between the DBS concentration and the plasma 
concentration (R2 = 0.872), with a slope of 0.709 and intercept of -0.182 (Figure 2). The 
lower DBS concentration probably results from pazopanib’s high plasma protein binding 
causing a higher concentration in the plasma relative to blood cells. 
Based on this weighted Deming fit, the plasma concentration could be back 
calculated using the formula: [pazopanibcalculated plasma] = ([pazopanibDBS] + 0.182) / 0.709 
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(Figure 3). Correction for patient-specific hematocrit when calculating the plasma 
concentration, did not improve the correlation between the calculated and measured 
plasma concentrations compared with the empirical Deming regression formula. This 
suggests that even though hematocrit influences the analytical results (as seen in the DBS-
specific validation tests) in the clinical setting it is not the most important factor driving 
the variability between the two methods. 
Despite the good correlation between plasma and DBS samples, 20.8% of the 
calculated plasma concentrations deviated more than 20% from the measured plasma 
concentration (Figure 4). Taking into account the excellent analytical performance of the 
assay during the validation with the laboratory spots (Table 2) it is likely that the variability 
arises during the clinical spotting procedure. 
This is supported by the results of the DBS samples measured in duplicate. As 
even in these samples, which were taken from the same patient at the same time, 
differences of up to 17.2% were observed (Figure 5). Spot quality, volume and 
(in)homogeneity are the likely factors that cause this variability. Since these samples were 
taken from the same patient at the same time, blood hematocrit could not explain this 
difference. Using a larger 6 mm punch resulted in a small reduction of the imprecision 
(Figure 6). But using the 6 mm punch would require patients to produce larger spots, 
leading to use of larger blood volumes and most likely to a larger number of samples 
smaller than the punch size. 
Acknowledging the above, care should be taken to inspect the quality of the spot 
before measurement. Very large, very small or irregular spots should not be used, as 
parameters such as spot homogeneity and volume seemed more important than 
hematocrit during the clinical validation study. Careful instruction and training of patients 
in the sampling procedure should thus considered important when using this method, but 
a recent study in breast cancer patients treated with tamoxifen shows the feasibility of 
DBS self-sampling.25 
In guiding pazopanib therapy it will be particularly important to identify patients 
above or below the PK target of ≥20 μg/mL. When the calculated pazopanib plasma 
concentration was used to identify patients below the PK target level of ≥20 μg/mL, the 
DBS method was in agreement with the plasma method in 91.4% of the cases. This makes 
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the DBS method acceptable for the proposed purpose of guiding pazopanib therapy, with 
relevant practical advantages over the plasma method. Furthermore in light of the 
intrapatient variability (CV) of pazopanib of 24.7%,7 the discrepancy between the two 
analytical methods will have little effect on the clinical application. As patients with a Cmin 
around the 20 μg/mL threshold (e.g., 15–25 μg/mL) would require repeated 
measurements of the pazopanib concentration, regardless of the analytical method used. 
An earlier method for the quantification of pazopanib in DBS has been 
described,26 when this method was used to compare calculated versus measured plasma 
pazopanib concentrations in paired samples, 92.6% of the samples were within the 
predefined deviation of ±25% in the Bland–Altman analysis. When applying these (wider) 
acceptance criteria to our current method a similar percentage of 88.2% was found. 
However the earlier method used the patient’s hematocrit in calculating the plasma 
concentration. This is a significant disadvantage if the method is to be applied to patient 
self-sampling, as calculation of the pazopanib plasma level would still require a visit to the 
clinic to measure a patient’s hematocrit. With the current method there was no need to 
use the patient’s hematocrit and no such correction was used during our clinical validation 
study, making it more suited to a patient self-sampling approach. Given the well-
established exposure–response relationship of pazopanib, a fast and minimally invasive 
DBS method might help implementation of an individualized dosing approach or TDM. 
Patients would be able to take DBS samples at home and send these at ambient 
temperatures (these were shown to be stable for at least 398 days) to the analytical 
laboratory. The pazopanib DBS concentration could then be measured before the next 
visit to the clinic and the plasma concentration could be calculated using 
[pazopanibcalculated plasma] = ([pazopanibDBS] + 0.182)/0.709. Subsequently an assessment of 
the Cmin could be made by the treating physician and a dose adjustment could be 
considered for patients with a low pazopanib exposure to optimize their treatment. 
 
CONCLUSION 
An LC–MS/MS method for the quantitative determination of pazopanib in DBS was 
developed and successfully validated in accordance with FDA and EMA guidelines and 
European Bioanalysis Forum recommendations for DBS method validation. The DBS 
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concentrations showed a good correlation with the plasma concentrations (R2 of 0.872) 
and could be used to determine a calculated plasma concentration. The DBS method can 
be used for pharmacokinetically guided dosing of pazopanib therapy. 
 
FUTURE PERSPECTIVE 
The described method is suitable for the application to TDM of pazopanib, with relevant 
advantages over plasma quantification (e.g., patient friendly sampling and sample 
stability) and no need to correct for patient hematocrit. The availability of this assay 
facilitates further implementation of TDM of pazopanib and enables more personalized 
treatment with this drug. But further prospective clinical trials are needed to demonstrate 
the added value of an individualized dosing strategy for pazopanib based a measured drug 
concentration. 
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Genomic precision medicine 
The first part of this thesis represents contemporary efforts to make anti-cancer 
treatment more precise. As mentioned in Chapter 1, many patients still do not benefit 
from systemic treatment or they experience excessive side effects. Internationally, there 
are many consortia that aim to find biomarkers that predict for treatment effect or for the 
occurrence of side effects. The ultimate goal in this quest is to prevent patients from being 
treated with ineffective drugs and to prevent patients from experiencing (unnecessary) 
heavy side effects. The Dutch Center for Personalized Cancer Treatment (CPCT) is an 
example of such a collaboration. The aim of the CPCT is to collect fresh frozen tumor 
biopsies on a large scale and to identify predictive biomarkers in the DNA of these 
biopsies. 
 
CPCT studies 
The backbone of the biopsy collection is the “CPCT-02” study (NCT01855477), in which 
patients that are planned to be treated with systemic anti-cancer treatment are included. 
After inclusion, these patients are biopsied from a – preferably metastatic – tumor lesion 
before start of the treatment. The fresh frozen biopsies are shipped to a central facility, 
where they are further processed, i.e. the percentage of tumor cells is determined and if 
that is sufficient (>30%), DNA is isolated from the macrodissected tumor cells. In case 
there is sufficient DNA (>500 ng), next-generation sequencing (NGS) is performed on it. 
Meanwhile, the clinical patient data is being collected in an electronic case record form 
(eCRF), from which the important clinical endpoints can be distracted. For the primary 
analyses, the DNA sequencing results and the clinical outcome are compared in order to 
identify somatic genetic alterations that can potentially serve as a predictive biomarker for 
the effectivity of a selected anti-cancer agent. In Chapter 2, a part of the logistical process 
of CPCT is outlined. It was already known that performing biopsies from metastatic lesions 
is a relatively safe procedure. However, we have also shown in this chapter that the 
central storage of fresh frozen biopsies from multiple clinical centers is feasible, which 
enabled us to set up a large biobank with high-quality tumor DNA from these biopsies. At 
start of the study, only three hospitals were affiliated to this initiative, being the 
Netherlands Cancer Institute, Amsterdam, the Erasmus MC Cancer Institute, Rotterdam, 
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and the UMC Utrecht. Once the process of biopsy collection and storage was set up in 
these centers, many other Dutch oncology centers have joined the CPCT, resulting in a 
unique collaboration that completely covers the Netherlands.  
The main objective of the CPCT-02 is to identify somatic genetic aberrations 
predictive for treatment outcome. As the spectrum of genetic aberrations investigated is 
extremely large, especially with the continuous development of DNA sequencing 
techniques, and as the effects on treatment outcome might be subtle, large numbers of 
patients are required to have sufficient power for the analyses. Hence, it is estimated that 
no less than tens – or even hundreds – of patients are required for each analysis. As each 
administered drug exhibits a different working mechanism, they should be investigated 
separately. Therefore, it is fundamental that tumor tissue and patient characteristics are 
collected on a large scale, as is being done in CPCT. Currently, CPCT is focusing on 
performing high-throughput DNA sequencing, but since the biopsies are stored fresh 
frozen – and not formalin-fixed and paraffin-embedded (FFPE) – they can also be used for 
analyses on other platforms, such as for RNA sequencing or proteomics. 
During the last years, when the CPCT was already initiated, several relevant 
findings have been reported. For example, the idea that genetic aberrations carry out their 
effects irrespective of tumor type has – at least partially – been refuted. For example, 
targeting mutated BRAF in colorectal cancer appeared to be ineffective,1 whereas it had 
been found earlier that BRAF mutated melanoma responded very well to BRAF inhibition.2 
This effect was found to be caused by different activity of EGFR between the two tumor 
types, which results from the different embryological origin of the tissue.3 Due to this 
context-dependency, it would be very helpful to discover what (histological) tumor types 
are susceptible to the investigated treatment. That way, patients can be recruited to 
specific trials based on the molecular characteristics of their tumor and the low number of 
patients can efficiently be allocated to the most informative trial. Unfortunately, even 
then the matter is probably much more complex than illustrated above. From in vitro 
studies, we have tried to identify genetic aberrations that are predictive for cisplatin 
response. We did so by comparing sensitivity analyses for genetic mutations in different 
cell lines from the Erasmus MC and from the public COSMIC database.4 Strikingly, and 
unfortunately, these sensitivity analyses had very different – if not completely opposite – 
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biopsies. 
 
CPCT studies 
The backbone of the biopsy collection is the “CPCT-02” study (NCT01855477), in which 
patients that are planned to be treated with systemic anti-cancer treatment are included. 
After inclusion, these patients are biopsied from a – preferably metastatic – tumor lesion 
before start of the treatment. The fresh frozen biopsies are shipped to a central facility, 
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and the UMC Utrecht. Once the process of biopsy collection and storage was set up in 
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effects irrespective of tumor type has – at least partially – been refuted. For example, 
targeting mutated BRAF in colorectal cancer appeared to be ineffective,1 whereas it had 
been found earlier that BRAF mutated melanoma responded very well to BRAF inhibition.2 
This effect was found to be caused by different activity of EGFR between the two tumor 
types, which results from the different embryological origin of the tissue.3 Due to this 
context-dependency, it would be very helpful to discover what (histological) tumor types 
are susceptible to the investigated treatment. That way, patients can be recruited to 
specific trials based on the molecular characteristics of their tumor and the low number of 
patients can efficiently be allocated to the most informative trial. Unfortunately, even 
then the matter is probably much more complex than illustrated above. From in vitro 
studies, we have tried to identify genetic aberrations that are predictive for cisplatin 
response. We did so by comparing sensitivity analyses for genetic mutations in different 
cell lines from the Erasmus MC and from the public COSMIC database.4 Strikingly, and 
unfortunately, these sensitivity analyses had very different – if not completely opposite – 
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results, which made it impossible to generate a predictive gene signature. Therefore, we 
were not able to set up a prospective clinical study to validate it. The irreproducibility of 
sensitivity analyses on cell lines was later confirmed on a larger scale, when results from 
the Cancer Genome Project (CGP) and the Cancer Cell line Encyclopedia (CCLE) were found 
to be highly discordant.5 The authors conclude, justly, that experimental and analytic 
uniformity is lacking and should be optimized, especially when these experiments are to 
serve as the basis for further clinical research.6 
As generating hypotheses for targeted anti-cancer treatment appears to be much 
more complex than expected, several initiatives have started giving targeted therapies to 
patients with other tumors than those for which the therapy has been registered. In a 
small set of patients, these targeted agents are aimed at the molecular aberrations, which 
they are known to effectively target in another cancer type, without anteriorly 
investigating the biological mechanism in a preclinical setting. The SHIVA trial7 pioneered 
this type of research by randomizing almost 200 patients to either a targeted therapy 
against a proven molecular aberration or to treatment at the physician’s choice. 
Regrettably, patients in the targeted therapy arm did not have better progression free 
survival (PFS) rates than those in the control arm. These results seem to provide an 
additional message that targeting molecular mechanisms, regardless of tumor type, is 
based on an oversimplified model of tumor biology. Additionally, 40% of the completely 
analyzed tumors did not harbor a mutation that was considered targetable by one of the 
drugs available to this initiative, which is most likely an illustration of the lack of adequate 
therapies to target all investigated molecular aberrations. In addition to this study, several 
other initiatives have been initiated to test the effectivity of targeted therapies outside 
their indication. Each target in the SHIVA trial was only represented by a small number of 
patients across several tumor types, which might have camouflaged successes in one of 
the subsets. The new trials are being performed on a much larger scale and, moreover, are 
designed to investigate the effect of each actionable aberration by itself. The CPCT, for 
example, has initiated a trial (“DRUP protocol”) in which small patient cohorts are created 
to assess the effectivity of a drug per genetic aberration per tumor type. The data are 
then, more importantly, shared in an even larger collaboration, Global Alliance for 
Genomic Health (GA4GH).8 Once the first results from these trials become available, we 
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will be able to see if the previous studies have just been too small or if we have a too 
simplistic view on tumor biology. 
We already know that our current methods of (genetic) biomarker discovery are 
complicated by several other biological issues, of which the most complicated one appears 
to be tumor heterogeneity. Molecular tumor characteristics are subject to change at 
several levels: metastatic lesions can differ from each other and from the primary tumor, 
each lesion itself can contain multiple heterogeneous areas and the molecular 
characteristics can also change over time.9 Although we know that heterogeneity can have 
both diagnostic and therapeutic implications on precision medicine, it remains unclear 
how to take it into account. For example, it is not known if the mutational profile in a 
single biopsy from a metastatic tumor lesion is representative for the mutational status of 
the tumor as a whole, if that abstraction of total tumor burden exists at all. Liquid 
biopsies, containing circulating tumor cells (CTCs) or DNA (ctDNA) that have been shed 
into the systemic circulation, have been proposed to cover that mutational status of the 
total tumor burden10-12 and are less invasive to obtain than tumor biopsies. However, 
analyzing any circulating tumor material is still accompanied by a lot of diagnostic issues, 
such as capturing CTCs or determining what part of the ctDNA to sequence. Furthermore, 
it remains to be seen whether the hypothesis of circulating biomarkers being 
representative for all tumor burden is a valid one and – if existing – a clinically relevant 
one that can be used to direct the choice of therapy, as has only been described 
incidentally up till now.13, 14 Despite its disadvantages, intratumoral molecular profiling 
remains the golden standard for assessing mutational status and only direct comparison 
between different platforms can show which platform is the most useful, especially since 
there are a lot of differences between the sequencing results of solid and liquid biopsies.15  
Not only tumor material can be analyzed in multiple ways. While being key in the 
assessments of novel treatment strategies, the quantification of an intervention on clinical 
outcome is also not as straightforward as often presented. As quality of life is difficult to 
structurally assess, overall survival (OS) is regarded as the best clinical endpoint. However, 
it can take some time to reach that endpoint, especially in the less aggressive tumor types. 
In drug development, quick assessment of a drug’s effectiveness is vital for efficient 
research and the use of OS would cause this early phase research to be very time-
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into the systemic circulation, have been proposed to cover that mutational status of the 
total tumor burden10-12 and are less invasive to obtain than tumor biopsies. However, 
analyzing any circulating tumor material is still accompanied by a lot of diagnostic issues, 
such as capturing CTCs or determining what part of the ctDNA to sequence. Furthermore, 
it remains to be seen whether the hypothesis of circulating biomarkers being 
representative for all tumor burden is a valid one and – if existing – a clinically relevant 
one that can be used to direct the choice of therapy, as has only been described 
incidentally up till now.13, 14 Despite its disadvantages, intratumoral molecular profiling 
remains the golden standard for assessing mutational status and only direct comparison 
between different platforms can show which platform is the most useful, especially since 
there are a lot of differences between the sequencing results of solid and liquid biopsies.15  
Not only tumor material can be analyzed in multiple ways. While being key in the 
assessments of novel treatment strategies, the quantification of an intervention on clinical 
outcome is also not as straightforward as often presented. As quality of life is difficult to 
structurally assess, overall survival (OS) is regarded as the best clinical endpoint. However, 
it can take some time to reach that endpoint, especially in the less aggressive tumor types. 
In drug development, quick assessment of a drug’s effectiveness is vital for efficient 
research and the use of OS would cause this early phase research to be very time-
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consuming. Therefore, surrogate endpoints that are reached much quicker, such as 
progression free survival (PFS) or tumor response according to RECIST,16 better suit this 
setting. In Chapter 3, we investigated another surrogate endpoint, the time to progression 
(TTP) ratio. The TTP ratio was found to be significantly correlated to OS and was even 
better than RECIST in predicting for OS in some patients in this study. Now that drug 
efficacy is being tested earlier during clinical research, the TTP ratio seems to be a valid 
alternative to be used as endpoint for that analyses. 
 
Conclusions on genetic biomarker discovery 
Genomic medicine has advanced greatly during the last two decades. In the 20th century, 
systemic cancer treatment almost exclusively consisted of (combined) chemotherapeutic 
regimens, which were generated much more with empirical than with biological research. 
Now that the increasing knowledge on tumor biology has found its way into the clinic, 
both in diagnostics and in therapeutics, a lot of different classes of drugs have taken the 
place of conventional chemotherapy in cancer treatment. Nevertheless, “old fashioned” 
chemotherapy remains the cornerstone of treatment for the majority of cancer types, 
which illustrates that we are still unable to fully understand what is happening inside (and 
around) tumor cells and how we can reverse all these proliferative processes. However, 
the substantial improvements achieved in cancer treatment over last decades cannot be 
neglected and future research on molecular biomarkers should be aimed at determining 
what type of diagnostic platform is superior, which can only be achieved by direct 
comparison of the available platforms and is likely to be different within the context of 
each tumor type. As these assessments require a lot of resources, e.g. tumor samples, 
their blood samples, clinical data, a network to collect all these and especially a lot of 
funding to finance it, small-scale initiatives by individual institutions should be regarded as 
obsolete. Only by combining (international) efforts the most fundamental questions in this 
field can be addressed in a scientifically proper manner and the CPCT is a prototype in that 
context, combining the resources from almost all Dutch oncology centers into an 
international network of similar collaborations.8  
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Pharmacokinetic precision medicine 
In addition to the molecular characteristics of tumor cells, another main determinant of 
treatment outcome in humans is the amount of anti-tumor drug reaching the tumor sites. 
But the ideal way to determine how much drug reaches the tumor remains a black box. A 
generally accepted surrogate for drug exposure to the tumor is systemic exposure, which 
is evidently easier to sample and to monitor. For some anti-cancer agents, predominantly 
for tyrosine kinase inhibitors (TKIs), it has been found that systemic drug exposure is 
correlated to clinical outcome.17, 18 Logically, the next step in improving clinical outcome is 
optimizing the exposure in patients that experience little effect due to low drug 
concentrations or in those that experience much toxicity due to high drug concentrations. 
Part of this mechanism is already incorporated in the way most anti-cancer drugs, 
especially the chemotherapeutic agents, are being dosed, i.e. based on body surface area 
(BSA). That way, big patients get higher doses and little patients small doses, which should 
ultimately lead to equal systemic drug concentrations. In Chapter 4, however, we argue 
that correcting doses for BSA is an outdated principle and cannot be justified by a 
scientific rationale. Unfortunately, the BSA-guided dose corrections have been 
implemented from the start of clinical oncology research and, hence, no empirical 
evidence is available for other – more simple and practical – dosing algorithms to be (at 
least) equal to it.  
 Most recently developed drugs, including TKIs, are being administered in a flat 
dose, which eliminates the false security of BSA guided dosing being accurate. There are 
still many other factors contributing to inter-individual variation (IIV) in drug exposure, as 
is illustrated by the large coefficient of variation (CV) for many TKIs, such as sorafenib. In 
Chapter 5, we have shown that the activity of the OATP1B membrane transporters 
contributes significantly to the pharmacokinetics of sorafenib’s metabolite sorafenib-
glucuronide (SG). By inhibiting OATP1B function with rifampin in sorafenib-treated 
patients, we were able to inhibit biliary secretion of SG, which caused SG to accumulate 
systemically. Although we predicted that this reduced SG secretion would lead to reduced 
enterohepatic circulation of sorafenib and consequently, to lower systemic sorafenib 
concentrations, we did not observe this effect in our study. However, to fully disprove this 
mechanism of reduced sorafenib exposure and thus of reduced sorafenib anti-cancer 
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effects, studies with prolonged OATP1B inhibition are needed. As this study did not take 
clinical outcome of the altered sorafenib PK into account, we have retrospectively 
analyzed a sorafenib-treated cohort of patients in Chapter 6. In that study, we assessed if 
genetic polymorphisms in the enzymes involved in the PK of sorafenib and its metabolites 
were associated with clinical outcome. We found that single nucleotide polymorphisms 
(SNPs) in SLCO1B1, which encodes for OATP1B1, is associated with the incidence of 
sorafenib-induced adverse events. This can biologically be explained by increased toxicity 
in case of reduced OATP1B1 function. Although we have not been able to directly assess 
the relation between SG accumulation and toxicity, the results from these two chapters 
are highly suggestive for a causal relation between the two. However, clinical 
implementation of structural SLCO1B1 genotyping before commencing treatment with 
sorafenib is not likely in the near future. First, it is not known either if upfront sorafenib 
dose reductions in patients with an unfavorable pharmacogenetic profile results in less 
toxicity and – equally important – comparable anti-cancer effects. On that behalf, it would 
be interesting to see if patients with a genetic predisposition to sorafenib toxicity are 
more prone to other OATP1B inhibiting stimuli, such as comedication with clarithromycin 
or ramipril. Furthermore, as sorafenib does not frequently lead to catastrophic toxicity, 
such as in fluoropyrimidine-treated patients with a DPYD deficiency19 or as in 
azathioprine-treated patients with a TPMT deficiency,20 OATP1B1 genotyping will to be 
cost-effective in sorafenib treated patients, whereas the other mentioned examples are.21, 
22  
 
Therapeutic drug monitoring (TDM) 
For drugs with a large intrapatient variability in systemic exposure, determining only the 
optimal starting dose will probably not suffice to optimize treatment outcome. Systemic 
drug concentrations will have to be followed during treatment in order to verify that the 
exposure is still within the therapeutic window. For a TKI like imatinib, for instance, it has 
been found that the systemic exposure decreases with 30% within the first three months 
of treatment and stabilizes thereafter.23 Being attributed to differential absorption 
between patients at first, it was later speculated24 that the decrease could be caused by 
reduced alpha-1 acid glycoprotein (AGP) levels, which is an acute phase protein that was 
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thought to lower on treatment due to less tumor burden or fading surgical effects. In 
Chapter 7, however, we did not observe significant or clinically relevant changes in AGP. 
On the other hand, we confirmed that imatinib concentrations remarkably lowered after 
the first month of treatment, albeit less than the 30% decrease that was described earlier. 
By disproving this AGP-based theory, we have again lost sight of a possible biological 
rationale for the systemic imatinib exposure to decrease. This means that it is not possible 
to extrapolate measured (trough) concentrations at 1 month, used to determine the 
relation of PK to treatment effect,18 to concentrations at other time points. In itself, that 
does not have to be a problem, if everyone were to use that same time point to measure 
imatinib trough concentrations. In reality, three retrospective studies have described a 
much higher incidence than the 25% (lowest quartile) of patients that have imatinib 
concentrations below the (assumed) target for efficacy.25-27 In these studies, however, 
patients were sampled at random time points, mostly far beyond the third month of 
treatment, which logically results in a larger proportion of patients below the threshold. In 
a disturbing way, this illustrates the lack of uniformity between different studies that 
investigate TDM of imatinib in GIST patients. Based on the currently available evidence, 
we may conclude that patients with GIST that are being treated with imatinib have better 
progression free survival when their systemic trough concentration is above 1100 ng/mL 
after the first month of treatment, that there is currently no algorithm to predict at what 
concentration a patient’s exposure will stabilize after the third month of treatment and 
that there is no clear evidence what trough concentration discriminates best for efficacy 
after the third treatment month. Regarding the latter conclusion, it would be interesting 
to have trough concentrations at different time points compared to clinical outcome, 
imatinib is given for years and as it might be beneficial to verify if there is sufficient 
imatinib exposure at a later time point, e.g. after 1 year. Possibly, a lower threshold might 
suffice at that moment, although that scenario seems to be unrealistic given the recent 
finding that prolonged adjuvant imatinib leads to better treatment outcome.28 
Additionally, tumor characteristics appear to play a role in the needed exposure as well: 
patients with a somatic KIT mutation in exon 9 benefit more from imatinib 800 mg daily 
than from 400 mg, whereas patients all other GIST subtypes benefited equally from both 
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imatinib exposure at a later time point, e.g. after 1 year. Possibly, a lower threshold might 
suffice at that moment, although that scenario seems to be unrealistic given the recent 
finding that prolonged adjuvant imatinib leads to better treatment outcome.28 
Additionally, tumor characteristics appear to play a role in the needed exposure as well: 
patients with a somatic KIT mutation in exon 9 benefit more from imatinib 800 mg daily 
than from 400 mg, whereas patients all other GIST subtypes benefited equally from both 
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doses.29 It is therefore likely that patients with a KIT exon 9 mutations have a higher 
systemic exposure threshold for efficacy than others. 
As for imatinib, a target trough concentration for pazopanib efficacy (of 20.5 
μg/mL) has been distilled from early phase studies.17 In those studies, 30% of patients did 
not reach the target concentration after four weeks of treatment. In Chapter 8, we 
therefore investigated if increasing the pazopanib dose in those patients would raise their 
trough concentrations above the set target. In more than half of the patients with a 
trough concentration below the target, we were able to raise that concentration above 
that target by increasing the dose. Now that PK-guided pazopanib dosing is proven 
feasible, subsequent studies should investigate the benefit that patients experience from 
correcting a (too) low systemic exposure. The problem of frequent outpatient visits for the 
blood draws to monitor pazopanib concentrations has been tackled in Chapter 9, where 
concentrations measured on dried blood spots (DBS) were proven to be similar to those 
measured from plasma samples. 
 
Conclusions on pharmacokinetics 
As said, there are two main pillars in pharmacokinetics: determining the correct starting 
dose and – if necessary – maintaining sufficient systemic exposure. Both serve the same 
goals of optimizing anti-cancer effects and reducing (long term) toxicity. Pretreatment 
dose adjustments are currently reserved for patients at high risk of toxicity, e.g. elderly 
patients and those with a poor performance status, significant comorbidity or poor renal 
or liver function. Pharmacogenetics or potential drug-drug interactions are, at least in 
oncology, rarely used to base a dose alteration upon. In the context of the other pillar, 
maintaining sufficient exposure, one can question the clinical importance of a precisely 
right starting dose, especially when the first drug monitoring is being performed quickly 
after treatment start. Hence, maintaining adequate systemic exposure seems of more 
importance. Although TDM is also infrequently applied in oncology, systemic drug 
exposure of many anti-cancer agents has been linked to treatment outcome, increasingly 
in a prospective setting.30, 31 High-quality randomized trials are needed to prove that 
systemic exposure is indeed correlated to clinical outcome, but these trials are hard to 
perform, as patients are reluctant to enter such a trial, which necessitated the Sarcoma 
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Alliance for Research through Collaboration to terminate their phase III study on this 
subject. More surprisingly, physicians appear to be reluctant to follow up the dosing 
advice.32 This seems to indicate that medical oncologists can be categorized as believers or 
non-believers, which makes it hard for the believers to perform the necessary research 
required for an honest evaluation of TDM. Therefore, studies to investigate TDM in 
oncology need to be set up in an innovative design. Example can be taken of the 
researchers that have explored the usefulness of concomitant prednisone during 
docetaxel treatment in prostate cancer, who have not randomized their patients to a 
treatment arm, but who have compared treatment outcome at two different hospitals 
with a different docetaxel treatment protocol (with and without concomitant 
prednisone).33 This study design can also serve as a bridge between TDM believers and 
non-believers, who are already practicing according to their belief anyway. 
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De afgelopen decennia heeft de medicamenteuze behandeling van kanker zich sterk 
ontwikkeld. Hoewel opereren in het overgrote deel van de gevallen vereist is voor 
genezing, zorgt de behandeling met medicijnen in toenemende mate voor een betere 
overleving.  In de tweede helft van de 20ee eeuw werden de eerste stappen naar een 
systemische behandeling van kanker gezet met de introductie van chemotherapie. 
Sindsdien heeft er veel onderzoek plaatsgevonden en is het inzicht in welke biologische 
mechanismen een rol spelen in tumoren sterk verbeterd. Dit heeft aan het einde van de 
vorige eeuw geresulteerd in de ontwikkeling van nieuwe geneesmiddelen voor de 
behandeling van kanker, zoals tyrosine kinase remmers (TKIs) en anti-hormonale 
middelen. Deze nieuwe middelen zijn gericht op het remmen van de signalen die 
aanzetten tot celdeling. Deze signalen zijn binnen een kankercel overactief en stimuleren 
daarmee ongeremde celdeling. Oorspronkelijk werd vermoed dat deze middelen door hun 
gerichte werkingsmechanismen een stuk minder giftig zouden zijn dan conventionele 
chemotherapieën, die hun effect op tumoren – en helaas ook op gezonde cellen –  
uitoefenen door de celdeling te remmen. De proliferatieve signalen, die door de nieuwe 
middelen worden geremd, blijken ook een rol te spelen in de fysiologie van gezonde cellen 
en het remmen daarvan leidt dus – net als bij chemotherapie – tot bijwerkingen. De 
uitdaging voor het hedendaagse onderzoek is om te ontdekken welke patiënten geen baat 
hebben van behandeling, omdat deze behandeling geen effect heeft of omdat de 
behandeling teveel bijwerkingen geeft. In dit proefschrift staan twee methoden 
beschreven om de medicamenteuze behandeling van kanker preciezer op de individuele 
patiënt af te stemmen: 1. op basis van genetische afwijkingen in de tumor en 2. op basis 
van de verdeling van het geneesmiddel in het lichaam. Dit laatste wordt ook wel 
farmacokinetiek genoemd.  
 
Genetische afwijkingen in de tumor 
Veel nieuwe behandelingen zijn al gericht op genetische afwijkingen binnen een tumorcel. 
Het medicijn imatinib is bijvoorbeeld alleen effectief bij gastro-intestinale 
stromaceltumoren (GIST) als die een mutatie in het KIT-gen bevatten. Datzelfde geldt voor 
een ander medicijn in dezelfde klasse van geneesmiddelen: vemurafenib, dat wordt 
toegepast bij melanomen met een zogenaamde BRAF-mutatie. Er zijn echter ook nog veel 
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anti-kanker geneesmiddelen waarvoor zo’n genetische biomarker nog niet ontdekt is. Om 
die reden werken vele ziekenhuizen in Nederland samen binnen het Center for 
Personalized Cancer Treatment (CPCT). Binnen het CPCT wordt in tumoren gekeken naar 
genetische afwijkingen die mogelijk de uitkomst van de medicamenteuze behandeling van 
kanker kunnen voorspellen. Voordat patiënten beginnen met die behandeling, wordt er 
een biopt uit de tumor genomen, bij voorkeur uit een uitzaaiing. Als er voldoende biopten 
zijn van patiënten die eenzelfde behandeling hebben gehad, wordt gekeken of de 
patiënten die goed op de behandeling reageerden een ander genetisch profiel van hun 
tumor hadden dan degenen die niet goed reageerden. Voordat de biopten op grote schaal 
verzameld en geanalyseerd kunnen worden, moet duidelijk zijn dat deze procedures veilig 
zijn en dat het verkregen tumormateriaal goed geanalyseerd kan worden. Uit een analyse 
na de eerste 500 biopsieprocedures blijkt dat dit het geval is, zoals staat beschreven in 
Hoofdstuk 2 van dit proefschrift. Hiermee is de weg vrijgemaakt om op grote schaal 
tumorbiopten te verzamelen en inmiddels zijn er een groot aantal Nederlandse 
ziekenhuizen bij dit netwerk aangesloten.  
 Naast het vinden van (genetische) biomarkers voor de uitkomst van de 
behandeling, is de ontwikkeling van nieuwe geneesmiddelen een andere belangrijke pijler 
binnen het oncologische onderzoek. Om die ontwikkeling zo efficiënt mogelijk te laten 
verlopen, is het een uitdaging om zo vroeg mogelijk te zien hoe effectief een 
geneesmiddel is. In Hoofdstuk 3 staat beschreven dat de verhouding tussen de natuurlijke 
groeisnelheid van een tumor en de duur van de behandeling een goede voorspeller is voor 
de effectiviteit (gemeten met 3D-beeldvorming) van behandeling met everolimus.  
 
 
Farmacokinetiek 
Naast kenmerken van de tumor, waarop een geneesmiddel kan aangrijpen, is het net zo 
belangrijk dat er voldoende geneesmiddel bij de tumor aankomt. Ten eerste is het 
belangrijk om een goede startdosering te kiezen, die afgestemd is op de individuele 
patiënt. Veel geneesmiddelen, met name chemotherapieën, worden nog gedoseerd op 
basis van lichaamsoppervlakte (‘body-surface area’; kortweg BSA). BSA wordt berekend 
door middel van een formule, waarin lengte en gewicht worden meegenomen. In 
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anti-kanker geneesmiddelen waarvoor zo’n genetische biomarker nog niet ontdekt is. Om 
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patiënt. Veel geneesmiddelen, met name chemotherapieën, worden nog gedoseerd op 
basis van lichaamsoppervlakte (‘body-surface area’; kortweg BSA). BSA wordt berekend 
door middel van een formule, waarin lengte en gewicht worden meegenomen. In 
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Hoofdstuk 4 wordt uitgelegd waarom deze formule vaak geen toereikende correctie biedt 
voor de startdosis van geneesmiddelen binnen de oncologie. Wij menen dat een startdosis 
die in principe bij elke patiënt hetzelfde is, niet perse slechter hoeft te zijn dan doseren op 
basis van BSA.  
 Lengte en gewicht zijn niet de enige factoren die van invloed zijn op de 
farmacokinetiek van een geneesmiddel. Elk geneesmiddel wordt bijvoorbeeld actief in en 
uit de bloedbaan opgenomen door membraantransporters, die onder andere op 
levercellen, darmcellen en tumorcellen zitten. Om tot een patiëntgerichte dosering te 
komen moeten we dus beter rekening gaan houden met deze factoren. In Hoofdstuk 5 is 
gekeken in welke mate de specifieke OATP1B transporteiwitten betrokken zijn bij de 
farmacokinetiek van het middel sorafenib. Hoewel dit onderzoek op cellijnen, muizen en 
patiënten is uitgevoerd, heeft dit onderzoek niet geheel in kaart kunnen brengen wat de 
daadwerkelijke consequenties van de veranderde farmacokinetiek op de klinische effecten 
van sorafenib zijn. Daarom is in Hoofdstuk 6 onderzocht of patiënten met een genetische 
afwijking in deze transporter meer bijwerkingen van sorafenib hadden dan degenen met 
een normaal functionerend eiwit. Deze hypothese is inderdaad bevestigd: afwijkingen in 
het gen dat codeert voor OATP1B1 waren geassocieerd met het optreden van 
bijwerkingen.  
 Omdat de concentraties van het geneesmiddel in het bloed ook tijdens de 
behandeling kunnen veranderen, is het belangrijk om de concentraties periodiek te blijven 
controleren. Van imatinib is bijvoorbeeld bekend, dat de concentraties na drie maanden 
met 30% dalen. De oorzaak daarvan is vooralsnog onbekend. Hoewel anderen eerder 
hebben beweerd dat een gelijktijdige daling van de concentraties van het eiwit AGP in de 
bloedbaan de reden zou kunnen zijn, is in Hoofdstuk 7 aangetoond dat hiervan niet zozeer 
sprake is. Verder onderzoek zal moeten uitwijzen of patiënten met een te lage 
blootstelling aan imatinib wellicht beter af zijn met een dosisverhoging. Datzelfde geldt 
ook voor patiënten die met pazopanib, wederom een ander middel in dezelfde klasse, 
behandeld worden. In Hoofdstuk 8 staat beschreven dat relatief lage concentraties in het 
bloed veilig gecorrigeerd kunnen worden door de dosis geleidelijk te verhogen. Opnieuw 
zal vervolgonderzoek moeten uitwijzen of dit daadwerkelijk tot betere resultaten leidt. 
Door de concentraties te meten in bloed uit een vingerprik in plaats van uit een buis 
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bloed, zou het vervolgen van de geneesmiddelenconcentraties een stuk 
patiëntvriendelijker kunnen verlopen. Dat de metingen met een vingerprik dezelfde 
resultaten geven als met de standaard bloedafnames, hebben we aangetoond en staat 
beschreven in Hoofdstuk 9.  
  
Conclusies 
De ontwikkelingen binnen de oncologie hebben de laatste jaren een vlucht genomen. 
Toch blijft er nog veel ruimte voor verbetering. In dit proefschrift staan een aantal 
voorbeelden van het preciezer maken van de medicamenteuze behandeling door op zoek 
te gaan naar nieuwe (genetische) aangrijpingspunten in de tumor, of door de blootstelling 
aan het geneesmiddel te optimaliseren. Doordat de bestaande onderverdeling van 
tumoren op basis van celtype zal versplinteren, moet toekomstig onderzoek voor elk van 
deze subtype tumoren uitwijzen welk middel daar het beste tegen werkt en bij welke 
blootstelling dat het beste gebeurt. 
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DANKWOORD 
Aan het tot stand komen van dit proefschrift hebben zoveel mensen bijgedragen, dat dit 
hoofdstuk niet toereikend is om iedereen daar persoonlijk voor te bedanken. Toch zal ik 
proberen dat zo volledig mogelijk te doen, te beginnen bij alle patiënten die hebben 
deelgenomen aan de hier beschreven studies. Hun bereidheid om dit belangeloos te doen 
is het fundament van klinisch wetenschappelijk onderzoek. 
 
Mijn beide promotoren ben ik niet minder dank verschuldigd. Prof. dr. Sleijfer, Stefan, ik 
vind het wonderbaarlijk hoe je mij hebt kunnen begeleiden naast al je andere 
werkzaamheden. Je drukke agenda deed niets af aan de vakkundige manier waarop je me 
– altijd op korte termijn – niet alleen van opbouwende kritiek voorzag, maar ook de 
nodige sturing hebt gegeven bij het uitvoeren van de CPCT-studies. De hartelijke woorden, 
die je altijd graag voor me over had, zal ik nog lang meenemen. Prof. dr. Mathijssen, Ron, 
jij blijft me altijd verbazen met de persoonlijke manier waarop je alle promovendi 
begeleidt en met de oneindige gedrevenheid waarmee je je doelen nastreeft. Ik vind het 
bijzonder hoe je deze hele nieuwe groep succesvol hebt opgebouwd. De ontwikkeling die 
ik in Rotterdam heb doorgemaakt is grotendeels te danken aan de ruimte en het 
vertrouwen, die je me daarvoor hebt gegeven. In het bijzonder ben ik jullie beiden enorm 
dankbaar voor jullie actieve betrokkenheid in het afgelopen jaar. 
 
Prof. dr. Huitema, Prof. dr. Van Schaik en Prof. dr. Voest, dank dat jullie dit manuscript 
hebben willen beoordelen als leescommissie. Prof. dr. Aerts, Prof. dr. Van Gelder, Prof. dr. 
Gelderblom en Prof. dr. Schellens, dank dat jullie bereid zijn om in de oppositie plaats te 
nemen.  
 
Dr. Lolkema, Martijn, mijn ‘slakkenfenotype’ sloot niet altijd aan bij de manier waarop jij 
dingen graag geregeld ziet. Toch hebben we – sinds je mij bij mijn eerste 
wetenschappelijke stappen binnen de interne oncologie begeleidde - samen een aantal 
mooie projecten uitgevoerd. Uit het feit dat je me naar Rotterdam gevolgd bent, maak ik 
op dat je mijn vertragende invloed stiekem bent gaan waarderen. Dank voor je 
begeleiding tijdens de afgelopen jaren.  
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Dr. Eskens, Ferry, onze grote plannen voor wetenschappelijke samenwerking bleken niet 
allemaal te realiseren. Alsnog heb je een groot aandeel bij een aantal hoofdstukken in dit 
proefschrift. Daarnaast heb je mijn klinische activiteiten de afgelopen jaren 
gesuperviseerd en heb je mij geholpen om de medische wetenschap in die klinische 
context te leren plaatsen. Dank voor je enorme betrokkenheid. 
 
Dear Sharyn and Alex, many thanks for supervising and coordinating the rifampin study 
and especially for the stay in Memphis. You’ve really introduced me into the fundamental 
part of science. Alice, Shuiying and Aksana, thank you for taking me through all the 
different experiments and for looking after me during the two weeks I was at your lab. 
 
Christa en Geert, jullie hebben je als eerste gewaagd aan de logistiek van de CPCT-studies 
en jullie inspanningen zijn essentieel geweest voor alles wat er nu binnen het CPCT 
gebeurt. Christa, de ‘bioptenpaper’ is grotendeels door jouw inspanningen tot stand 
gekomen. Dank voor al jullie moeite die in deze projecten is gaan zitten. Fleur, het was 
mooi om samen de tweede generatie CPCT-promovendi te vormen bij alle (niet-
wetenschappelijke) CPCT-activiteiten. Succes met de laatste loodjes. 
 
Remy Verheijen, dank voor de prettige samenwerking bij de laatste twee hoofdstukken. 
Kers op de taart was de samenwerking tijdens de derde helft bij de laatste ESMO. Succes 
met het afronden van je eigen proefschrift.  
 
Hoewel er uiteindelijk weinig next-generation sequencing resultaten in dit proefschrift 
terug te vinden is, ben ik veel dank verschuldigd aan allen die hebben geprobeerd om mij 
daar iets over bij te brengen. Marco, Annelies en vooral Ies , jullie stonden altijd klaar in 
Utrecht om de gapende hiaten in mijn kennis geduldig te vullen. Veel dank daarvoor. 
Daniel, onze regelmatige discussies over de resultaten van onder meer de CPCT-01 
hebben helaas (nog) niet geleid tot iets publicabels, maar hopelijk troost het je dat ik er in 
ieder geval een hoop van geleerd heb. Jozien Helleman, John Martens en Erik Wiemer, 
jullie hebben veel met mij om de tafel gezeten om een mooie klinische studie (de CPCT-
04) op te zetten, die helaas nooit van de grond is gekomen. Dat er nooit meer een CPCT-
Dankwoord | 193 
 
studie met rugnummer 04 zal spelen, beschouw ik als terecht respect naar de 
inspanningen die jullie in dit project hebben gestoken. 
 
Bij het verzamelen van alle (klinische) data heb ik de nodige hulp gehad uit meerdere 
windrichtingen. Vooral tijdens de eerste jaren van mijn promotietraject was ik kind aan 
huis bij het CTC van het Erasmus MC. Hoewel vrijwel iedereen van het CTC een bijdrage 
heeft geleverd, wil ik Willeke Bolle, Susan Marinissen, Nelly van der Meer, Robert 
Oostrum, René Vernhout, en Patricia de Vos in het bijzonder danken. Gea van der Hout, 
Lakshmi Mani, Jennifer Samson en Wendy Vorstenbosch, jullie hebben allemaal veel werk 
op de afdeling verricht voor de in dit proefschrift beschreven studies, waarvoor ik jullie erg 
dankbaar ben. Alle stafleden en fellows van het Erasmus MC, bedankt voor jullie actieve 
betrokkenheid bij het benaderen van patiënten voor de studies. De mensen op alle 
verschillende secretariaten (G4, D3, Balie B, behandelcentra, B0zuid) bedankt voor jullie 
hulp bij de planning, in het bijzonder Willy Bierwith, José de Lange en Eline van Munster. 
Marianne Keessen en Ida van Belle, jullie hebben veel betekend voor de logistieke 
processen binnen het CPCT en dus ook voor het tot stand komen van dit proefschrift, veel 
dank daarvoor. Erik van Werkhoven en Henk Botma, dank voor jullie geduld bij het 
verwerken en aanleveren van de klinische CPCT-data. Nicolle Besselink en Jan Beekhuis, 
dank voor jullie gastvrijheid in Utrecht als ik weer eens samples kwam brengen of halen. 
Esther Oomen – de Hoop, dank voor je hulp en opbouwende kritiek bij het stroomlijnen 
van vrijwel alle statistische analyses binnen het PK-lab. Samira, jij hebt je ontfermt over 
alle samples die ik aanleverde voor de PG analyses. Veel dank voor je snelle reacties. 
 
Uiteraard hoort iedereen van het PK-lab (“Translationele Farmacologie”) ook in dit 
dankwoord thuis. Peter, alleen de metingen van midazolam en imatinib benaderen niet 
hoeveel farmacologische kennis van jou in dit proefschrift verwerkt zit. Dank voor alle 
sturing op dat gebied. Inge en Mei, jullie ook bedankt voor het werk dat jullie in alle 
analyses hebben zitten. Vooral van de momenten van bespiegeling op Be-462 heb ik de 
afgelopen jaren genoten. Patricia, we hebben nooit samengewerkt, maar wel vier jaar lang 
schuin achter elkaar gezeten. Bedankt voor alle gezelligheid. Bimla en Robert, dank voor 
jullie noeste arbeid op B0zuid. Het was altijd fijn om even bij jullie te buurten. Jacqueline, 
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dank dat je me hebt ingewerkt op de Daniel, zoals bij het opstellen van de AGP-studie, 
maar vooral bij de verplichte rondleiding langs het dakterras. Van onze discussies over de 
zin van de wetenschap en van andere zaken heb ik (meestal op dat dakterras) genoten. 
Annemieke en Lisette, jullie hebben me de weg gewezen op de centrum locatie. Hoewel 
de kamer soms wat aan de warme kant was, was het leuk om daar samen met jullie te 
zitten. Helaas hebben jullie inmiddels allemaal de oncologie verlaten, maar hopelijk 
vinden we later nog een andere manier om weer samen te werken. Roelof, dank voor je 
positieve inbreng op het lab de afgelopen jaren. De bourgondische derde helften (ESMO in 
Wenen tijdens Oktoberfest...) waren altijd een waar genoegen. Als je nog een keer wat 
over de sora-rifa wil weten, dan weet je me te vinden. Leni, zowel aan de sorafenib- als 
aan de pazopanib-studies heb jij een grote bijdrage geleverd. Dank dat je mij op weg hebt 
geholpen bij de klinische uitvoering van die studies. Veel succes en plezier bij de volgende 
stappen die je binnen de wetenschap aan het maken bent. Astrid en Evelien, een bezoek 
aan/van jullie hoorde bij een werkdag op de Daniel en dat heeft zeker bijgedragen aan het 
werkplezier daar. Bodine, Emma, Femke, Florence, Koen, Stijn en Peric, jullie zijn in de 
loop van de tijd het lab binnen gedruppeld. Het is jammer om straks niet meer dagelijks 
met jullie op het lab te zitten. Allemaal veel succes en vooral plezier de komende jaren. 
Hopelijk houden jullie me een beetje op de hoogte van de ontwikkelingen. Pim, Anne en 
Edwin, ik heb jullie mogen begeleiden bij het schrijven van jullie masterscripties, die 
allemaal tot een (naderende) publicatie hebben geleid. Jullie hebben me regelmatig 
nieuwe dingen geleerd, maar het was vooral leuk om met jullie samen te werken. Edwin, 
heel gaaf dat je nu doorgaat met de onderzoekslijn waar je je masterscriptie mee begon. 
Esther, Jaco, Nick en Wendy, dank dat jullie me geadopteerd hebben in tijden van 
eenzaamheid aan de overkant van de gang. Het was altijd prettig om tijdens of na de lunch 
even met jullie over de zin van het leven te kunnen praten.  
 
Bijzondere dank gaat uit naar mijn paranimfen. Bart, onze studententijd stond bol van de 
onsuccesvolle avonturen: (licht) roeien, WECO, zanglessen, voetballen, etc. Gelukkig 
hebben we er wel veel plezier aan beleefd. Nadat we (gelijktijdig) afstudeerden is het 
allemaal wat serieuzer geworden en nu mogen we ook bijna tegelijk ons proefschrift 
verdedigen over bijna hetzelfde onderwerp. Dat maakt het mooi om jou als paranimf 
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naast me te hebben. Misschien hebben we in de wetenschap dan eindelijk iets gevonden 
wat we wel samen kunnen. Arjan, ik vind het geweldig dat jij ook naast me staat bij de 
verdediging. Vroeger stonden we vaak samen op de voetbal- of tennisbaan, wat voor mij 
als 2 jaar oudere broer niet altijd even goed voor mijn zelfvertrouwen was. Toen je later 
nog wel eens een zinnetje uit mijn schoolverslagen wilde overnemen voor die van jezelf, 
had ik weer even de illusie om je grote broer te kunnen spelen. Inmiddels ben je me weer 
ouderwets links en rechts aan het inhalen met al je opleidingen en met je eigen 
promotietraject. Hoewel ik me daar eigenlijk boos om zou moeten maken, ben ik vooral 
hartstikke trots op wat je allemaal aan het klaarspelen bent. Dounia, jij bent natuurlijk 
stiekem de motor achter Arjan en het is hartstikke mooi dat jij inmiddels een onderdeel 
van de familie bent. 
 
Ma van Stuijvenberg en de hele schoonfamilie, dank voor de warme manier waarop ik zo 
snel welkom ben geheten binnen jullie familie. Ik kijk uit naar de jaren die nog komen. 
 
Lieve pa en ma, aan jullie heb ik te danken dat ik hier überhaupt sta. Mam, jij was 
misschien wel de grootste drijfveer om toch geneeskunde te gaan doen. Pa, jouw 
onvermoeibare pogingen om me warm te maken voor de wetenschap lijken nu (hoewel 
On the origin of species nog altijd ongelezen in de kast staat) pas eindelijk tot me door te 
dringen. Ik ben jullie enorm dankbaar voor jullie grenzeloze steun en voor alles wat ik aan 
jullie te danken heb. Daarbovenop heb ik het laatste half jaar nog meer bewondering voor 
jullie beiden gekregen. Ik hoop nog heel lang van jullie te kunnen genieten. 
 
Lieve Andrieske, ongeveer aan het begin van mijn promotietraject leerden wij elkaar 
kennen. Vanaf toen was al duidelijk dat wij bij elkaar horen en dat gevoel is sindsdien 
alleen nog maar sterker geworden. Ik ben enorm blij dat wij de rest van ons leven aan 
elkaar vast zitten en dat we komend jaar gaan trouwen. Onze toekomst samen gaat alleen 
nog maar mooier worden. 
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